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ABSTRACT 
 
Osteosarcoma is a highly aggressive malignant tumor arising from the bone and most commonly 
affecting children and young adults. The aim of this experimental study was to investigate the 
utility of herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV-TK/GCV) suicide gene 
therapy and oncolytic virotherapy against osteosarcoma. A high gene transfer rate is an important 
prerequisite for successful gene therapy. Therefore, the capacity of lenti-, adeno- and Sindbis virus 
vectors to efficiently transfer a therapeutic gene into osteosarcoma cells was studied. Adeno- and 
lentivirus vectors demonstrated successful transfer of HSV-TK – green fluorescent protein (TK-
GFP) suicide-marker fusion gene into three different osteosarcoma cell lines. The subsequent GCV 
treatment produced efficient cell killing in all of the studied osteosarcoma cell lines. However, since 
100 % gene transfer rates cannot be achieved with current vector systems, lateral spread of the toxic 
effects to the neighbouring tumor cells, termed as a bystander effect, plays an important role in the 
eventual therapeutic outcome of the HSV-TK/GCV treatment. The extent of the bystander effect 
varied between different osteosarcoma cell lines, suggesting that there might be variation in the 
therapeutic efficacy between different osteosarcoma tumors or subpopulations of tumor cells in a 
single tumor. Evaluation of Sindbis virus vector led to the observation that this vector type could 
propagate in BHK-21 cells used for vector production. Since wild-type reversion of the vector with 
the two vector production systems used in this study has not been reported before, the underlying 
mechanisms of vector propagation were analyzed further to determine i) could the vector spreading 
be utilized to enhance gene transfer efficiency or ii) would it pose a safety risk. In addition to non-
replicative vectors, oncolytic viruses capable for selective replication in malignant cells and tumor 
cell killing have been studied against cancer. In this study, two oncolytic viruses, a conditionally 
replicating adenovirus ∆24 and an oncolytic Semliki Forest virus vector VA7-EGFP, were studied 
against osteosarcoma in vitro and in vivo. Both vectors could destroy human osteosarcoma cell 
cultures and showed therapeutic effects in subcutaneous human osteosarcoma xenograft tumors. 
Compared to ∆24, VA7-EGFP was more efficient and was evaluated further in a highly aggressive 
orthotopic mouse osteosarcoma model. In this model, intratumoral VA7-EGFP treatment 
significantly improved survival of the treated mice compared to control animals. As a conclusion, 
both HSV-TK/GCV approach and oncolytic virotherapy deserve further investigations to evaluate 
their effects in combination with the chemotherapeutic agents currently used against osteosarcoma. 
Moreover, it would be of great interest to combine these treatment strategies to immunopotentiation 
gene therapy to enhance their efficacy against distant osteosarcoma metastases.  
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EGFR  = epidermal growth factor receptor 
eIF-2α  = α subunit of eukaryotic polypeptide chain initiation factor 2 
ER  = endoplasmic reticulum 
EtBr  = ethidium bromide 
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Fas  = a proapoptotic gene also known as TNFRSF6, APO-1, APT1 and 
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FFM  = fentanyl-fluanison-midazolam (mixture for anesthesia) 
G-CSF  = granulocyte colony stimulating factor 
GCV  = ganciclovir 
GCV-3P  = ganciclovir triphosphate 
GFP  = green fluorescent protein 
GM-CSF  = granulocyte macrophage colony stimulating factor 
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HAdv  = human adenovirus 
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HGF-SF  = hepatocyte growth factor-scatter factor 
HIC-1  = hypermethylated in cancer-1  
HIV  = human immunodeficiency virus  
HSV  = herpes simplex virus 
HSV-TK  = herpes simplex virus type 1 thymidine kinase 
hTERT  = human telomerase reverse transcriptase promoter 
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1   INTRODUCTION 
 
Osteosarcoma is an aggressive malignant mesenchymal tumor characterized by the production of 
immature bone or osteoid by tumor cells (Carrle and Bielack, 2006; Marina et al., 2004). The 
incidence of osteosarcoma is highest among adolescents and young adults. In this age group, the 
higher incidence is associated to the adolescence growth spurt (Carrle and Bielack, 2006). The 
second peak in the incidence occurs after 50 years of age and is related to predisposing inherited 
disorders, such as Paget's disease (Dorfman and Czerniak, 1995; Kansara and Thomas, 2007). 
Osteosarcoma typically metastasizes into the lungs already at an early phase of the disease. The 
progression of lung metastases is the most common factor leading to the eventual death of patients. 
Although the development of adjuvant and neoadjuvant chemotherapy has dramatically improved 
the prognosis of osteosarcoma patients during the last decades, those patients presenting with 
radiologically detectable pulmonary metastases have a dismal prognosis. Furthermore, prognosis of 
patients with recurrent disease or tumors at unresectable locations remains poor. For these patients 
new safe and effective therapeutic options against osteosarcoma are needed (Carrle and Bielack, 
2006; Kansara and Thomas, 2007; Marina et al., 2004). 
 Gene therapy means transferring nucleic acids into cells in order to treat or cure 
diseases. It was first introduced for treatment of monogenic inheritable disorders (Blaese et al., 
1993; Blaese et al., 1995). However, currently it is also studied as a treatment of diseases with more 
complex aetiology, such as cancer, cardiovascular diseases, infections, neurologic and ocular 
diseases (www.wiley.co.uk/genmed/clinical, accessed December 2008). Virus vectors are 
commonly utilized as vehicles for therapeutic gene transfer. They are modified replication 
incompetent viruses that contain the therapeutic gene as a part of their genome. Another way to 
utilize viruses as cancer therapeutics is the use of oncolytic viruses. These are viruses that either 
naturally or after modifications, specifically replicate in malignant cells and thereby destroy them 
(Young et al., 2006). 
 In the present study novel treatment options against osteosarcoma were sought from 
the fields of gene therapy and virotherapy. Additionally, the ability of different virus vectors to 
transfer genes into osteosarcoma cells was studied in order to find appropriate tools for therapeutic 
gene transfer.    
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2   LITERATURE REVIEW 
 
Cancer arises from malfunction of genes 
 
Cancer is the
 
third most common cause of death worldwide after cardiovascular diseases and 
infections (World Health Organization, The Global Burden of Disease: 2004 update,   
www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf, accessed 
January 2009). In Finland, about 27 000 new cancer cases are diagnosed each year and the 
incidence is increasing due to the aging of the population (Finnish cancer registry, 
www.cancerregistry.fi, accessed December 2008). In view of the major impact to the population 
health and the devastating consequences to individuals if curative treatment cannot be offered, this 
group of diseases has long been the focus of intensive research.  
 Cancer is caused by abnormal function of genes. Malignant cells typically do not 
follow the normal rules of tissue organization, cell division and apoptosis. They can divide in an 
uncontrolled way, invade through tissue boundaries as well as metastasize to distant locations in the 
body. All these characteristics are related to the aberrant function of the genome in cancer cells 
(Hanahan and Weinberg, 2000). Accumulation of mutations, including deletions, amplifications and 
point mutations, in genes that have important functions in the regulation of cell cycle and cell 
division, DNA repair and apoptosis is involved in the process of malignant transformation. 
Additionally, abnormal functions of genes encoding various growth factors or their receptors and 
genes involved in growth inhibitory signalling and interaction with or degradation of the 
extracellular matrix are common in malignant tumors. Genes having influence on angiogenesis or 
cell adhesion contribute to tumor development into more aggressive forms with the capability for 
invasion and metastasis (Hanahan and Weinberg, 2000). It has been proposed that there are six 
fundamental alterations in cell physiology that are important in acquisition of malignant phenotype: 
self-sufficiency in growth signals, insensitivity to growth inhibitory signals, evasion of programmed 
cell death, unlimited potential for cell division, sustained angiogenesis and capability for tissue 
invasion and metastasis (Hanahan and Weinberg, 2000). The mutations leading to these alterations 
can be either inherited or sporadic. Still, only a small fraction of all cancer cases are hereditary (i.e. 
familial), while etiology of most malignant tumors is sporadic (Tamura et al., 2004).  
 There is increasing evidence for the important role of epigenetic changes in cancer 
pathogenesis, including general hypomethylation of the genome and hypermethylation of promoter 
regions (Jones and Baylin, 2002). Tumor suppressor genes are frequently hypermethylated as a 
17 
 
result of increased activity or deregulation of DNA methyltransferases (DNMTs), followed by 
histone deacetylation (Jones and Baylin, 2002; Li et al., 2005). Hypermethylation-mediated 
transcriptional silencing of tumor suppressor genes is recognized as an important pathogenetic 
mechanism in several cancers. The importance of this phenomenon is demonstrated by studies on 
BRCA1. Previously, this gene was assumed to be important only in familial form of breast cancer 
through germ-line mutations of BRCA1. More recent studies have revealed that 10-15 % of women 
with non-familiar breast cancer have tumors in which this gene is hypermethylated (Esteller et al., 
2000). In particular, epigenetic changes may represent an important connection between 
environmental factors and cancer (Herceg, 2007). Although epigenetic changes are usually 
considered as reversible, recent studies suggest that some of the cancer-related epigenetic 
alterations can be inherited through the germline for several generations (Fleming et al., 2008). 
 In addition to transcriptional silencing mediated by DNA hypermethylation, tumor 
suppressor genes can be silenced post-transcriptionally by microRNAs (miRNAs). They are non-
protein encoding endogenous small RNAs that have important regulatory functions in animals and 
plants. MiRNAs regulate gene expression at the translational level through mRNA decay initiated 
by miRNA-guided rapid deadenylation (Zhang et al., 2007). It has been found that several miRNAs 
are directly involved in the development of human cancers, including leukaemia, lung, breast, brain, 
liver and colon cancer (Zhang et al., 2007). Some miRNAs may play a role as tumor suppressors 
(let-7) or oncogenes (mir-17-92) and miRNAs that regulate cell proliferation and apoptosis have 
been found. In fact, more than 50 % of miRNA genes are located in cancer-associated genomic 
regions or in fragile sites. This suggests that miRNAs may have a more important role in cancer 
pathogenesis than previously thought (Zhang et al., 2007). The development of micro-array 
technology and bioinformatics has been a revolution for research focusing on cancer genetics and 
epigenetics. These novel methods are rapidly increasing the available information on cancer 
molecular biology. 
 
Cancer gene therapy 
 
Overview 
 
Gene therapy, i.e. transfer of a gene or genes into the target tissue in order to yield a therapeutic 
effect, has been widely studied for the treatment of cancer during the past two decades. Several 
distinct gene therapy strategies have been studied with promising results in vitro and in vivo, 
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including mutation compensation, antiangiogenic, immunopotentiation and suicide gene therapy 
approaches.  
The aim of the mutation compensation gene therapy is to transfer a wild-type tumor 
suppressor gene into tumor tissue that harbours a mutated form of that gene. Two tumor suppressor 
genes of key importance in cancer pathogenesis, p53 and Rb, have been extensively studied in 
context of mutation compensation gene therapy (Meng and El-Deiry, 1998). However, curative 
treatment with mutation compensation gene therapy would require transduction of every tumor cell 
and this cannot be achieved with the current gene transfer tools. Therefore this treatment modality 
should always be combined with other cancer therapeutic options. It is notable that restoration of 
p53 function can lead to enhanced sensitivity to chemotherapeutic agents (Ganjavi et al., 2005; 
Song and Boyce, 2001; Tsuchiya et al., 2000a) and therefore could be used to sensitize a tumor to 
conventional chemotherapy.    
Antiangiogenic gene therapy is targeted to the tumor vasculature in order to inhibit 
tumor growth by suppressing formation of new vessels. This can be achieved by inhibiting vascular 
endothelial growth factor (VEGF) or its receptors. The most important molecule promoting tumor 
angiogenesis is VEGF (also termed as VEGF-A). The VEGF family includes also five other known 
members: placental growth factor (PlGF), VEGF-B, VEGF-C, VEGF-D and VEGF-E (McMahon, 
2000), however, VEGF-E is not found in mammals. VEGFs bind into their dimeric tyrosine kinase 
receptors on endothelial cells (VEGFR1, VEGFR2, VEGFR3) (McMahon, 2000). Antisense 
oligonucleotides inhibiting VEGF or ribozymes designed against VEGFR1 mRNA (Angiozyme) or 
targeting VEGFR1 (a.k.a. Flt-1) or VEGFR2 (a.k.a. KDR) mRNA have been studied for inhibition 
of VEGF signalling by facilitating the degradation of mRNA (Döme et al., 2007; McMahon, 2000). 
Another strategy is to use vectors encoding soluble VEGF receptors. The soluble receptors bind 
VEGFs, blocking their binding to and activation of their endogenous receptors or to form dimers 
with the endogenous VEGF receptors inactivating the receptor (McMahon 2000; Grothey and Ellis 
2008). The antiangiogenic treatment alone cannot eradicate tumors, since small clusters of tumor 
cells can survive without formation of new vessels. Additionally, due to the genetic flexibility of the 
tumor cells they have been shown to escape anti-angiogenic therapy by utilization of alternative 
vascularisation mechanisms (Döme et al., 2007), such as vascular co-option or vasculogenic 
mimicry (Maniotis et al., 1999). These observations support combining anti-angiogenic treatments 
to other treatment modalities. 
In immunopotentiation gene therapy of cancer, two basic approaches have been 
utilized. First strategy is enhancement of tumor cell recognition by transduction with MHC class I 
molecules (Witlox et al., 2007) or by transferring genes encoding tumor antigens to antigen 
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presenting (dendritic) cells (Frolkis et al., 2003; Nencioni et al., 2003). Second approach is to 
enhance the efficacy of the immune system including genetic modification of T-lymphocytes to 
improve their ability to recognize tumor cells or general boosting of the immune system via transfer 
of genes encoding cytokines or other co-stimulatory molecules (Lafleur et al., 2001; Tsuji et al., 
2002; Worth et al., 2000). Cytokine IL-12 is a central intermediary in several functions of the 
immune system, including stimulation of T lymphocytes and NK cells and regulation of several 
important cell adhesion molecules. IL-12 promotes IFN-γ production by T cells and NK cells, 
enhances ICAM-1 expression in presence of IFN-γ and with IL-18 enhances anti-tumor activity of 
NK cells (Liebau et al., 2002; Liebau et al., 2004; Witlox et al., 2007).  
Dose-limiting bone marrow toxicity is a common problem with several 
chemotherapeutic drugs. Chemoprotective gene therapy involves protection of hematopoietic stem 
cells against toxic effects of chemotherapy via transfer of drug resistance genes, such as MDR1. 
This strategy enables the use of high dose chemotherapy regimens with improved anti-tumor 
efficacy (Zaboikin et al., 2006). 
Suicide gene therapy (also known as gene-directed enzyme prodrug therapy or 
molecular chemotherapy) is based on transfer of a suicide gene followed by administration of non-
toxic prodrug that is then converted into a toxic form by an enzyme encoded by the transgene. The 
advantage of this strategy is that not every tumor cell needs to be transduced due to the so-called 
bystander-effect, i.e. spreading of toxic compounds formed in transduced cells to neighbouring cells 
extracellularly or via intercellular connections called gap-junctions. Several enzyme-prodrug 
systems have been studied for this purpose, including herpes simplex virus type I thymidine kinase 
(HSV-TK)/ ganciclovir or acyclovir, bacterial cytosine deaminase (CD), derived from Escherichia 
coli or Saccharomyces cerevisiae)/5-fluorocytosine (5-FC), bacterial nitroreductase/ CB1954 and 
cytochrome P450/ cyclophosphamide as well as many others (Witlox et al., 2007). As part of this 
study, the utility HSV-TK/ganciclovir suicide gene therapy as a potential strategy for treatment of 
osteosarcoma was evaluated in vitro (II). Therefore a more detailed review on this topic is included 
in the following section.     
 
HSV-TK/ganciclovir suicide gene therapy 
 
Currently, the HSV-TK/ganciclovir approach is the most extensively studied suicide gene therapy 
modality. It was shown to significantly improve the survival of patients with high grade malignant 
glioma in a randomized, controlled trial. Herpes simplex type I thymidine kinase (HSV-TK) -
encoding gene was transferred to malignant cells with multiple injections of adenovirus vector into 
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the resection cavity walls after tumor evacuation, followed by administration of the nucleoside 
analogue ganciclovir (GCV) (Immonen et al., 2004). GCV (Cymevene
®
) is an anti-herpesvirus drug 
licenced for treatment of life threatening cytomegalovirus (CMV) infections or severe CMV 
retinitis in immunosuppressed patients (Pharmaca Fennica 2009, www.terveysportti.fi, accessed: 
January 2009). Its antiherpetic properties are due to its action as a specific substrate for viral 
thymidine kinase enzyme that is three orders of magnitude more efficient in phosphorylating GCV 
compared to any human nucleoside kinase (Aghi et al., 2000). HSV-TK converts the nucleoside 
analogue to its phosphorylated form (GCV-P), which is subsequently converted to the 
triphosphorylated form (GCV-3P) by cellular kinases (Aghi et al., 2000). GCV-3P closely 
resembles 2’-deoxyguanosine triphosphate and is therefore incorporated to newly synthesized DNA 
during cell division. GCV has hydroxyl groups analogous to the 3’ and 5’ hydroxyl groups of the 
endogenous nucleosides, permitting chain elongation. However, its incomplete sugar ring makes 
GCV as a poor substrate for the DNA polymerase and almost invariably leads to chain termination 
either immediately after GCV incorporation or after addition of one more nucleotide beyond GCV 
(Ilsley et al., 1995) and thus DNA damage finally leads to cell death. The mechanisms of GCV 
induced cell death are still incompletely understood, however, most reports indicate that it occurs 
via apoptosis (Beltinger et al., 1999; Freeman et al., 1993; Tomicic et al., 2002a; Tomicic et al., 
2002b; Wei et al., 1999b). However, the exact mechanisms may be different in distinct cell types 
and some reports suggest that also necrosis may play a role in GCV mediated cell death (Thust et 
al., 2000; Tomicic et al., 2002a). 
 For example, compared to mutation compensation gene therapy of cancer, HSV-
TK/GCV gene therapy has an important advantage: not all tumor cells need to be transduced to treat 
the tumor. This is explained by a phenomenon termed as the bystander effect, first discovered by 
Moolten and Wells (Moolten and Wells, 1990). An in vitro, transduction rate of only 10 % was 
enough to induce complete destruction of the tumor cell culture. Furthermore, subcutaneous tumors 
showed complete regression, when only 10 to 50 % of the tumor cells expressed HSV-TK (Freeman 
et al., 1993; Rainov et al., 1996; Takamiya et al., 1992).  The bystander effect is largely dependent 
on the number of cell-to-cell contacts, since it has been shown that transfer of GCV-3P, the toxic 
metabolite of GCV to neighbouring cells occurs via intercellular structures called gap junctions 
(Dilber et al., 1997; Fick et al., 1995; Touraine et al., 1998; Vrionis et al., 1997). However, other 
mechanisms mediating bystander cell killing have been postulated to exist. It has been shown that 
in some cell lines, the effect is mediated by transfer of conditioned medium from HSV-TK 
transduced and GCV treated cells to non-treated cells. This is possibly explained by ingestion of 
apoptotic vesicles released from treated cells by the non-treated cells (Freeman et al., 1993). In 
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addition, animal studies have demonstrated that immune mediated distant bystander effect may 
occur (Barba et al., 1994; Gagandeep et al., 1996), sometimes leading to immune-mediated 
regression of distant metastases during the HSV-TK/GCV treatment (Kianmanesh et al., 1997). 
However, this effect may be restricted to certain anatomic locations such as liver and certain animal 
models, since most reports have not demonstrated any therapeutic effect against distant metastatic 
lesions. In addition to immune mediated enhancement of HSV-TK/GCV gene therapy, dividing 
endothelial cells may be sensitive to transduction and HSV-TK mediated cell destruction, leading to 
tumor ischemia (Ram et al., 1994).   
 
 
Figure 1. Virus vector-mediated HSV-TK gene transfer results in HSV-TK expression in tumor 
cells. The viral thymidine kinase enzyme converts the prodrug GCV to GCV-P, which is further 
phosphorylated by cellular kinases to GCV-3P. The GCV-3P is able to diffuse to neighbouring cells 
and is incorporated into the cellular DNA during cell division, finally leading to cell death of both 
HSV-TK expressing and neighbouring cells (bystander effect). 
 
 The most common adverse effects of GCV include neutropenia, anemia dyspnoea and 
diarrhea. These occur in more that 10 % of GCV treated patients (Pharmaca Fennica 2009, 
www.terveysportti.fi, accessed: January 2009). With respect to the other common side effects 
(occurring in 1 to 10 % of patients), potentially severe consequences may result from hematologic 
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side effects (such as thrombocytopenia, leukopenia and pancytopenia), infections (including sepsis), 
eye symptoms (such as retinal detachment), hepatic failure and renal failure. Notably, infertility 
may occur in less than 1 % of male patients and both sexes should be instructed to use 
contraception during the treatment, males also for at least 3 months after the treatment. Based on 
preclinical studies, GCV is mutagenic and teratogenic. For these reasons, it cannot be used during 
pregnancy. Furthermore, the safety of the agent during lactation or in children has not been 
evaluated. However, it should be remembered that many drugs currently used for cancer 
chemotherapy have comparable or even much poorer safety profiles. The reported side effects of 
GCV are summarized in (Pharmaca Fennica 2009, www.terveysportti.fi, accessed: January 2009). 
In addition to GCV, several other nucleoside analogs have been evaluated as prodrugs 
for HSV-TK suicide gene therapy in order to improve efficacy and safety of this therapeutic 
modality. Purine analogs, such as acyclovir (ACV, a clinically used antiherpetic drug that has less 
adverse effects compared to GCV), penciclovir (PCV), buciclovir (BCV) and lobucavir (LBV); and 
pyrimidine analogs, such as 1-β-D-arabinofuranosylthymine (araT) and 5-iodo-5-amino-2-5-
dideoxyuridine (AIU, a prodrug that has low toxicity in vivo), and others have been evaluated. 
However, compared to ACV, araT and AIU, a 5000-fold enhancement in cytotoxicity was observed 
when glioma cells were treated with the same concentration of GCV (Shewach et al., 1994). 
Another group evaluated six pyrimidine and six purine nucleoside analogs in human osteosarcoma 
cells (Degreve et al., 1999). The pyrimidine analogs showed only minimal bystander effect, 
possibly due to their dependence on viral TK for both mono- and diphosphorylation. In contrast, the 
purine analogs depend on viral TK only for monophosphorylation. It has been shown that the 
nucleoside monophosphate is the predominant form that passes through gap junctions (Aghi et al., 
2000). However, none of the other five evaluated purine analogs could challenge GCV when both 
efficacy and selectivity of the cytotoxic effect were taken into consideration (Degreve et al., 1999).   
 Another strategy to improve the efficiency of the TK/GCV therapy is to modify the 
prodrug-converting enzyme. Random sequence mutagenesis of the HSV-TK nucleoside binding site 
has been utilized to generate mutant HSV-TK enzymes for enhanced prodrug conversion (Black et 
al., 1996). In a mouse xenograft tumor model, a ten times lower dose of GCV was sufficient to 
induce similar therapeutic effects in tumors expressing mutant HSV-TK, compared to tumors 
expressing wild-type HSV-TK (Black et al., 1996). Furthermore, thymidine kinases of other viruses 
have been studied. When GCV was used as a prodrug, equine herpes virus type 4 thymidine kinase 
(EHV4-TK) showed improved efficiency compared to that of HSV-TK (Loubiere et al., 1999). 
 To enhance the therapeutic efficacy, HSV-TK/GCV suicide gene therapy has been 
studied in combination with other anti-cancer treatments. HSV-TK/GCV treatment was found to 
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have a synergistic effect with temozolomide against malignant glioma tumors (Rainov et al., 2001). 
Studies in subcutaneous colon cancer and glioma mouse models have demonstrated synergistic 
effects e.g. with a topoisomerase I inhibitor topotecan (Wildner et al., 1999b), thymidylate synthase 
inhibitors (Wildner et al., 1999a) and a polyamine biosynthesis inhibitor DFMO (Wahlfors et al., 
2006), respectively, when used in combination with HSV-TK/GCV treatment.     
 
Oncolytic virotherapy 
 
The idea of using viral replication and subsequent cell destruction in treatment of malignant 
diseases emerged for the first time more than a century ago. A report by Dock in 1904 documented 
dramatic remission of leukemia in a patient who had suffered from influenza infection (Dalba et al., 
2005). The first documented results about the use of an oncolytic virus were published in 1922 by 
Levaditi et al., who demonstrated that vaccinia virus inhibited various mouse and rat tumors (Dalba 
et al., 2005). During the period between 1950’s and 1980’s, safety and efficacy of oncolytic 
virotherapy were reported in several anecdotal and formal clinical trials. Multiple live, attenuated 
viruses were studied for experimental treatment of cancer patients, including adenovirus, Semliki 
Forest virus, Newcastle virus, Sendai virus, rabies virus, measles virus, mumps virus, influenza 
virus and others (Chiocca, 2002). During the past 20 years, increasing knowledge on molecular 
mechanisms of viral replication and cytotoxity as well as capability to modify virus genome and 
molecular structures has lead to re-emergence of oncolytic virotherapy research. More effective 
oncolytic viruses have been designed with improved targeting to tumor tissue.  
 First genetically engineered oncolytic virus was thymidine kinase deleted HSV-1 
(termed as dlsptk) that was demonstrated to improve survival in nude mice with intracranial 
gliomas after intratumoral inoculation (Martuza et al., 1991). Since deletion of thymidine kinase 
gene ablated sensitivity to anti-herpetic drugs, later studies on oncolytic herpes viruses have utilized 
other deletions, such as of γ-34.5 (neurovirulence gene) or ICP6 (ribonucleotide reductase) to target 
the viral propagation to malignant cells (Kirn et al., 2001; Mineta et al., 1994; Mineta et al., 1995; 
Whitley et al., 1993). Thus, the idea that an oncolytic virus could be dependent on specific defects 
in cellular pathways that are associated with tumorigenesis, has now been widely utilized for 
targeting of oncolytic viruses, including oncolytic herpes simplex- and adenoviruses (Chiocca, 
2002) as well as investigating mechanisms of tumor-selectivity of naturally occurring oncolytic 
viruses, including reovirus, measles virus, Newcastle disease virus (NDV) and others (Russell, 
2002).   
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Virus vectors, oncolytic viruses and their wild-type counterparts 
 
Several viruses have been engineered for therapeutic purposes. Modified viruses, called virus 
vectors, can be used as transgene carriers for therapeutic gene transfer. In this application, the 
transgene is incorporated into the virus genome under control of an exogenous promoter. The virus 
vectors can be either replication competent or, more commonly, replication incompetent. To create 
space for the transgene and to delete the capacity for self-sufficient viral replication, the genes 
encoding the structural proteins of the virus or genes involved in viral pathogenicity are removed 
from the vector genome (Verma and Weitzman, 2005). During the production of replication 
incompetent virus vectors, the structural components of the virus must be provided in trans, for 
example by co-transfection of the producer cells with plasmids containing the genes of the 
structural proteins (Verma and Weitzman, 2005). The characteristics of some of the most widely 
studied replication deficient virus vector types are summarized in Table 1.  
 In most cancer gene therapy applications, the restriction of the transgene expression 
into the malignant tissue is highly important when the therapeutic response is pursued but without 
severe adverse effects. Different strategies for virus vector targeting have been designed. For virus 
vectors that have a DNA genome, tissue or tumor specific promoters can be used to drive the 
therapeutic transgene. These are promoters regulating expression of genes that are known to be 
expressed only in certain cell types or tissues (Sadeghi and Hitt, 2005; Waehler et al., 2007). In case 
of osteosarcoma, for example, osteocalcin promoter has been utilized. Osteocalcin is a protein that 
is selectively expressed in osteoblasts, but also in osteoblast lineage derived osteosarcoma cells 
(Sadeghi and Hitt, 2005). Cancer cell specific promoters, such as telomerase promoter (hTERT), 
have also been characterized and used (Wirth et al., 2005). By using this approach (called 
transcriptional targeting), more selective vectors can be constructed. However, transcriptional 
targeting is not applicable for RNA virus vectors that do not undergo reverse transcription. 
 Another widely utilized strategy is transductional targeting of viral vectors. It can be 
used alone or in combination with transcriptional targeting for improved vector safety (Reynolds et 
al., 2001; Waehler et al., 2007). This approach involves modification of the virion surface proteins 
that mediate attachment and/or entry of the vector particle into the target cells. This can be achieved 
by pseudotyping vectors (the original viral attachment proteins are replaced with counterparts from  
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Table 1. Viral vectors. Based on (Burton et al., 2002; Cuchet et al., 2007; Tenenbaum et al., 2003; 
Waehler et al., 2007; Verma and Weitzman, 2005; Yang et al., 1997) 
 
 
Vector 
 
 
Insert size 
 
Infective 
titer 
 
Genomic 
integration 
 
Expres-
sion 
Transducti
on of non-
dividing 
cells 
 
Current 
problems 
Retrovirus 8 kb 10
7
-10
10
 Integrating Stable long 
term 
expression 
possible 
No Risk of insertional 
mutagenesis, due to 
low in vivo gene 
delivery mainly 
used for ex vivo 
transduction 
 
Lentivirus 9 kb 10
6
-10
10
 Integrating Stable long 
term 
expression 
possible 
Yes Risk of insertional 
mutagenesis, 
relatively low 
infective titers may 
compromise in 
vivo applications 
 
Adenovirus 8-10 kb, for 
gutless 
vectors 
about 30 kb 
10
10
-10
12
 Episomal* Transient 
high  
expression 
levels 
Yes Pre-existing 
neutralizing 
antibodies and 
immune responses 
may compromise 
gene transfer 
 
AAV <4.9 kb  
(10 kb after 
hetero-
dimerization 
of two AAV 
virions) 
10
12
 Mainly 
episomal 
(1/1000 of the 
infective units 
integrate) 
Stable, 
mainly 
episomal 
long term 
expression 
possible 
Yes Small insert size, 
difficulties in large 
scale production of 
helper virus free 
AAV preparations, 
risk of insertional 
mutagenesis? 
 
HSV 30 kb, for 
amplicons 
152 kb 
10
8
-10
11
 Episomal** Transient Yes Immunogenicity 
and toxicity 
problems, potential 
reactivation and 
recombination with 
latent wt HSV 
* in vitro evidence on low frequency (0.001 to 1 % of cells) genomic integration (Harui et al., 1999; 
Hillgenberg et al., 2001; Mitani and Kubo, 2002). ** one report indicates low frequency (< 0.2 % of 
cells) genomic integration at high MOIs in rodent cells in vitro (Roemer et al., 1992). 
 
a different virus during vector packaging). One option is to use bispecific adaptor molecules 
binding simultaneously to the vector and to the target cell receptor. These include receptor-ligand 
complexes, chemical conjugation (such as PEGylation) of targeting ligads to viruses and avidin-
biotin adaptor systems involving coating of biotinylated vectors with avidin conjugated ligands 
(Waehler et al., 2007). Malignant cells express some of their surface receptors differently compared 
to normal cells. As an example, epidermal growth factor receptor (EGFR) is upregulated in several 
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cancers and EGFR targeted vectors have also been studied in osteosarcoma (Witlox et al., 2002). 
However, EGFR genetic heterogeneity has been postulated as a mechanism for acquired resistance 
of non-small cell lung cancer against gefininib therapy (a monoclonal anti-EGFR antibody) (Jiang 
et al., 2008).  Tumor cell heterogeneity is likely to complicate also transductional targeting of viral 
vectors, indicative of the possibility that a resistant tumor cell population may still exist after 
treatment. 
 As discussed in the previous chapter, alternative way to use viruses as cancer 
therapeutics is to utilize their natural capacity to replicate and induce cell lysis and/or evoke 
immune responses against infected cells. Several viruses have a natural tropism for malignant cells 
(Everts and van der Poel, 2005). Other viruses have been modified to selectively replicate in tumor 
cells (Everts and van der Poel, 2005). Multiple strategies have been applied to create viruses 
capable for selective oncolysis or to further improve the selectivity of viral oncolysis. First, deletion 
of the viral genes that are responsible for the capability of the virus to modify the cellular 
environment suitable for viral replication has been used to create conditionally replicating 
adenoviruses (Everts and van der Poel, 2005).  Second, structural proteins of virus that are 
important in attachment of virus to cells can be modified to target the virus to receptors frequently 
over-expressed in malignant tumors (Witlox et al., 2004). Third, selectivity of oncolysis can be 
established or improved by replacing endogenous promoters of viral genes that are crucial for 
successful replication with tissue specific promoters (Everts and van der Poel, 2005). Furthermore, 
RNA viruses, which typically have highly plastic genome, can be targeted to cancer cells using 
serial passaging in conditions that will create a selective advantage for the viral mutants or 
quasispecies that can effectively infect and replicate in malignant cells. Vaccine strains of several 
RNA viruses, originally created using serial passaging, have been studied as oncolytic agents with 
promising results (Russell, 2002).  
Some studies indicate that combining virotherapy to immunosuppressive treatment 
enhances the therapeutic effect (Chiocca, 2002; Ikeda et al., 1999). However, risk of uncontrolled 
viral replication should be carefully evaluated with this type of combination therapies. Furthermore, 
to improve the therapeutic efficiency, armed therapeutic viruses (ATVs) have been constructed. 
These oncolytic viruses carry therapeutic transgenes in addition to viral genes. When using ATVs, 
virotherapy can be combined to different gene therapy strategies, for example to 
immunopotentiation or suicide gene therapy (Chiocca, 2002).  However, if one is using 
proapoptotic genes to arm these viruses, the timing of the effects of the transgene expression is 
essential for efficiency, since premature cell death during virus replication can compromise virus 
production (Witlox et al., 2007).  
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Lentivirus vectors 
 
During the last decade, lentivirus vectors have became one of the most widely studied vector types 
(Trono, 2002). Lentiviruses belong to retroviruses and like retrovirus vectors, the lentivirus vectors 
integrate into the host cell genome providing a stable long term transgene expression (Trono, 2002). 
Therefore, they are an attractive tool for corrective gene therapy of inherited genetic disorders as 
well as for other gene therapy applications in which long term transgene expression is beneficial. 
However, unlike the retrovirus vectors based on oncoretroviruses (typically Moloney murine 
leukaemia virus, MoMLV), lentivirus vectors can also infect non-dividing cells (Trono, 2002). This 
is advantageous in many gene therapy applications, including cancer gene therapy, because in the 
target tissues, even in malignant tumors, the dividing cell population represents only a small 
fraction of all potential target cells. The most frequently used subset of lentivirus vectors are HIV-1 
-based vectors. This is due to the extensive knowledge on HIV-1 structure and biology, which has 
been acquired during the battle against wild type HIV-1, the causative agent of acquired 
immunodeficiency syndrome (AIDS). AIDS is characterized by depletion of CD4+ T-cells (helper 
T cells), subsequent immunosuppression and multiple opportunistic infections, eventually leading 
to death (Huovinen et al., 2003). Despite of the development of highly active antiretroviral therapy 
(HAART) that has significantly improved the prognosis of HIV-1 infected patients in the developed 
countries, the HIV-1 infection is still invariably fatal and curative treatment does not exist. Taking 
into account the severity of the clinical syndrome caused by wild type HIV-1, vectors based on 
other lentiviruses, including less pathogenic HIV-2 (Arya et al., 1998) and non-human lentiviruses 
have also been created (Curran et al., 2000; Johnston et al., 1999; Mangeot et al., 2000; Metharom 
et al., 2000; Mitrophanous et al., 1999; Mselli-Lakhal et al., 1998; Negre et al., 2000; Schnell et al., 
2000). However, this chapter is focused on HIV-1 based lentivirus vectors. 
 HIV-1 is an enveloped positive strand reverse transcribing RNA virus (Trono, 2002). 
Structure of HIV-1 genome is presented in Figure 2. The roles of the genes and genetic elements in 
the HIV-1 genome are summarized in the Table 2. The structure of HIV-1 virion and the replication 
cycle of HIV-1 are illustrated in Figure 3. A and B, respectively. It includes reverse transcription 
from the positive strand RNA genome of HIV-1 by viral reverse transcriptase, resulting in a full-
length linear cDNA (provirus precursor), which then integrates to the host cell genome. The viral 
RNAs needed for translation of HIV-1 proteins as well as genomic RNAs packaged to new virus 
particles are then transcribed from the integrated provirus (Trono, 2002).   
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Figure 2. Genomic organization of HIV-1. The tat and rev exons are connected with lines. LTRs 
are regulatory regions located at both ends of the HIV-1 genome. Each LTR contains an U3, R and 
U5 region. The U3 contains binding sites for cellular transcription factors and the R region includes 
the trans-activation response element (TAR), needed for Tat-mediated trans-activation. The gag 
gene codes for the proteins of nucleocapsid. The pol gene encodes three viral enzymes: protease 
(PR), reverse transcriptase (RT) and integrase (IN). The env gene encodes the gp160 polypeptide 
precursor for gp120 and gp41. The accessory genes include: tat, rev, nef, vif, vpr and vpu.  Based on 
(Sierra et al., 2005) and http://it.stlawu.edu/~tbudd/hivgenome.html.  
 
Table 2. Roles of the HIV-1 genes in the viral life cycle. Based on (Abbas and Lichman, 2005; 
Sierra et al., 2005). 
 
 
Gene or region 
 
 
Roles in HIV-1 life cycle 
LTR Integration of viral DNA into host cell genome, contains U3, R and U5 
regions. U3 harbors binding sites for host transcription factors. R contains the 
trans-activation response element (TAR) responsible for Tat-mediated 
transactivation. 
gag Nucleocapsid core and matrix proteins 
pol Reverse transcriptase, protease, integrase and ribonuclease 
env Viral envelope proteins (gp120 and gp41) mediate CD4 and chemokine 
receptor binding and membrane fusion, inhibit serum complement 
vif Enhances infectivity of virions 
vpr Promotes nuclear import of viral DNA, G2 cell cycle arrest 
tat Needed for elongation of viral transcripts, inhibits host cell PKR activity, 
modulates chemokine signalling 
rev Promotes nuclear export of incompletely spliced or unspliced viral RNAs 
vpu Targets CD4 to proteasome, destabilizes MHC I and enhances release of 
virus from cells 
nef Endocytosis of host cell CD4 and MHC I molecules, interferes with MHC II 
processing, enhances release of virus from cells 
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To produce replication defective vectors, the cis-acting sequences of the virus genome must be 
segregated as much as possible from the trans-acting sequences (Trono, 2002). Upon vector 
production, the producer cells are transfected with the packaging constructs encoding the virus 
proteins and the vector plasmid encoding the vector RNA genome. The vector genome is then 
packaged into vector particles that are formed from the structural proteins of the virus together with 
a host cell -derived lipid bilayer. The RNAs produced from the packaging constructs do not include 
packaging signal and thus are not packaged into the vector particles. In this case, the resulting 
vectors do not contain genetic code for proteins needed for formation of new virus particles and are 
therefore replication deficient (Trono, 2002).  
In the first generation HIV-1-derived lentivirus vectors designed for therapeutic gene 
transfer, the structural genes were divided into two distinct plasmids and the third plasmid encoded 
the vector genome (Naldini et al., 1996; Parolin et al., 1994). The first generation three-plasmid 
packaging system, developed by Naldini et al. became the prototype on which nearly all subsequent 
lentivirus vector systems were based (Naldini et al., 1996; Trono, 2002). The first plasmid was a 
packaging construct containing the complete HIV-1 genome except for the LTRs and packaging 
signal (ψ). Additionally, the transcription of the env reading frame was blocked. The 5΄LTR was 
replaced with the CMV promoter and the 3΄LTR with the polyadenylation signal from the insulin 
gene. The second plasmid provided a heterologous envelope, usually either the VSV-G or the MLV 
amphotropic envelope (Ampho) (Trono, 2002). VSV-G is advantageous for vector pseudotyping, 
since it binds to ubiquitous phospholipids components of the cell membrane turning the vector 
pantropic (Burns et al., 1993). Furthermore, the VSV-G pseudotyped vector particles are 
remarkably stable and can be stored for extended periods and concentrated using ultracentrifugation 
(Bartz and Vodicka, 1997). The third plasmid coded for the vector genome, involving the packaging 
signal (ψ) and a transgene under control of an exogenous promoter, flanked by the LTRs. 
Despite the risk that replication competent lentivirus (RCL) could emerge during 
vector production with the first generation packaging system seemed to be only theoretical, since no 
RCL could be verified in the vector preparations (Trono, 2002), the possibility to delete the HIV-1 
accessory genes from the vector packaging system was investigated (Kafri et al., 1997; Kim et al., 
1998; Zufferey et al., 1997). In the second generation lentivirus vectors, all the genes important in 
the life-cycle and virulence of the wild-type HIV-1 had been removed. Thus, even if multiple 
recombination events would lead to formation of RCL, the wild-type HIV-1-like pathogenic 
properties could not be reconstituted (Trono, 2002). 
 
30 
 
 A.                                        
 
 B. 
 
 
Figure 3. HIV-1 virion structure (A). The lipid bilayer is of cellular origin and includes about 72 
spikes of the viral Env glycoproteins and some cellular proteins. The core includes following 
structural proteins: MA (matrix protein or p17); CA (capsid protein or p24); NC (nucleocapsid 
protein or p7) and p6 (not indicated in the figure): this domain of the p55 is required for the last 
stages of viral assembly, efficient release from the cell and internalization of the Vpr protein into 
the assembled virion. HIV-1 replication cycle (B). The main steps are numbered from 1 to 6. (1) 
Virus binds to CD4 and the appropriate coreceptors, fusion to the cellular membrane and release of 
viral nucleocapsid into the cytoplasm. (2) Reverse transcription of viral RNA by the reverse 
transcriptase (RT). (3) The double-stranded proviral DNA migrates into the cell nucleus and is 
integrated into the cellular DNA by the integrase (IN). (4) The proviral DNA is transcribed by the 
cellular RNA polymerase II. (5) Translation of viral mRNAs. (6) Transport of viral proteins and 
genomic RNA to the cellular membrane and assembly. Immature virions are released. Polypeptide 
precursors are processed by the viral protease (PR) to produce mature viral particles. Based on 
(Sierra et al., 2005) 
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The second generation packaging construct contains gag, pol, tat and rev genes. Tat is a strong 
transcriptional activator and plays an important role in HIV-1 pathogenesis. Additionally, it is 
involved in the pathogenesis of Kaposi΄s sarcoma (Bartz and Emerman, 1999; Federico, 1999). 
Therefore, in the third generation packaging systems, tat has been removed. This is possible when 
the U3 region of the 5΄LTR is replaced with a constitutively active promoter such as CMV 
promoter. The deleted U3 region contains a cis-activating TAR element, where tat-protein binds to 
mediate its regulatory effects (Trono, 2002). Additionally, in the third generation packaging 
systems, rev is provided on a fourth plasmid (Trono, 2002). However, even with these 
improvements, the integrated provirus genome retained the ability for transcription of the full-
length vector genome. Therefore, co-infection with wild-type HIV-1 would lead to propagation and 
subsequent mobilization of the vector. To avoid this, vectors with self-inactivating (SIN) LTRs 
have been constructed. In these third generation vectors, an inactivating deletion has been made into 
the U3 region of the 3΄LTR (Dull et al., 1998). As a result of this deletion, the promoter activity of 
3΄LTR is lost which renders the provirus as being transcriptionally inactive. Bukovsky et al. 
demonstrated that in SIN vector -transduced cells, no vector mobilization could be detected after 
subsequent infection with wild-type HIV-1 (Bukovsky et al., 1999).  
A major hurdle for safe clinical lentivirus vectored gene therapy is insertional 
mutagenesis and oncogene activation upon vector integration. Attempts to eradicate the risk of 
insertional mutagenesis involve generation of integrase-defective lentiviral vectors and replacement 
of HIV-1 integrating capacity with a heterologous, site-specific mediator of genomic integration, 
such as yeast Flp recombinase (Moldt et al., 2008). However, these systems are under development 
and their utility for sustained in vivo gene expression remains elusive. Additionally, due to the 
severity of the disease caused by HIV-1, risk of wild-type reversion of lentivirus vectors remains a 
safety concern. Still, a study investigating first generation lentiviral vector mediated anti-HIV-1 
gene therapy in HIV-1 infected patients did not report any RCL formation through recombination of 
wt HIV-1 and the VSV-G pseudotyped HIV-1 based lentivirus vector (Levine et al., 2006).  
 
Adenovirus vectors and oncolytic adenoviruses 
 
Adenovirus vectors have been widely utilized for gene therapy studies both in preclinical and 
clinical settings. These vectors transduce both quiescent and dividing cells of various types. 
Adenovirus vectors were long considered as non-integrating vectors. However, recent studies 
demonstrated that adenoviral vectors occasionaly integrate into the host cell genome (Harui et al., 
1999; Hillgenberg et al., 2001; Mitani and Kubo, 2002). After irradiation of cell cultures, 
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adenovirus vector integration can occur in up to 15 % of cells (Zeng et al., 1997). Adenovirus 
vectors are commonly used for cancer gene therapy that aims to destroy the tumor tissue. In these 
gene therapy modalities, transient expression elicited by the adenoviral vector is sufficient for a 
therapeutic effect.  
To date, 52 serotypes of human adenoviruses have been found. They are classified 
into seven species (human adenovirus A to G) (Jones et al., 2007). Adenoviruses are non-
enveloped, icosahedral viruses of 60-90 nm in diameter. They have a linear double-stranded DNA-
genome of 30-40 kb (Volpers and Kochanek, 2004).  
 
 
 
Figure 4. Adenovirus virion structure, based on (Volpers and Kochanek, 2004). 
 
The structure of the adenovirus virion is presented in Figure 4. (Volpers and 
Kochanek, 2004).  Shortly, the main component of the capsid is hexon. The homotrimeric hexon 
capsomers form the 20 triangular faces of the icosahedron. In each of the 12 vertices, there is a 
penton capsomere composed of penton base and fiber proteins. The latter forms a spike-shaped 
protrusion with a terminal globular domain or “knob” that is responsible for the attachment of the 
virus to its primary receptor (Volpers and Kochanek, 2004; Zhang and Bergelson, 2005). In 
addition to hexon and penton capsomeres, there are several hexon-associated proteins (IIIa, VI, VIII 
and IX) that have capsid-stabilizing function (Volpers and Kochanek, 2004). The dsDNA genome is 
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located in the virion core with DNA-associated proteins (V, VII and X, the last also termed as Mu) 
and terminal protein (TP) that serves as a primer for DNA replication (Volpers and Kochanek, 
2004). 
 Human adenoviruses (HAdvs) are known to cause a variety of clinical symptoms, 
depending on the serotype in question. These include upper and lower respiratory tract infections, 
gastroenteritis, keratoconjunctivitis, acute hemorrhagic cystitis, meningoencephalitis and hepatitis 
(Jones et al., 2007). Additionally, after initial Ad5 infection, the early viral genes E1A and E1B can 
maintain life-long latency in pulmonary tissues (Yang et al., 2008). There is an association between 
this type of adenoviral latency and chronic pulmonary diseases, such as COPD (Hayashi, 2002).  
However, the exact role of the adenoviral genes in the pathogenesis of COPD is still incompletely 
understood.   
The coxsackie- and adenovirus receptor (CAR) is the primary receptor for human 
adenoviruses, except for group B that mostly utilizes CD46 (Persson et al., 2009; Roelvink et al., 
1998). Still, some of the group B adenoviruses (including Ad3, Ad7p, Ad14 and Ad11p) utilize an 
alternative receptor other than CD46 (Tuve et al., 2006) that is highly expressed in several 
malignant tumor types and is therefore of interest for vector targeting (Raki et al., 2007). The knob 
domain of the homotrimeric fiber binds to CAR, mediating virus attachment to the cell (Volpers 
and Kochanek, 2004; Zhang and Bergelson, 2005). Subsequently, an RGD-motif located in the 
penton base interacts with a cell surface integrin molecule (αvβ1, αvβ3 or αvβ5) that plays a role as a 
secondary or internalization receptor and triggers the virus entry via clathrin-dependent receptor-
mediated endocytosis (Li et al., 2001; Wickham et al., 1993). The endosomal uptake of the virus is 
then followed by release to the cytoplasm, stepwise uncoating and microtubuli-assisted transport of 
the core protein -coated viral genome to the nucleus (Greber et al., 1993).  
 A special feature of adenovirus vectors is their tropism to the liver. This was recently 
shown to essentially result from interaction between blood clotting factor X and adenovirus hexon 
and subsequent binding to the heparin sulphate proteoglycans on the hepatocytes (Parker et al., 
2006; Waddington et al., 2008). The liver tropism can be efficiently blocked with warfarin or X-bp, 
a factor X binding protein isolated from Deinagkistrodon acutus snake venom. Alternatively, liver 
tropism can be blocked using mutated hexon protein or hexon of HAdv-48 or HAdv-26 
(Waddington et al., 2008).   
 The genomic organization of the type 5 adenovirus and different vector types is 
illustrated in Figure 5. The first adenoviral gene to be expressed is the immediate early E1A gene 
coding for transcriptional transactivators of the early genes of adenovirus (E1B, E2A, E2B, E3 and 
E4) as well as protein functions involved in cellular transformation and cell cycle progression to S  
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Figure 5. Wild-type adenovirus genomic organisation and composition of different adenovirus 
vector types. Promoters are indicated as arrowheads. Early (E) and late (L) mRNAs are depicted by 
thin and heavy arrows, respectively. Based on (Volpers and Kochanek, 2004). 
 
phase, a prerequisite for adenovirus propagation (Volpers and Kochanek, 2004). The E2 region 
encodes for the proteins involved in the replication of viral genome: DNA polymerase, DNA 
binding protein and the precursor of the terminal protein (Volpers and Kochanek, 2004). The 
inverted terminal repeats (ITRs) at both ends of the adenovirus genome serve as origin of 
replication and contain cis-acting elements required for replication (Volpers and Kochanek, 2004). 
The capsid and core proteins and a cysteine protease important for proteolytic processing of TP and 
other structural proteins are under control of a common major late promoter. Before translation of 
these viral proteins, a sophisticated splicing process of long precursor transcripts takes place. Virion 
assembly begins in the nucleus about eight hours after onset of the infection followed by proteolytic 
maturation of the virions. Finally, cell lysis occurs 30-40 h post-infection and the viral life cycle is 
completed by release of progeny virus particles (Volpers and Kochanek, 2004). The genes and cis-
acting elements of the adenovirus are summarized in Table 3.   
 Most adenovirus vectors are based on Ad2 or Ad5, since these serotypes are 
associated with mild or asymptomatic infections. In the first generation adenovirus vectors, the E1 
gene region is replaced with a transgene that is expressed from an exogenous promoter, such as 
consitutively active CMV promoter. Since the transactivating and transforming functions of the E1 
are ablated, the vectors are not capable of replication. For vector production, the E1 needs to be 
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L1                L2             L3                L4                            L5
E1 (+/-E3) -deleted vector
(1st generation vector)
E1 (+/ E3) + E2/4 deleted vector
E2B                                                E2A                                             E4
Transgene
Transgene  -    -
(2nd generation vector)
High-capacity vector
("gutless" vector)
∆E1                                                                                 ∆E2          ∆E3                     ∆E4
Transgene IITransgene I
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transcomplemented by a producer cell line that is stably transformed with the E1 (Fallaux et al., 
1998; Graham et al., 1977; Schiedner et al., 2000). The first generation vectors can contain an 
additional deletion of the E3 that is dispensable for adenovirus replication in cell culture, resulting 
in transgene capacity of 8 kb. The first generation adenoviral vectors can be produced in high titers 
of up to 10
12
 to 10
13
 vector particles per ml, which is a marked advantage. However, several 
preclinical and clinical studies have revealed disadvantages with the first generation adenovirus 
vectors. Despite the E1 deletion, low level expression of the viral genes occur in transduced cells, 
leading to direct toxicity and the induction of immune responses against viral gene products 
(Volpers and Kochanek, 2004). It has been shown that cytotoxic a T-lymphocyte response can lead 
to clearance of transduced cells and to a short duration of the transgene expression (Yang et al., 
1995; Yang et al., 1994). On the other hand, in some applications, including vaccine development 
and cancer gene therapy, the capability to evoke a vigorous immune response can be beneficial 
(Volpers and Kochanek, 2004). 
 In the second generation adenovirus vectors, additional deletions or mutations have 
been made to inactivate the E2 and/or E4 genes. More complex complementing producer cell lines 
have been developed for vector production. Extended transgene expression and decreased 
immunogenicity has been demonstrated, but the second generation vectors cannot provide the 
ultimate solution for immunogenicity or transgene capacity problems (Volpers and Kochanek, 
2004). 
 One of the complicating issues in the adenovirus vector production is the ability of the 
vector genome to undergo homological recombination with the transcomplementing adenoviral 
sequences in the producer cells, giving rise to contaminating propagation competent viruses or virus 
like particles. Attempts to solve this problem include development of helper cells with no sequence 
homology to the vector genome (Fallaux et al., 1998). It has been shown that even a single short 
stretch homology between the vector genome and the producer cell can lead to the formation of 
propagation competent helper dependent virus-like particles (Murakami et al., 2002). 
 The third generation adenovirus vectors were constructed by deleting other adenovirus 
genes. The latest third generation vectors, called as high-capacity, gutless or helper-dependent 
adenovirus vectors retain only the ITRs and the packaging signal (ψ) They can accommodate up to 
36 kb inserts (Russell, 2000; Volpers and Kochanek, 2004). With these vectors, the transgene 
expression was dramatically increased and extended compared to first and second generation 
adenovirus vectors, making these vectors potential tools for gene therapy of inherited diseases, such 
as cystic fibrosis, or other applications requiring long-term transgene expression (Russell, 2000). 
Problems were related to the vector production that is more complicated than with first and second  
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Table 3.  Adenoviral genes and their functions. Based on the following references: (Andersson et 
al., 2005; Everts and van der Poel, 2005; Greber et al., 1996; Hasson et al., 1989; Hong et al., 2005; 
Lee et al., 2004; Leppard, 1997; Lichtenstein et al., 2004; Ostapchuk et al., 2006; Russell, 2000; 
Rux and Burnett, 2004; Törmanen et al., 2006; Weber and Anderson, 1988), 
http://medschool.slu.edu/mmi/faculty/wold.html 
 
 
Gene 
 
 
Functions 
E1A  
   243R,   
   289R 
 
Functionally similar, bind to several cellular proteins, interfere with the cell division process, 
mediate cell cycle transition to S phase by binding Rb, leading to release of E2F transcription 
factor, modulate cell transcription in favour of virus replication, suppresses IFN mediated 
antiviral response  
E1B 
   19K 
   55K 
 
Bcl-2 homolog, inhibits cell death 
Binds to and inactivates p53 (E4 orf6 also involved) 
E2A 
   DBP 
 
viral DNA replication followed by transcription of late genes (L1-5), interacts with a number of 
cellular factors 
E2B 
   TP, Pol 
 
viral DNA replication followed by transcription of late genes (L1-5), interacts with a number of 
cellular factors 
E3 
   12.5K 
   6.7K 
   gp19K 
   ADP 
   RIDα, RIDβ 
    
 
 
 
  14.7K 
 
Unknown function 
Inhibits TRAIL apoptosis (with RID, degrades TR2) 
Inhibits killing by CTLs 
Adenovirus death protein; promotes cell lysis and virus release 
Together form the RID-complex, which degrades EGFR and inhibits: 
- TNF apoptosis: internalization of TNFR1 
- TNF-induced synthesis of AA 
- FasL apoptosis: degrades Fas 
- TRAIL apoptosis: degrades TR1 and, together with 6.7K degrades TR2 
Inhibits TNF apoptosis, TNF induced synthesis of AA, FasL apoptosis and TRAIL apoptosis 
E4 
   orf1 
   orf2 
   orf3 
   orf4 
    
   
   orf6 
  
   orf6/7 
 
Facilitates transformation 
Unknown function 
Interacts with E1B 55K, relocates nuclear PODs, promotes late protein production 
Inhibits E1A, activates E2F, binds to DNA-PK, prevents viral DNA concatenation (and possibly 
apoptosis), involved in alternative RNA splicing 
Interacts with E1B 55K facilitating RNA metabolism, involved in E1B 55K p53 binding, binds to 
DNA-PK, prevents viral DNA concatenation (and possibly apoptosis), promotes late protein 
production 
Modulates E2F activity 
 
generation vectors. The helper-dependent adenovirus vectors are produced in E1 complementing 
producer cells with the assistance of a complementing helper virus that provides the other viral 
proteins. The vectors are then purified from the helper virus using a CsCl gradient. However, 
problems related to vector instability and helper virus contamination have complicated the 
production of third generation vectors (Russell, 2000). Further efforts have been made to solve the 
problem of contaminating helper-virus. Utilization of the Cre recombinase expressed by producer 
cells for excision of the loxP-flanked packaging signal from the helper virus genome has been  
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Table 3. (continued) 
 
 
Gene 
 
 
Functions 
L1 
   52/55K 
   IIIa 
 
Assembly 
Structural protein associated with penton base, involved in virus penetration to cell 
L2 
   III 
   VII 
   V 
   Mu (X) 
 
Penton base, virus penetration to cell 
Core protein with histone-like function 
Core protein, associated with viral DNA and penton base 
Core peptide, precursor promotes expression of E2B TP 
L3 
  VI 
   II 
   23K (Pr) 
 
Hexon minor polypeptide, stabilization/assembly 
Hexon monomer 
Adenovirus protease, required for virus entry 
L4 
   100K 
   33K 
   22K 
   VIII 
 
Acts as chaperone for hexon folding, assists formation of trimeric hexon capsomers 
Alternative RNA splicing factor 
Viral DNA encapsidation 
Hexon minor polypeptide, stabilization/ assembly 
L5 
   IV 
 
Fibre 
IX Hexon minor polypeptide, stabilization/ assembly 
IVa2 Viral DNA encapsidation 
VA RNAs 1 & 2 Not translated to proteins, suppress host cell antiviral defence and RNA interference 
 
helpful in eliminating the helper virus contamination (Parks et al., 1996; Russell, 2000; Volpers and 
Kochanek, 2004).  
 In addition to the evolution of the adenovirus vectors described above, several hybrid 
vectors utilizing adenovirus vector backbone supplemented with elements of other vector systems 
have been created. For example, hybrid vectors have been created with AAV to enable AAV Rep 
protein mediated stable integration (Fisher et al., 1996; Recchia et al., 1999). Alternatively, a 
eukaryotic transposase (Sleeping Beauty) has been employed to facilitate stable integration of 
transgene from high capacity adenovirus vector (Yant et al., 2002). 
 Another approach to modify adenovirus for therapeutic purposes is to exploit its 
natural capacity to replicate and induce cell lysis. First genetically modified oncolytic adenovirus 
virus, Onyx-015 carried a deletion in the virus genome resulting in lack of E1B 55kD viral protein. 
E1B 55kD protein associates with p53 protein and it was initially discovered through studies 
showing that tumor selectivity of this virus resulted from its inability to inactivate p53 in normal 
cells (Bischoff et al., 1996). Functional p53 was proposed to lead to apoptosis of infected cells, 
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hampering the viral replication. Defects in the p53 pathway are frequently found in several cancers. 
However, later studies have questioned the mechanisms of Onyx-015 tumor selectivity (Goodrum 
and Ornelles, 1998; Hall et al., 1998; Rothmann et al., 1998). In addition, the role of p53 during 
adenoviral infection was discovered to be more complex and p53 has been later utilized to augment 
cytotoxic effects of CRAds (van Beusechem et al., 2002). Onyx-015 has been evaluated in several 
clinical phase I-II trials against head and neck cancer, metastatic colorectal cancer, ovarian cancer 
and pancreatic cancer (Ganly et al., 2000; Kasuya et al., 2005; Nemunaitis et al., 2000; Nemunaitis 
et al., 2007; Reid et al., 2005; Vasey et al., 2002). In these studies, Onyx-015 was found to be safe 
and well tolerated. However, the therapeutic efficiency as a single treatment modality is limited and 
better results have been reported when Onyx-015 has been combined with conventional therapy 
(Kumar et al., 2008). Also, TNF suppression by etanercept (Enbrel
®
) may increase the efficacy of 
intravenously administered Onyx-015, a phenomenon that deserves further study (Nemunaitis et al., 
2007).   
Later, several other genetically modified oncolytic adenoviruses, also termed as 
conditionally replicative adenoviruses (CRAds) have been extensively studied. Another CRAd, Ad5 
based Δ24 was created by deleting a 24 bp region of the E1A, coding for Rb binding motif (Fueyo 
et al., 2000). This oncolytic adenovirus selectively replicates in malignant cells with a defective 
p16/Rb/E2F signalling circuitry. The inactivation of the p16/Rb/E2F pathway is one of the most 
frequent changes observed in malignant cells. It has been proposed that some type of inactivation of 
this cell cycle regulatory pathway would be one of the fundamental changes leading to malignant 
phenotype and possibly present in all malignant tumors (Hanahan and Weinberg, 2000). 
Additionally, a number of CRAds, based on tumor selective expression of genes required for viral 
replication (such as E1A) under the control of a tumor or tissue specific promoter, have been 
constructed (Alemany et al., 2000).  
 The increased knowledge on the roles of adenoviral proteins and their interactions 
with cellular components and the host immune system has lead to selective restoration of the 
initially removed viral sequences to the CRAds or high capacity adenovirus vectors. E3 region was 
initially deleted from the otherwise complete Ad5 backbone used for construction of Onyx-015 and 
Δ24. However, it was demonstrated that including the E3 in the CRAd genome lead to improved 
oncolysis compared to respective oncolytic virus with E3 deletion (Suzuki et al., 2002). In more 
recent CRAds carrying a tumor targeting deletion identical to that of the original Δ24, the E3 has 
therefore been restored (Witlox et al., 2004). Also, overexpression of adenovirus death protein 
(ADP) (Yun et al., 2005) or removal of gene for E1B 19kDa protein with apoptosis inhibiting 
function can lead to enhanced oncolysis (Liu et al., 2004). In the case of high capacity adenoviral 
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vectors, restoration of some of the E4 genes protects the vector transduced cells against T-cell 
response (Kaplan et al., 1999; Lusky et al., 1999; Russell, 2000; Yew et al., 1999).   
Armed CRADs carrying transgenes to potentiate the therapeutic effect have been 
developed. AdΔ24-p53 that expressed p53 in the E3 region demonstrated improved oncolytic effect 
in most tumor cell lines and xenograft models (van Beusechem et al., 2002). In addition, an AdΔ24 
carrying HSV-TK gene has been evaluated in combination with ganciclovir. It was reported to have 
enhanced oncolytic potency (Wildner et al., 1999c), but the results are considered controversial 
(Hakkarainen et al., 2006).  Also, it has been demonstrated that expression of CD (Δ24-hyCD) in 
combination with 5-FC improved oncolytic activity of Δ24 (Conrad et al., 2005). Furthermore, 
CE/CPT-11 enzyme prodrug therapy has been combined with Δ24. However, it was noted that 
CPT-11 inhibited adenoviral propagation at low concentrations (Oosterhoff et al., 2005; Witlox et 
al., 2007).  
 
Alphavirus vectors and oncolytic alphaviruses 
 
Alphavirus vectors are known to be capable for transducing a variety of different cell types. They 
have also the advantage of high transgene expression levels. These vectors are suitable for short 
term transgene expression; the transgene expression level peaks within 24 to 48 hours (Lundström, 
2002). The transgene expression starts very rapidly, in our experience in less than five hours the 
first fluorescent marker gene expressing cells can be detected.   
 The members of the alphavirus genus infect several vertebrate species, ranging from 
fish to reptiles and mammals   (Strauss and Strauss, 1994). This group of enveloped positive strand 
RNA viruses has a very wide geographical distribution (Strauss and Strauss, 1994). Alphaviruses 
replicate in both arthropod and vertebrate cells. In arthropods, the alphavirus infection is persistent 
and life-long in contrast to the situation in vertebrates where these viruses cause an acute, usually 
short-duration infection characterized by inhibition of host cell protein synthesis in the infected 
cells, high-level production of new virions, lytic replication cycle and subsequent viremia. The 
alphaviruses typically have an alternating life cycle between an insect vector and a vertebrate host. 
For transmission between vertebrate hosts, they require a hematophagous insect vector or blood 
contact (Strauss and Strauss, 1994). 
  Alphaviruses are often divided into Old World and New World alphaviruses, on the 
basis of their geographical distribution. Based on serological cross-reactivity, the alphavirus genus 
is divided into seven complexes. Furthermore, based on sequencing of the members of these 
serocomplexes, the alphaviruses have been grouped into three larger groups. The VEE/EEE group 
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includes encephalitogenic New World alphaviruses i.e. Venezuelan equine encephalitis and Eastern 
equine encephalitis viruses. SF group includes i.e. Semliki Forest virus and Ross River virus. SIN 
group includes i.e. Sindbis virus, the geographically most widely distributed alphavirus that has 
been isolated at several locations throughout the Old World (Strauss and Strauss, 1994). 
Interestingly, one of the New World alphaviruses, Western equine encephalitis virus (WEE), has 
been found to be a recombinant of EEE- and Sindbis virus-like ancestors (Weaver et al., 1997). In 
addition, there are a few ungrouped alphaviruses (Strauss and Strauss, 1994). 
 The alphavirus particle is comprised of 240 copies of the capsid protein, forming the 
virus capsid. This is surrounded by host-derived lipid bilayer containing 240 units of the envelope 
glycoproteins E1 and E2, arranged in 80 trimeric groups of E1/E2 heterodimers (called spikes), 
together forming the virus envelope (Strauss and Strauss, 2001). The spikes are arranged in an 
icosahedral shape in T=4 lattice (Strauss and Strauss, 2001). In SFV, the E3 protein is 
noncovalently bound to the spike E1/E2 heterodimer (Garoff and Simons, 1974) but in Sindbis 
virus this protein is lost during the virion assembly (Mayne et al., 1984). In addition, small 
quantities of the fourth structural protein, hydrophobic peptide 6K, can be isolated from virions 
(Gaedigk-Nitschko and Schlesinger, 1990).  
 The alphaviruses have a capped and polyadenylated positive strand RNA genome of 
11-12 kb, packed into the capsid. The genomic organization is presented in Figure 6. (Strauss and 
Strauss, 1994). The replicase -encoding area (nsP1-4 genes) is located at the 5' end and occupies 
two thirds of the total length of the alphaviral genome (Strauss and Strauss, 1994). The structural 
protein -encoding genes (C, E3, E2, 6K and E1) are located at the 3' end and comprise the 
remaining one third of the genome. The structural protein open reading frame (ORF) is under the 
control of 26S subgenomic promoter. After virus entry, the virus genome functions as a messenger 
RNA and the replicase proteins are translated directly. The viral replicase synthesizes negative 
strand RNA from the positive strand RNA genome. The negative strand genome is then used as 
template for both replication of the positive strand genome and transcription of subgenomic RNA 
encoding structural proteins of the virus. The transcription and translation of alphaviral proteins is 
presented in Figure 6. (Strauss and Strauss, 1994) 
The 5' nontranslated region (5' NTR) is believed to interact with host cellular factors, 
enabling viral replication. The first 44 nucleotides form a hairpin structure and have been suggested 
to serve as promoter for positive strand RNA synthesis by viral replicase from negative strand 
template (Niesters and Strauss, 1990). The 3' NTR is mandatory for the negative strand synthesis 
(and therefore also for viral replication) and it contains a 19-nt motif serving as a promoter for  
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Figure 6. Alphavirus replication and translation. The non-structural proteins and their processed 
products are shown above. Termination at the leaky opal termination codon (star) results in P123 
polyprotein that acts as a proteinase to process the non-structural polyproteins. The proteinase 
domain is found in the nsP2 region. Readthrough of the opal codon produces P1234, which can 
form an active replicase. The subgenomic 26S RNA is expanded below to show the structural open 
reading frame and its translation products. Based on (Strauss and Strauss, 1994).  
 
negative strand synthesis (Hajjou et al., 1996). However, the alphavirus replicase is capable of 
jumping from one template to another, or to other sites in the original template, resulting in a 
frequent recombination (Hajjou et al., 1996). This mechanism of recombination, known as template 
switching, has also been observed in other RNA viruses (Domingo and Holland, 1997). However, 
unlike RNA viruses in general, when natural virus isolates have been analyzed, alphaviruses have 
demonstrated remarkable genetic stability (Strauss and Strauss, 1994). One possible explanation for 
this is the alternating life cycle of these viruses: the virus must survive in very different intracellular 
environments, such as vertebrate cells and insect cells. Therefore, in the natural environment, there 
may be only little space for genetic variation without losing viral fitness for either of the host cell 
types. The roles of the alphaviral proteins are summarized in Table 4.    
Three members of alphavirus genus have been modified to serve as gene transfer 
vectors: Sindbis virus (SIN), Semliki Forest virus (SFV) and Venezuelan equine encephalitis virus  
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Table 4. Alphaviral proteins and their functions. Based on (Vähä-Koskela, 2007). 
 
 
Protein 
 
 
Roles in the virus life cycle 
 
References 
nsP1 Methyltransferase and guanylyltransferase activities, part of the 
RNA capping complex 
Major role in minus-strand synthesis 
Anchors the replicase complex to intracellular membranes 
(amphipathic peptide domain of nsP1) 
(Ahola and Kääriäinen, 1995) 
 
(Shirako et al., 2000) 
(Spuul et al., 2007) 
nsP2 Participates in initiation of RNA capping (N-terminal domain  
has 5'- nucleoside triphosphatase and helicase activity)  
Papain-like thiol protease activity of the C-terminal domain is 
needed for processing of the non-structural polyprotein and plays 
a role in the initiation of 26S mRNA synthesis 
Shut down of the host cell transcription and translation, prevents 
activation of the IFN inducible antiviral defence 
Contains nuclear localization signal 
(Gomez de Cedron et al., 1999; Rikkonen et al., 
1994a; Vasiljeva et al., 2000) 
(Strauss and Strauss, 1994; Suopanki et al., 1998) 
 
 
(Frolova et al., 2002) 
 
(Rikkonen et al., 1994b) 
nsP3 Essential component of the replicase complex, the exact role is 
still unknown 
May be strain specific  
(Vähä-Koskela, 2007) 
 
(Tuittila et al., 2000) 
nsP4 RNA dependent RNA polymerase activity 
Cytoplasmic nsP4 concentration is highly regulated for optimal 
virus replication  
Mutations of nsP4 rendering Sindbis virus replication 
temperature sensitive have been characterized 
(Lin et al., 2000) 
(de Groot et al., 1990; de Groot et al., 1991) 
 
(Hahn et al., 1989) 
 
C Capsid protein, a C-terminal protease domain autocleaves the 
capsid protein from the structural polyprotein  
Interacts with ribosomes before nucleocapsid assembly and 
during disassembly 
C-terminal domain binds other capsid protein molecules and C-
terminal tail of E2 
N-terminal domain is positively charged and binds viral RNA 
 
N-terminal domain is also important for capsid-capsid 
interactions and may contribute virion stability 
(Melancon and Garoff, 1987) 
 
(Singh and Helenius, 1992; Singh et al., 1997) 
 
(Choi et al., 1996; Lee et al., 1996) 
 
(Frolova et al., 1997; Geigenmüller-Gnirke et al., 
1993; Owen and Kuhn, 1996; Weiss et al., 1994) 
(Forsell et al., 1996; Forsell et al., 2000)  
E3 Signal peptide for the membrane translocation of E2 into the 
endoplasmic reticulum (ER). After furin protease cleavage, E3 is 
released from cells.  
In SFV,  part of the E3 protein is incorporated into virion 
(Mayne et al., 1984) 
 
 
(Garoff and Simons, 1974) 
E2 Transmembrane envelope glycoprotein with receptor binding 
sites and epitopes for species-specific neutralizing antibodies  
Conserved cytoplasmic tail binds to capsid protein 
(Paredes et al., 1998; Smith et al., 1995) 
 
(Lee et al., 1996; Owen and Kuhn, 1996; Skoging 
et al., 1996) 
6K Signal peptide for E1, important for virus budding and virion 
integrity, small amounts are incorporated into the virion 
(Gaedigk-Nitschko and Schlesinger, 1990; 
Liljeström et al., 1991; McInerney et al., 2004; 
Sanz et al., 2003) 
E1 Envelope protein that is not well exposed in the virion surface but 
is readily accessible for antibodies at the plasma membrane of 
infected cells, used to determine cross-reactivity between 
alphaviral species 
A class II membrane fusion protein carrying a fusion peptide in 
the ectodomain  
(Wolcott et al., 1982; Wolcott et al., 1984) 
 
 
 
(Lescar et al., 2001) 
 
(VEE) (Atkins et al., 2008; Davis et al., 1996; Liljeström and Garoff, 1991; Xiong et al., 1989). 
Sindbis virus is the geographically most widely distributed member of the alphavirus genus (Strauss 
and Strauss, 1994). Birds are primary vertebrate hosts for Sindbis and the virus is transmitted by 
mosquitos (Kurkela et al., 2008). Several isolates have been made throughout the Old World 
(Strauss and Strauss, 1994). Most wild type and all laboratory Sindbis strains are considered non-
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pathogenic to humans (Strauss and Strauss, 1994). However, Sindbis strains in northern Europe 
cause fever, rash and polyarthritis (Ockelbo disease, Pogosta disease and Karelian fever in Sweden, 
Finland and Russia, respectively) and strains in South Africa can cause rash and fever (Kurkela et 
al., 2005; Kurkela et al., 2004; Laine et al., 2004; Niklasson et al., 1984).   
SFV is an Old World alphavirus that was first isolated in 1942 from Aedes abnormalis 
mosquitos in western Uganda (Smithburn and Haddow, 1944). (McIntosh et al., 1961)In mice, SFV 
infection can cause fatal encephalitis, subacute non-fatal demyelinating meningoencephalomyelitis 
or persistent subclinical CNS infection, depending on the mouse strain, age and immunological 
status, and the SFV strain (Fazakerley, 2002). L10 and V13 strains that are derived from the first 
SFV isolate (Bradish et al., 1971)are highly neurovirulent in mice and lead to fatal encephalitis in 
immunocompetent mice of all ages (Bradish et al., 1971).  However, avirulent SFV strains, such as 
A7 and its derivative A7(74) are harmless to mice older than three weeks (Bradish et al., 1971).  
SFV A7 derives from a strain isolated from Aedes argenteopunctatus mosquitos in Namancurra, 
Mozambique in 1959 and passaged seven times through neonatal mouse brain (McIntosh et al., 
1961). The SFV A7(74) strain was obtained from the heterogeneic SFV A7 strain by two 
subsequent plaque-purifications in chicken embryo cells combined with selection of the least 
virulent clones (Bradish et al., 1971). 
Whereas other members of the SFV group, such as Ross River virus (RRV) and 
Mayaro virus cause polyarthritis in humans (Soden et al., 2000; Tesh, 1982), SFV has been linked 
to human disease only on two reported occasions. Mathiot and co-workers reported an outbreak of 
human SFV infections in Central African Republic during the year 1987. The virus was isolated 
from sera of 22 patients presenting with fever, severe persistent headache, myalgia, arthralgia, and a 
convalescence marked by asthenia. Most patients were French soldiers who had recently arrived in 
the region (Mathiot et al., 1990). Willems and co-workers reported the only known fatal human 
SFV infection in a laboratory worker who had been working with SFV Osterrieth strain in 
Germany. The 26-year-old patient developed fever and headache followed by coma and death. 
Notably, the patient had previous 1-year history of purulent bronchitis, suggesting possible 
underlying immunocomprimization (Willems et al., 1979).  
Most VEE subtypes are considered as sylvatic viruses. They are associated to sporadic 
human causes and rare equine outbreaks. Subtype varieties IAB and IC cause periodic epidemics 
and rare equine epizootics (Strickland, 2000). The primary vertebrate hosts for VEE are birds that 
often have a non-symptomatic infection (Huovinen et al., 2003). However, during epidemics, horses 
are the principal amplifier hosts with mosquitos or other hematophagous insects serving as vectors. 
Neither human-mosquito-human nor person-to-person transmission has been documented. Human 
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VEE infection usually leads to febrile illness characterized with chills, malaise, severe headache, 
myalgia, lumbosacral pain, nausea, vomiting and prostration, which may be followed by diarrhea 
and sore throat. Neurologic disease occurs in about 4 % of infected chidren below 15 years of age 
but is rare in adults. The overall fatality rate in encephalitic cases is about 20 %, but in children 
below 6 years of age the fatality rate is higher, 35 % (Strickland, 2000). 
For gene transfer purposes, three main types of alphavirus vectors have been created. 
These include replication competent, replication deficient and DNA layered (or DNA based) 
alphavirus vectors (Lundström, 2002). The replication competent alphavirus vectors, such as the 
VA7-EGFP used in the present study, contain both non-structural and structural open reading 
frames of the alphavirus genome, along with an additional subgenomic promoter followed by the 
transgene. Due to the endogenous oncolytic properties of Semliki Forest and Sindbis viruses, 
replication competent alphavirus vectors can be utilized in cancer virotherapy. Attenuated Sindbis 
and SFV strains have been studied as oncolytic viruses due to their endogenous capacity to target 
and kill tumor cells (Määttä et al., 2007; Unno et al., 2005; Vähä-Koskela et al., 2006). In this 
application, the vectors may carry either a marker gene or a gene with immunomodulatory or other 
functions to potentiate the therapeutic effect of the oncolytic vector.  
 Replication deficient alphavirus vectors have been created by replacing the structural 
genes of the virus with the transgene. In this case, during vector production, the vector genome 
needs to be supplemented with a helper construct coding for the structural proteins of the virus. 
Stable packaging cell lines have been created to enable the large-scale production of both SFV and 
Sindbis vectors (Polo et al., 1999). However, the production of replication deficient alphavirus 
vectors has been complicated by the emergence of propagation-competent vector during the vector 
production. There have been several attempts to eradicate this problem, including construction of 
split helper systems for Sindbis, SFV and VEE vector production (Frolov et al., 1997; Pushko et al., 
1997; Smerdou and Liljeström, 1999).  Frolov et al. constructed chimeric split helper RNA for the 
production of Sindbis virus vectors. In this approach, the helper RNA was divided into two parts, 
one coding for capsid and the other coding for envelope glycoproteins. Unfortunately, for efficient 
expression of the envelope genes, an enhancer element located within the capsid sequences was 
needed. For this reason, an extensively deleted capsid gene with preserved enhancer function of 
another alphavirus, RRV, was inserted into the envelope encoding part of the split helper RNA 
(Frolov et al., 1997). In the case of VEE, incorporation of an enhancer element was not required for 
efficient expression of envelope proteins (Pushko et al., 1997). Still, in the SFV split helper system, 
incorporation of the SFV capsid gene derived enhancer element into the envelope coding 
component of the helper RNA was required (Smerdou and Liljeström, 1999). In addition, for 
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improved safety, the SFV capsid gene was mutated to abolish its self-cleaving activity. This self-
cleaving activity is dispensable in the split helper system but necessary if a full-length genome is 
reconstituted through recombination (Smerdou and Liljeström, 1999). Another approach to solve 
this problem is to genetically modify the vector envelope in such a way that the vector particles are 
not infective unless pretreated with a proteolytic enzyme or antibody (Berglund et al., 1993; Ohno 
et al., 1997).   
 The DNA layered alphavirus vectors are plasmids that contain an exogenous 
promoter, such as CMV, RSV or RNA polymerase II promoter, to drive expression of self-
replicating RNA molecules that contain the alphaviral non-structural genes and the transgene under 
the control of the 26S subgenomic promoter. This type of vector design enables direct transfection 
of plasmid DNA, high expression levels due to replication of the messenger RNA coding for the 
transgene and excludes the possibility of wild-type reversion since the viral structural genes are not 
included. Generally, in vivo gene transfer via naked-DNA injection is complicated by inferior 
efficiency compared to virus vector mediated transduction (Waehler et al., 2007). However, for 
some applications, such as vaccination, high gene transfer rates are not mandatory. Naked-DNA 
vaccines have demonstrated promising results in small animal models. Good safety profile along 
with cost-effective large-scale production has made this type of vaccines the topic of intensive 
research (Chiarella et al., 2008). So far, the clinical trials with DNA vaccines have failed to translate 
the good preclinical results to clinical efficacy (Ljungberg et al., 2007). DNA-based alphavirus 
vectors have been studied for vaccination (Ljungberg et al., 2007; Miller et al., 2008; Ramirez et al., 
2008). They have shown enhanced immunogenicity compared to conventional DNA-based vaccines 
(Leitner et al., 2004). This is due to their capacity to multiply the antigen-encoding vector RNA and 
induce innate antiviral responses and apoptosis (Leitner et al., 2006; Leitner et al., 2004; Leitner et 
al., 2003). 
 
Host immune responses against virus vectors and oncolytic viruses 
 
Human immune defence against viruses consists of innate and adaptive immunity. The innate 
immune system reacts immediately (or in hours) but less specifically compared to the adaptive 
immune system, which is highly specific and effective, but needs days to react against a pathogen 
without previous exposure and a few weeks to reach its full efficacy (Abbas and Lichman, 2005).  
The innate immune defence includes protection by epithelial barriers, induction of 
inflammation, activation cascade of complement and cellular immune responses by NK cells and 
phagocytes (neutrophils and macrophages) (Abbas and Lichman, 2005). Complement activation can 
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occur in an antibody-dependent or -independent manner. The latter complement activation pathway 
is based on less specific recognition of foreign surface structures but the activation starts within 
minutes. NK cells are lymphocytes that lack receptors capable for highly specific recognition of 
pathogens, typical of the T and B lymphocytes in the adaptive immune system. NK cells recognize 
pathogens less specifically but much faster than T or B cells and are important during the first hours 
of the immune response. They can destroy virus-infected or malignant cells. Neutrophils and 
macrophages are able to phagocytise viruses and other pathogens or small particles. This does not 
preclude specific recognition of the target, but phagocytosis of pathogens covered by antibodies or 
complement is especially effective (Huovinen et al., 2003).  
Macrophages and dendritic cells (also termed as antigen presenting cells or APCs) are 
capable for presenting foreign antigens to and activating the cells of the adaptive immune system. 
Macrophages phagocytise microbes, degrade them and present fragments on their surface MHC II 
molecules. Dendritic cells capture microbial protein antigens. They have a stronger capacity for 
activation of adaptive immune system cells compared to macrophages. After ingesting antigens, 
dendritic cells travel to the lymph nodes for antigen presentation (Abbas and Lichman, 2005; 
Huovinen et al., 2003).  
The adaptive immune system comprises of pathogen-specific cellular and humoral 
immune responses by T cells and B cells, respectively (Abbas and Lichman, 2005). T cells can be 
classified as CD4+ (helper) and CD8+ (cytotoxic) lymphocytes (CTLs). CD4+ lymphocytes have 
an integral role in the adaptive immune system. They orchestrate the functions of the effector cells 
of adaptive immune system by activating other cells of the immune system. During HIV infection, 
destruction of the CD4+ T cell population leads to severe immune deficiency and eventually death 
caused by opportunistic infections (Strickland, 2000).  
A naïve T cell is activated by a dendritic cell or a macrophage when its T cell receptor 
binds to the corresponding antigen presented on the MHC I or MHC II molecule. The co-receptors 
CD8 and CD4 recognize MHCI and MHCII molecules, respectively. Furthermore, for successful 
activation, simultaneous binding of CD28 to the B7 molecule on the surface of antigen presenting 
cell is required (Abbas and Lichman, 2005).   
B cells possess the capacity for antigen presentation. Small concentrations of microbe-
derived proteins are present in the blood during infection and are captured via B cell receptors by B 
cells. Subsequently, B cells present the antigens on their MHC II molecules. Activated CD4+ T cell 
can activate a B cell presenting its specific antigen directly by binding the antigen and MHC II and 
secreting B cell stimulating cytokines (interleukins 2, 4, 5, 6 and 10) (Huovinen et al., 2003). 
However, if the T cell has not been activated previously, it needs a simultaneous contact to a 
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dendritic cell or macrophage in order for B7 signal to activate the B cell. In certain situations, such 
as in case of bacterial lipopolysaccaride antigens, also the B cell can activate the T cell 
independently from other antigen presenting cells. This mode of activation leads to IgM synthesis 
and clonal B cell proliferation. The expansion of a B cell clone leads to the formation of a new 
germinal center in a lymph node or spleen. To avoid apoptosis, these activated B cells still need to 
contact a follicular dendritic cell to obtain once more its specific antigen. Then, the activated B cell 
presents the antigen to CD4+ T cell and binds with CD40 receptor to CD40 ligand on the T cell. 
After this, the B cell survives for longer times and can shift IgM production to IgG, IgA or IgE, 
depending on cytokines controlling this shift. The majority of these B cells differentiate into plasma 
cells for large scale production of antibody but some become memory cells that persist for years and 
during reinfection lead to rapid production of more specific and effective IgG class antibodies 
(Huovinen et al., 2003). 
Cytokines are soluble small protein or peptide transmitters that are secreted by 
immune system cells. They have important roles in modulating the functions of the immune system 
and in signalling between different immune system cells. The majority of the cytokines have 
multiple different functions. There are many different cytokines e.g. interleukins (IL-1 – IL-12 that 
are secreted by leukocytes and function as signalling molecules between them), interferons 
(discussed below), hematopoietic growth factors (such as granulocyte macrophage and granulocyte 
colony stimulating factors GM-CSF and G-CSF), transforming growth factors (TGF-α and TGF-β) 
and chemokines (attract immune cells into the inflammatory site).     
 The first line defence against viruses is characterized by induction of interferons 
(IFNs), inducible innate cytokines that have a pivotal role in early antiviral response. IFNs have 
multiple immune system -modulating functions in both innate and adaptive immune cells. Type I 
IFNs include IFNα and IFNβ, which have an integral role in the early antiviral defence and 
induction of the antiviral state in the host cells (Stark et al., 1998). They are secreted by almost 
every cell type during virus infection and bind to the IFNα/β receptors on the neighbouring cells, 
leading to activation of the Jak/STAT signalling pathway and induction of an antiviral state 
characterized by expression or down-regulation of hundreds of IFN regulated genes (Katze et al., 
2002). NK cell activation is enhanced by type I IFNs and they function to destroy virus-infected 
cells before the progeny viruses are released. Type II IFN, or IFNγ, is synthesized only by NK cells 
and certain T lymphocytes as a response to mitogenic and antigenic stimuli (Farrar and Schreiber, 
1993). IFNγ has only moderate antiviral activity (Farrar and Schreiber, 1993). It has an important 
role in the activation of macrophages and in the restriction of Th2 type immune responses 
(Huovinen et al., 2003). Additionally, a new IFN subtype, type III IFNs, consisting of IFNλ1, IFN 
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λ2 and IFN λ3 (also termed as interleukins 29, 28A and 28B) has been recently described (Kotenko 
et al., 2003; Li et al., 2008). Type III interferons show antiviral activity against several viruses and 
are able to trigger apoptosis via the type III IFN receptor (Ank et al., 2006; Li et al., 2008).  
During their evolution, viruses have developed multiple ways to circumvent the 
antiviral actions of the host immune defence (Alcami and Koszinowski, 2000; Tortorella et al., 
2000). Examples of viral immune evasion strategies are summarized in Table 5., with the emphasis 
on viruses that are utilized as vectors.  
In many ways virus vectors share the characteristics of the corresponding wild-type 
viruses. However, upon construction of non-replicative vectors, viral genes with 
immunomodulatory functions have been deleted. For example, adenoviral vectors lack E1A, which 
in addition to its other functions has an IFN response -suppressing role during wild-type virus 
infection (Alcami and Koszinowski, 2000). In the recent years, the need for investigating the effects 
of the host immune system to virus vectors has been generally recognized. The need for studies in 
this field is emphasized by the fact that in some instances, vector administration, especially at large 
doses, may produce severe or even fatal immune mediated toxicity (Raper et al., 2003).  
 Alphaviral vectors and oncolytic alphaviruses, due to their dsRNA nature, elicit a 
strong IFN response. The sensitivity to IFN-mediated antiviral defence may complicate the use of 
these agents to a variable extent. The available information of IFN inducing capacity of adeno- and 
lentiviral vectors is somewhat controversial (Brown et al., 2007; Rautsi et al., 2007; Zhu et al., 
2007). In addition to innate immune responses, especially adenoviral gene transfer is complicated 
by the pre-existing antibodies arising from previous wild-type adenovirus infection. Attempts have 
been made to solve this problem e.g. addition of shielding ligands to protect the vector from 
neutralizing antibodies (Hedley et al., 2006). Furthermore, upon re-administration of adenovirus 
vectors, the neutralizing effects of the antibodies that emerged after initial introduction of the vector 
can be circumvented by using vectors with modified fiber (Särkioja et al., 2008).  Oncolytic viruses 
are structurally and functionally even closer to the corresponding wild type viruses than virus 
vectors. However, also these contain deletions or modifications in their genomes compared to their 
wild-type counterpart viruses. Immune-mediated inactivation is a common problem in oncolytic 
virotherapy. Some reports indicate that simultaneous immunosuppressive treatment may enhance 
the efficacy of an oncolytic virus, such as Reovirus (Qiao et al., 2008; Smakman et al., 2006). On 
the other hand, in certain applications, such as cancer immunotherapy or vaccination, strong 
immune responses elicited by the vector can be beneficial.   
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Table 5. Viral immune evasion strategies. Based on following review and original articles: (Alcami 
and Koszinowski, 2000; Breakwell et al., 2007; Frolova et al., 2002; Mahr and Gooding, 1999; 
McInerney et al., 2005; Ryman and Klimstra, 2008; Tortorella et al., 2000) 
 
 
Target 
 
 
Virus 
Inhibition of humoral immune responses 
Inhibits soluble complement factors 
Blocks formation of membrane-attack complex by incorporation of 
host cell membrane components to virus envelope 
Inhibition of Fc dependent immune activation by viral IgG Fc 
receptors  
Downregulation of cell surface complement receptors 
 
HIV-1 (gp120-gp41)  
HIV-1, Vaccinia virus 
 
HSV-1 (gE-gI hetero-oligomer complex) 
 
HIV-1 
Interference with IFNs 
Inhibits Jak/STAT pathway 
Inhibits PKR activity 
 
 
 
 
Inhibition of type I IFN response 
Inhibition of  eIF-2α phosphorylation and translational arrest 
 
Inhibition of 2’5’OAS/RNase L system 
 
Adenovirus (E1A) 
Adenovirus (VAI RNA)  
HIV-1 (TAR RNA) 
HIV-1 (Tat) 
Baculovirus (PK2) 
HSV (ICP34.5) 
SFV and Sindbis virus (nsP2) 
SFV translation enhancer element helps viral 
mRNAs elude general translational arrest 
Reovirus (σ3) 
Inhibition and modulation of cytokines and chemokines 
Partial chemokine similarity, chemoattractant for monocytes 
Inhibition of TNF signalling 
 
HIV-1 (Tat) 
Adenovirus (E3 14.7K, E3 10.4/15.4K, E1B 
19K)  
Apoptosis inhibition 
Viral homolog of the anti-apoptotic protein 
Bcl-2  
Targets Fas for lysosomal degradation  
Inactivation of p53 
Caspase inhibiton  
 
 
 
Adenovirus (E1B-19K) 
 
Adenovirus (E3 10.4/14.5-RID complex) 
Adenovirus (E1B-55K)  
Adenovirus (14.7K) 
Vaccinia (SPI-2/B13R2) 
Baculovirus (p35, IAP) 
Interference with antigen presentation and modulation of MHC 
function to evade CTLs 
Binding and retention of MHC class I in ER 
Endocytosis of surface MHC class I and CD4 
Destabilization of MHC class I, targets CD4 to proteasome 
Interferes with MHC class II upregulation (IFNγ transduction 
cascade) 
MHC class II binding 
Interferes with MHC class II processing 
Interferes peptide translocation from proteasome to ER for 
participation to MHC I assembly  
 
 
Adenovirus (E3/19K)  
HIV-1 (Nef) 
HIV-1 (Vpu) 
Adenovirus (E1A) 
 
HSV (ORF14) 
HIV-1 (Nef) 
HSV (ICP-47) 
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Osteosarcoma 
 
Epidemiology, pathology, diagnosis and prognosis 
 
Osteosarcoma is the most common primary tumor of the bone, affecting mainly children and young 
adults (Carrle and Bielack, 2006). It is defined by the presence of malignant mesenchymal cells that 
produce osteoid or immature bone (Carrle and Bielack, 2006). In general, osteosarcoma is a rare but 
severe disease, with an estimated incidence of 8.7 per million in children younger than 20 years of 
age  (Marina et al., 2004). The peak incidence of the most frequent type of the disease, high-grade 
central osteosarcoma is in the second decade of life and seems to be related to the pubertal growth 
spurt (Carrle and Bielack, 2006). The tumors arise most frequently in the most active regions of 
growth, including distal femur, proximal tibia and proximal humerus (Kansara and Thomas, 2007; 
Marina et al., 2004), with about half of the cases originating around the knee (Marina et al., 2004). 
This points to some relationship between osteoblast activity and tumorigenesis (Kansara and 
Thomas, 2007). The second peak in the incidence of osteosarcoma takes place after the age of 50 
years (Dorfman and Czerniak, 1995).  This represents a different type of osteosarcoma which is 
linked to Paget's disease (Marina et al., 2004). 
 The symptoms of osteosarcoma are relatively unspecific. The most common symptom 
is pain for several weeks or months. The pain often begins insidiously but at the time patients seek 
medical attention, it is often present at rest and may disturb sleeping. The most frequent sign is a 
firm tender mass. Also, superficial erythema, venous distension or other signs of hypervascularity 
may be present. Additionally, there may be a limp, loss of function or decreased range of motion. 
Any of these symptoms or signs should lead to further clinical investigation (Klein and Siegal, 
2006). 
 In at least half of the cases, the conventional x-ray images indicate the correct 
diagnosis. Characteristic findings include an ill-defined radiodensity that occupies the metaphyseal 
region of a long bone and periosteal reaction. The intraosseos density often appears as a cloudy or 
fluffy area. When tumor growth and invasion reaches the outer surface of the bone, the periosteum 
is dissected from the bone. As a result, the cambium layer of the inner periosteum reacts by 
producing new bone. This is sometimes seen in radiographs as an incomplete bony shell that is 
attached to the bone surface on only one end and is discontinuous or open on the other end, termed 
as the Codmans angle (Klein and Siegal, 2006). MRI is used for further diagnostic investigation as 
well as for determination of the soft tissue component and extent of local invasion. CT imaging can 
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also be used, but to determine extent of the intramedullar tumor growth is inaccurate.  In general, 
MRI offers more accurate imaging of the soft tissue component (Marina et al., 2004). In addition, 
chest x-ray or pulmonary CT is taken for detection of possible pulmonary metastases. Of these, CT 
is more sensitive in detecting pulmonary metastases and is therefore the method of choice (Marina 
et al., 2004). Tc-99m bone scanning can be useful in the detection of distant bone metastases 
(Enneking and Kagan, 1975). At the time of diagnosis, 15-20 % of osteosarcoma patients have 
radiologically detectable metastases. However, 80 % of the patients have microscopic pulmonary 
metastases at the time of diagnosis and develop radiologically detectable metastases typically 18 to 
24 months later, if treated with surgical resection alone (Klein and Siegal, 2006; Marina et al., 
2004).  
 The diagnosis must always be confirmed with histopathologic analysis of tumor 
biopsy. Osteosarcoma has several anatomic and histologic variants (Klein and Siegal, 2006). Both 
anatomic location and histopathologic characteristics are of prognostic significance and influence 
into the selection of the treatment protocol (Klein and Siegal, 2006). Conventional osteosarcoma is 
typically a primary high-grade sarcoma that arises from the medullary cavity and is therefore 
termed as central osteosarcoma. The tumor cells vary from spindled to polyhedral and the nuclei are 
pleomorphic and hyperchromatic. Mitotic figures are present and atypical mitotic figures may also 
be identified. The tumor cells produce extracellular matrix that may be osseous, cartillageous or 
fibrous in various proportions. Based on the predominant type of the extracellular matrix, 
conventional osteosarcoma has been historically divided into osteoblastic, chondroblastic and 
fibroblastic subtypes. Conventional osteoblastic osteosarcoma is the most common subtype of 
osteosarcoma, representing 70 % of all osteosarcoma cases. The second most common subtypes are 
conventional chondroblastic and fibroblastic osteosarcoma, both representing about 10 % of all 
osteosarcoma cases (Gorlick et al., 2003; Hayden and Hoang, 2006; Kempf-Bielack et al., 2005; 
Thomas and Kansara, 2006). However, this division is largely artificial, since there are no statistical 
differences in the survival of the osteosarcoma patients with these three subtypes and the treatment 
is the same for these subtypes (Klein and Siegal, 2006).  In addition to medullary cavity, 
osteosarcoma can arise on the surface of bone, may be confined to the cortex or even appear in an 
extraskeletal location. Importantly, osteosarcomas arising from surface of bone are usually low 
grade in contrast to intramedullary osteosarcomas (Klein and Siegal, 2006). In addition to central 
high-grade conventional osteosarcoma and low-grade parosteal osteosarcoma, several rare subtypes 
of osteosarcoma exist. The different types of osteosarcoma are summarized in Table 6 (Klein and 
Siegal, 2006). The most widely used staging system is Enneking staging that classifies localized 
malignant bone tumors as stage I (low grade) and II (high grade). High grade tumors are further  
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Table 6. Osteosarcoma subtypes. Based on (Klein and Siegal, 2006) 
 
 
Osteosarcoma type 
 
 
Characteristics 
 
Proportion 
of all cases 
Central   
    High grade    
        Conventional Spindled to polyhedral tumor cells, pleomorphic nuclei, 
high mitotic rate, sometimes atypic mitotic figures, 
osseous, fibrous or cartillageous extracellular matrix in 
various proportions (division to osteoblastic, 
chondroblastic or fibroblastic osteosarcoma), production 
of bone or osteoid requirement for diagnosis 
 
90 % 
        Telangiectatic Histologically and radiologically resembles aneurysmal 
bone cyst 
 
rare 
        Small cell Histological features combining those of osteosarcoma 
and Ewing’s sarcoma, often very little mineralized 
matrix, small cells, hyperchromatic nuclei with very 
little nuclear pleomorphism, sometimes spindling of 
cells, production of osteoid is diagnostic  
  
1-2 % 
        Epitheloid So poorly differentiated that resembles poorly 
differentiated carcinoma, careful search for osteoid often 
needed for correct diagnosis 
 
rare 
        Osteoblastoma-like Resembles osteoblastoma, radiographic appearance may 
suggest malignant tumor, aneuploid mitotic activity and 
permeation of architecturally normal bone by the tumor 
are diagnostic, differential diagnosis is often difficult in 
small biopsy samples 
 
rare 
        Chondroblastoma-like Histology often closely resembles chondroblastoma, 
atypical mitotic activity and infiltration into 
intertrabecular spaces are diagnostic 
 
rare 
        Fibrohistiocytic Resembles histologically fibroblastic osteosarcoma,  
storiform arrangement and histiocytic giant cells 
 
rare 
        Giant cell-rich Benign multinucleated osteoclast resembling giant cells, 
may be mistaken histologically for giant cell tumors. In 
long bones, radiologic studies often suggest correct 
diagnosis, osteoid matrix is diagnostic 
rare 
    Low grade    
        Fibrous dysplasia-like Microtrabecular osseous matrix architecture in a bland 
fibrous stroma 
 
rare 
        Desmoplastic fibroma-like Resembles desmoblastic fibroma, scant bone formation rare 
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Osteosarcoma type 
 
 
Characteristics 
 
Proportion 
of all cases 
Surface   
    Low-grade    
        Parosteal May be confused with osteochondroma or osteoma, most 
commonly attached to the distal posterior femur. 
Radiologically the densest bone typically in the inner 
part, usually no periosteal reaction, an incomplete 
radiolucent line corresponding to the periosteoum to 
which the tumor is fixed at one point on the outside, 
sclerotic trabecular architecture. Very little maturation of 
the matrix into a lamellar architecture, a cellular 
cartilage cap external to the osseous portion can be 
present, intertrabecular spaces contain cellular fibrous 
tissue. 
< 5 % 
    Intermediate-grade    
        Periosteal Mainly cartilaginous matrix, arises between the costex 
and the cambium layer of the periosteum, most 
commonly in tibial or femoral diaphysis 
rare 
    High grade   
        Dedifferentiated parosteal About one out of four low-grade parosteal 
osteosarcomas contains a high grade component that 
may be radiologically seen as less mineralized area and 
sometimes results in cortical invasion.  
 
about 1 % 
        High-grade surface Radiographic appearance may be similar to low grade 
surface osteosarcoma or may a contain radiolucent 
component to variable extents, histologically entirely 
high grade, lack of periosteal reaction indicates surface 
origin 
  
rare 
Intracortical High grade osteosarcoma entirely confined within the 
bony cortex, cellular atypia and local aggressiveness 
distinguish it from osteoid osteoma or osteoblastoma. 
 
rare 
Gnathic Osteosarcoma of mandible or maxilla, typically leads to 
uncontrolled local disease but only a small minority of 
tumors lead to metastatic disease 
rare 
Extraskeletal   
    High-grade Occurs in late adulthood, most commonly in deep soft 
tissues (thighs, buttocks, upper extremities or 
retroperitoneum), the tumors demonstrate all types of 
high grade osteosarcoma that arise in bone 
 
rare 
    Low-grade Occurs in late adulthood, most commonly in deep soft 
tissues, histology as in skeletal low grade osteosarcomas 
rare 
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classified as stage IIA (the tumor does not penetrate the cortex) or stage IIB (penetrates through the 
cortex). Metastatic disease is classified as stage III (Enneking et al., 1980). Alternatively, TNM 
classification can be used (Sobin and Wittekind, 1997). 
 Radiologically purely sclerosing osteosarcoma may be difficult to diagnose in a small 
biopsy due to a process called normalization. This phenomenon is characterized by excessive 
production of bone matrix compared to the proportion of the tumor cells, which become 
incorporated into the osseous matrix and resemble normal osteocytes. In that case, the tumor cells 
are most easily identified at the advancing edge of the tumor. Notably, a similar process of 
normalization along with necrosis often takes place after successful chemotherapy given before 
definitive surgery (Klein and Siegal, 2006).     
Prognostic indicators of osteosarcoma include histologic type and grade, extent of the 
disease at the time of diagnosis (including presence or absence of radiologically detectable 
pulmonary metastases), size and location of the tumor, response to chemotherapy and surgical 
remission (Klein and Siegal, 2006; Tang et al., 2008). Without appropriate treatment, conventional 
high-grade osteosarcoma has an aggressive course with local and systemic disease progression 
leading to death within months (Carrle and Bielack, 2006). Prior to the introduction of 
chemotherapy in the 1970s, prognosis of patients diagnosed with a high-grade osteosarcoma was 
dismal. Treatment with either surgery and/or radiation therapy provided 2-year overall survival 
rates of 15-20 % (Dahlin and Coventry, 1967; Friedman and Carter, 1972; Marcove et al., 1970; 
Marina et al., 2004).  Two different clinical studies definitively showed the importance of adjuvant 
chemotherapy in improvement of the outcome for patients with a localized extremity osteosarcoma 
(Eilber et al., 1987; Link et al., 1986). Currently, using a multimodal approach including 
preoperative ("neoadjuvant") systemic polychemotherapy, local surgical therapy and postoperative 
("adjuvant") chemotherapy, long-term disease free survival can be achieved in 60-70 % of patients 
(Carrle and Bielack, 2006). However, patients with recurrent, metastatic or inoperable disease still 
have a poor prognosis. 
 
Current treatment modalities 
 
Today, multi-modal treatment of osteosarcoma is based on the use of chemotherapy along with 
radical surgery. Complete surgical removal of both the primary tumor as well as all the 
radiologically detectable metastases is a prerequisite for curative treatment (Carrle and Bielack, 
2006). Furthermore, because almost all patients have microscopic pulmonary metastases at the time 
of diagnosis, the role of systemic chemotherapy is essential for long-term survival (Carrle and 
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Bielack, 2006). However, chemotherapy alone is insufficient to reliably destroy either the primary 
tumor (Jaffe et al., 2002) or radiologically detectable metastases (Carrle and Bielack, 2006). 
Osteosarcoma tumors are generally relatively radioresistant. However, there is evidence that 
patients unable to undergo surgical resection or with microscopically positive margins following the 
tumor resection could benefit from high dose radiotherapy (Bielack et al., 2002; Link et al., 1986; 
Marina et al., 2004). The successful multi-modal treatment of osteosarcoma requires close 
interdisciplinary co-operation between orthopaedic and thoracic surgeons, radiologists, pathologists 
and oncologists (Carrle and Bielack, 2006).  
 Current treatment protocols of osteosarcoma usually employ chemotherapy both 
preoperatively (neoadjuvant chemotherapy) and postoperatively (adjuvant chemotherapy) (Carrle 
and Bielack, 2006). The three most active drugs are cisplatin (Platinol
®
; Bristol-Myers Squibb) 
(Baum et al., 1981; Gasparini et al., 1985; Marina et al., 2004; Ochs et al., 1978), doxorubicin 
(Adriamycin
®
; Pharmacia & Upjohn) (Cortes et al., 1978; Marina et al., 2004; Pratt and Shanks, 
1974) and high-dose methotrexate (Bielack et al., 2002; Link et al., 1986; Marina et al., 2004). 
Combination therapy with these three drugs is used for treatment of osteosarcoma.  
 There has been active research focusing on improvement of current chemotherapy 
protocols. In studies of the German-Austrian-Swiss Cooperative Osteosarcoma Study Group 
(COSS) the best results, with a 10-year survival rate of 71 %, were reported when ifosfamide was 
combined to the treatment described above (Fuchs et al., 1998). The Scandinavian Sarcoma Group 
(SSG) used the combination of cisplatin, doxorubicin and high-dose methotrexate and in poor 
responders replaced the regimen with a combination of ifosfamide and etoposide (Marina et al., 
2004). With this protocol they reported a 5-year overall survival rate of 74 %. However, the 
addition of ifosfamide to the standard treatment did not result in any significant survival advantage 
in a large, randomized North American study (Meyers et al., 2005). Therefore, the utility of 
combining ifosfamide to the treatment remains to be confirmed. Additionally, in a Scandinavian 
study efficiency of interferon-α (IFN-α) in the treatment of osteosarcoma was evaluated (Müller et 
al., 2005). IFN-α was used as a single adjuvant to surgery, resulting in complete remission for 69 % 
of patients (Strander et al., 1995). Metastasis-free and sarcoma specific 10-year survival rates were 
39 % and 43 %, respectively (Müller et al., 2005). 
 The primary aim of the chemotherapy is to eradicate the pulmonary micrometastases. 
Preoperative, i.e. neoadjuvant chemotherapy, was introduced to the standard treatment protocol, 
because it offers several advantages including: (i) gain of time for preparation of definitive surgery 
and limb-sparing procedures (Carrle and Bielack, 2006), (ii) delineation of tumor contributing to 
improved quality and adequacy of surgical margins and reduced rates of local recurrence (Bielack et 
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al., 2004; Carrle and Bielack, 2006; Hosalkar and Dormans, 2004; Picci et al., 1994)  and (iii) 
chance to evaluate the histological response to the treatment, one of the most reliable prognostic 
factors available (Bielack et al., 1996). Nonetheless, chemotherapy resistance may emerge, leading 
to recurrent disease. Possible mechanisms of drug resistance include alterations in: p-glycoprotein 
expression, multidrug resistance protein expression, topoisomerase II, glutathione S-transferases, 
DNA repair, drug metabolism or inactivation, and reduced intracellular influx (Gorlick et al., 2003).  
 The currently used multiagent chemotherapy is related to several acute and long-term 
side effects. High-dose methotrexate can potentially cause severe life-threatening toxicity, but in 
young patients it is generally well tolerated. However, the use of the high-dose methotrexate 
requires normal renal function and that hyperhydration, alkalinisation, strict methotrexate plasma 
level monitoring and adequate administration of the antidote calciumfolinat are guaranteed. 
Cisplatin treatment is associated with potential for causing hearing loss (Baum et al., 1981; Marina 
et al., 2004) and hypomagnesemia (Hayes et al., 1979) that can appear even years after completion 
of the treatment (Marina et al., 2000). Furthermore, doxorubicin can lead to anthracycline-induced 
cardiomyopathy (Goorin et al., 1981; Goorin et al., 1990; Krischer et al., 1997; Lipshultz et al., 
1995), which typically appears with high cumulative doses (Von Hoff et al., 1979). Methods to 
minimize the risk for this complication have been evaluated, including the use of dexrazoxane 
(Zinecard
®
; Pfizer Pharmaceuticals) (Wexler et al., 1996), continuous infusion doxorubicin and 
pegylated liposomal doxorubicin (Marina et al., 2002). In addition, the chemotherapy for 
osteosarcoma has potential to induce sterility (Marina et al., 2004; Meistrich et al., 1989). For post-
pubertal males, sperm banking is an option (Marina et al., 2004). Techniques for maintaining 
fertility in female patients are also under development (Marina et al., 2004). 
 After pre-operative chemotherapy, the tumor is surgically extirpated. The aim of the 
operation is a complete removal of the lesion along with adequate margins (Marina et al., 2004). 
The use of neoadjuvant chemotherapy and advances in tumor imaging and reconstructive surgery 
have made possible to avoid amputation of the affected limb in most cases. There are several types 
of reconstruction including vascularized or non-vascularized bone autografts, structural bone 
allografts and metallic endoprosthetics (Marina et al., 2004), though all options have their inherent 
advantages and disadvantages.  
 Non-vascularized autografts from the pelvis or other sites can be used for 
reconstruction of relatively small bone defects with good results (Alman et al., 1995). Vascularized 
autografts (e.g. from fibula) can be utilized for reconstruction of larger defects. They incorporate 
well and may even undergo remodelling. However, with autografts there is a risk for donor site 
morbidity (Marina et al., 2004).  
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 Structural bone allografts have no donor site morbidity but their major disadvantage is 
the difficulty of the graft to incorporate into the host bone (nonunion) and fracture (Marina et al., 
2004). Infections are also a significant risk (Alman et al., 1995; Dick and Strauch, 1994; Getty and 
Peabody, 1999; Hornicek et al., 1998; Lord et al., 1988; Mankin et al., 1996). However, structural 
bone allografts are a biological solution and in the absence of previously mentioned complications, 
they may last the lifetime of the patient {Alman, 1995 #481;Clohisy, 1994 #487;Hornicek, 1998 
#482;Mankin, 1996 #483; }. Osteoarticular allografts may be used for reconstruction involving 
joints (Clohisy and Mankin, 1994; Muscolo et al., 2000) resulting in a satisfactory function in 60-70 
% of patients in high-grade sarcomas (Marina et al., 2004). Diaphyseal defects can be reconstructed 
with intercalary allografts (Marina et al., 2004; Ortiz-Cruz et al., 1997; Weiner et al., 1996).  
 Metallic endoprosthetics are also available and can be used to achieve an immediate 
and stable reconstruction. However, their major drawback is eventual loosening or failure of 
components (Marina et al., 2004). Infections are also an important risk with endoprostheses (Grimer 
et al., 2000; Marina et al., 2004; Wirganowicz et al., 1999). Arthrodesis can sometimes be used. It 
allows a very durable reconstruction but the disadvantage is the lack of joint motion (Alman et al., 
1995; Marina et al., 2004). Even though the limb-salvage procedures have become the standard of 
care, amputation is still used in situations where this mode of treatment would compromise 
oncologic outcome (Marina et al., 2004).   
 Reconstructive surgery is challenging particularly in skeletally immature patients, 
since the reconstruction must accommodate for future growth. The most frequent locations of 
osteosarcoma are the areas of the strongest growth potential, especially around the knee. Therefore, 
most limb-sparing resections involve the major growth center (Marina et al., 2004). There are 
several expandable endoprostetics available for younger children (Finn and Simon, 1991; Grimer et 
al., 2000; Marina et al., 2004). However, their longevity is often poor and they must be revised 
when the skeletal maturity is reached (Marina et al., 2004). Tibia turn-up plasty (resulting in longer 
residual limb after an above-knee amputation) and rotationplasty (converting above-knee 
amputation functionally as a below-the-knee amputation) can be utilized for improved functional 
outcome in amputees (Marina et al., 2004). The disadvantages are related to the body image. 
 The anatomic location of the tumor strongly affects to the ease of resection and 
reconstruction. The proximal fibula, rib, clavicle, scapular body and most areas of the ilium, 
ischium and pubis can be removed without reconstruction with good functional results (Marina et 
al., 2004). On the other hand, periacetabular pelvic tumors are often very troublesome both in terms 
of resection and reconstruction (Marina et al., 2004). 
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Molecular biology of osteosarcoma 
 
Osteoblasts derive from multipotent mesenchymal stem cells. This differentiation is normally a 
strictly regulated process. Increasing knowledge on the role of stem cells in cancer development and 
analysis of pathologic and molecular features of osteosarcoma strongly suggests that osteosarcoma 
is caused by genetic and epigenetic disturbances in the osteoblast differentiation pathway (Tang et 
al., 2008; Thomas and Kansara, 2006).  
The majority of osteosarcoma tumors have complex unbalanced karyotypes and 
defects in p53 and retinoblastoma (Rb) pathways (Gorlick et al., 2003). Analysis of 128 
osteosarcoma tumors revealed that 70 % of the specimens were clonally abnormal (Bridge et al., 
1997; Gorlick et al., 2003). The ploidy number in osteosarcoma can vary from haploidy to near-
hexaploidy (Marina et al., 2004; Sandberg and Bridge, 2003). Structurally abnormal chromosomes, 
which were so badly deformed that they were impossible to identify, were found to occur in 58 % 
of OS tumor samples. Ring chromosomes (7 %) along with multiple numerical (65 %) and 
structural (72 %) abnormalities were also frequent (Bridge et al., 1997; Gisselsson et al., 2002; 
Gorlick et al., 2003). Gain of chromosome 1, loss of chromosomes 9, 10, 13 and/or 17 and a partial 
or complete loss of the long arm of chromosome 6 were frequent (Bridge et al., 1997; Gorlick et al., 
2003). Structural abnormalities of the following chromosomal regions were most commonly found: 
1p11-p13, 1p11-q12, 1q21-q22, 11p14-p15, 14p11-p13, 15p11-p13, 17p and 19q13 (Marina et al., 
2004; Sandberg and Bridge, 2003). Less frequently involved chromosomal regions included 13q14 
(locus of RB1), 12p12-pter (locus of KRAS), 6q11-q4 and 8p23 (Marina et al., 2004; Sandberg and 
Bridge, 2003).  
Most osteosarcomas have some type of combined defect in the Rb and p53 tumor 
suppressor pathways (Gorlick et al., 2003). Patients with germline mutations in p53 (Li-Fraumeni 
syndrome) or Rb (Retinoblastoma syndrome) are predisposed to develop osteosarcoma (Malkin, 
2001; Malkin et al., 1990; Quesnel and Malkin, 1997). Amplification of the 12q13 region that 
contains MDM2 and CDK4, or INK4A deletion can influence both the Rb and p53 pathways 
(Gorlick et al., 2003; Wei et al., 1999a). It is intriguing that when the p53 status was studied, it was 
concordant in all of the paired samples of primay osteosarcoma tumor and metastases. This 
observation suggests that the inactivation of the p53 pathway is an early event in osteosarcoma 
pathogenesis (Gokgoz et al., 2001). Interestingly, there is evidence that SV40, a DNA polyoma 
virus, may contribute to tumor occurrence in hereditary osteosarcoma. The SV40 large T antigen 
interacts with p53 and Rb and promotes cell proliferation by inhibiting p53 (Carbone et al., 1996). 
In two families with Li-Fraumeni syndrome, characterized by heterozygous germ-line p53 
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mutations, SV40 large T antigen was amplified and expressed in tumor cells that retained the wild-
type p53 allele (Malkin et al., 2001). The p53 and Rb pathways are illustrated in Figures 7 and 8, 
respectively. 
 
 
 
Figure 7. P53 mediated cell cycle arrest and induction of apoptosis. Based on (Kansara and 
Thomas, 2007). 
 
 Telomeres are nucleoprotein structures that protect the ends of chromosomes. Gradual 
shortening of telomeres occurs upon each cell division (Gorlick et al., 2003). In normal cells, which 
have a finite proliferative capacity, telomere shortening to a critical length triggers senescence 
through a p53-dependent process. A few cells may bypass this checkpoint and continue dividing 
until their telomeres are very short, leading to chromosomal instability and apoptosis (Gorlick et al., 
2003). Cancer cells typically are able to lengthen their telomeres via activation of telomerase or a 
recombination-based process termed as alternative lengthening of telomeres (ALT). Osteosarcoma 
cells may utilize either of these mechanisms. Most cancers utilize mainly telomerase activation. 
However, about half of the osteosarcoma tumors are dependent on ALT, which is associated with 
greater genetic instability and an increased number of translocations compared to cell lines 
dependent on telomerase activation (Kansara and Thomas, 2007; Scheel et al., 2001). Nonetheless, 
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telomerase is related to increased metastatic capacity compared to ALT according to studies 
conducted in mice (Chang et al., 2003). 
 
 
Figure 8. Rb mediated cell cycle transition to S phase. Based on (Kansara and Thomas, 2007). 
 
 In addition to Li-Fraumeni and Retinoblastoma syndromes, several other hereditary 
diseases that predispose to osteosarcoma have been recognized. These are summarized in Table 7. 
Paget’s disease is a hereditary disorder characterized by rapid bone remodelling leading to 
abnormal bone formation. About 1 % of patients with Paget’s disease develop osteosarcoma and 
these patients account for a substantial fraction of the osteosarcoma diagnosed after 60 years of age. 
Although the complete pattern of genetic abnormalities leading to Paget’s disease remains obscure, 
some of the genes involved in Pagetic osteosarcoma have been identified, see Table 7. (Kansara 
and Thomas, 2007).  
 RecQ helicases are conserved proteins that share a highly homologous DNA helicase 
domain. Germline mutations in RecQ helicase genes have been observed in many cancer 
predisposition syndromes, such as Rothmund-Thomson, Bloom and Werner syndromes (German, 
1993; Goto et al., 1996; Hickson, 2003; Wang, 2005; Wang et al., 2003), summarized in Table 7. 
Of these three syndromes, Rothmund-Thomson syndrome is related to the highest (32 %) and the 
most specific risk for developing osteosarcoma (Tang et al., 2008; Wang, 2005). In this patient 
group, the median age when osteosarcoma is diagnosed is a mere nine years (Wang et al., 2001).  
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Table 7. Inherited diseases that predispose to osteosarcoma (Kansara and Thomas, 2007). 
 
 
Syndrome 
 
 
Location 
 
Gene 
 
Function 
Li-Fraumeni 17p13.1 P53 DNA damage response 
Retinoblastoma 13q14.2 RB Cell cycle checkpoint 
Paget’s disease 18q21-q22 
5q31 
5q35qter 
LOH18CR1 
SQSTM1 
MAPK8 
IL-1/TNF signalling 
RANK signalling pathway  
Rothmund-Thomson  18q24.3 RTS  DNA helicase 
Werner 18p12-p11.2 WRN  DNA helicase 
Exonuclease activity 
Bloom 15q26.1 BLM  DNA helicase 
 
 Although the germline mutations explain part of the osteosarcoma cases, most 
osteosarcomas are sporadic. Despite intensive research, no consensus changes that could be found 
in all osteosarcoma tumors have been identified. Sporadic osteosarcoma tumors display a wide 
range of genetic abnormalities, summarized in Table 8. In addition to the genes presented in Table 
8, studies with transgenic mouse models have highlighted the potential role of several other genes 
in osteosarcomagenesis. C-fos proto-oncogen transgenic mice developed osteosarcomas and 
lymphomas (Grigoriadis et al., 1993; Wang et al., 1995). Overexpression of c-fos is also found in 
61% of osteosarcomas, especially in patients who developed metastases (Gamberi et al., 1998; Wu 
et al., 1990). Forty percent of mice that were heterozygotes for inactivation of both p53 and HIC1 
(Hypermethylated in cancer-1, a transcriptional repressor) developed osteosarcomas (Chen et al., 
2004). Neurofibromatosis 2 (Nf2) encodes Merlin, an ezrin-radixin-moesin related tumor 
suppressor protein. Nf2
-/-
 null phenotype turned out to be fatal during early embryogenesis, but Nf2 
heterozygote mice developed a variety of highly metastatic malignant tumors with long latencies, 
including osteosarcomas (McClatchey et al., 1998). Mice lacking both ARF and Bax developed 
carcinomas and sarcomas, including osteosarcoma (Eischen et al., 2002). Mice null for both 
p18INK4C and p53 developed a variety of sarcomas, including osteosarcoma (11 % of mice) 
(Damo et al., 2005).  
 Other genes associated to osteosarcoma include p19INK4D (a cyclin dependent kinase 
inhibitor involved in cell cycle regulation, found in 7 % of osteosarcomas) (Miller et al., 1997), 
bone morphogenetic protein receptor-II (BMPR-II, related to poor prognosis) (Gobbi et al., 2002; 
Yoshikawa et al., 2004), transforming growth factor-beta (TGFβ) isoforms, of which TGFβ3 is 
strongly related to disease progression (Kloen et al., 1997) and vascular endothelial growth factor 
(VEGF, expression correlated with survival) (Jung et al., 2005). Ezrin expression correlates with  
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Table 8. Genes that may play a role in sporadic osteosarcomagenesis. Based on (Kansara and 
Thomas, 2007). 
 
 
Location 
 
 
Defect  
 
% 
 
Gene 
 
Description 
 
Possible role 
7q21 DEL 
AMP 
41% 
13% 
TWIST Transcription factor TWIST 
contains bHLH domain 
Proliferation 
Suppresses bone 
differentiation 
8q24.12-
q24.13 
AMP 42% MYC v-myc avian 
myelocytomatosis viral 
oncogene homolog (c-myc) 
Proliferation 
9q21 MUT 5-15% CDKN2A 
(p16INK4A) 
Cyclin dependent kinase 
inhibitor 2A 
Cell cycle inhibitor 
9p21 MUT 9% CDKNA2 
(p14ARF) 
Cyclin dependent kinase 
inhibitor 
Cell cycle inhibitor 
9p21 MUT 10-14% CDKN2B 
(p15INK4B) 
Cyclin dependent kinase 
inhibitor 2B 
Cell cycle inhibitor 
10q26 LOH 60% BUB3 Spindle assembly mitotic 
checkpoint 
Chromosome 
homeostasis 
10q26 LOH 60% FGFR2 Fibroblast growth factor 
receptor 2 
Bone morphogenesis 
12q13 AMP 41% PRIM1 Primase polypeptide 1 Initiates or primes 
DNA synthesis 
12q13-
q14 
AMP 14-27% MDM2 Mouse double minute 2 
homolog 
Proliferation 
12q13-
q15 
AMP 36% TSPAN31 
(SAS) 
Tetraspanin 31 Cell growth 
12q13.3-
q14.1 
AMP 87% GLI1 Glioma associated oncogene 
homolog (zinc-finger 
protein) 
Cell growth 
13q14.2 LOH 50-70% RB1 Retinoblastoma 1 Tumor suppressor 
17p12-
p11.2 
AMP 13-29% TOP3A Topoisomerase III alpha DNA replication 
17p11.2 AMP 52% MAPK7 Mitogen activated protein 
kinase-7 
Proliferation 
17p11.2 AMP 50-72% COPS3 COP9 constitutive 
photomorphogenic homolog 
subunit 3 
Cell growth 
17p12-
p11.2 
AMP 50-72% PMP22 Peripheral myelin protein 22 Proliferation 
17p13.1 LOH 
RA 
PM 
75-80% 
10-20% 
20-30% 
TP53 protein p53 Tumor suppressor 
18q21.1 LOH 74% DCC Deleted in colorectal 
carcinoma 
Cell adhesion protein 
22q12.1 MUT 7% CHK2 Checkpoint kinase 2 DNA damage 
checkpoint 
AMP, amplification; LOH, loss of heterozygosity; RA, rearrangement; PM, point mutation; MUT, mutation 
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poor outcome in pediatric osteosarcoma (Khanna et al., 2004) and according to mouse studies, is 
overexpressed in highly metastatic osteosarcoma compared to tumors with lower metastatic 
capacity (Khanna et al., 2000). Furthermore, mutations causing excessive Wnt (Wingless and int) 
pathway signalling are associated to decreased survival and increased metastatic capacity (Hoang et 
al., 2004; Iwaya et al., 2003; Kansara and Thomas, 2007). Genes of special interest are those 
involved in bone differentiation, such as Runx2, the most proximal known regulator of bone 
development and Osterix, a transcription factor involved in osteoblast differentiation (Kansara and 
Thomas, 2007). Rb is known to physically interact and transactivate Runx2 (Ogasawara et al., 
2004; Thomas et al., 2001), which transactivates the Osterix promoter (Nakashima et al., 2002; 
Nishio et al., 2006). Matrix metalloproteinases (MMPs) are responsible for degradation of the 
extracellular matrix. Membrane-type MMP-1 overexpression correlates with poor prognosis in 
osteosarcoma patients (Uchibori et al., 2006). MMP-2 and MMP-9 overexpression in osteosarcoma 
cells lead to increased metastatic ability in vivo (Bjørnland et al., 2005). MMPs are inhibited by 
tissue inhibitors of matrix metalloproteinases (TIMPs). However, TIMP-1 may have a dual role in 
osteosarcoma, since it has been found to promote cancer cell survival and growth (Ferrari et al., 
2004; Hornebeck et al., 2005). C-met, a tyrosine kinase receptor of hepatocyte growth factor-scatter 
factor (HGF-SF) is expressed in human and canine osteosarcoma cells and may contribute to tumor 
cell proliferation and invasion (MacEwen et al., 2004). In addition, Fas signalling pathway may 
play a role in determining chemosensitivity and metastatic behaviour in osteosarcoma (Gorlick et 
al., 2003; Mitsiades et al., 2001; Poulaki et al., 2001; Worth et al., 2002). 
Compared to large number of studies describing genetic alterations in osteosarcoma, 
relatively few studies investigating epigenetic alterations in osteosarcoma have been published so 
far (Benassi et al., 2001; Benassi et al., 1999; Harada et al., 2002; Hou et al., 2006; Thomas and 
Kansara, 2006; Tsuchiya et al., 2000b). These studies have reported a close association between the 
aberrant methylation of p16 and Ras effector homologue (RASSF1A) genes. It is believed that 
hypermethylation and subsequent transcriptional silencing of tumor suppressor genes contributes to 
the neoplastic process by increasing the mutation rate (Jones and Baylin, 2002; Wajed et al., 2001). 
Although hypermethylation is considered as a reversible change, it is heritable from cell to cell. 
Since the alterations in methylation often occur early in disease, the analysis of cumulative 
methylation of a panel of several osteosarcoma associated genes with quantitative methylation 
sensitive PCR could be useful for sensitive detection of osteosarcoma cells present in resected 
tissue samples (Hou et al., 2006).         
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Gene therapy and virotherapy approaches  
 
It appears that improvement in the survival of osteosarcoma patients is approaching the limit 
achievable using the currently available chemotherapy agents (Marina et al., 2004). Therefore, 
novel treatment modalities are needed for osteosarcoma, especially for patients with clinically 
detectable metastases, tumors at unresectable locations or recurrent disease. 
 In the context of osteosarcoma, several gene therapy strategies have been evaluated. 
Since mutations associated with Rb-pathway and p53 are frequent in osteosarcoma tumors, the 
mutation compensation approach has been studied as a potential treatment against osteosarcoma 
(Witlox et al., 2007). Treatment with adenovirus vectors encoding functional Rb (Xu et al., 1996) or 
p16INK4A (Craig et al., 1998), an upstream mediator of the Rb, suppressed tumorigenicity of 
osteosarcoma cells.  However, the treatment was less effective in well-established xenograft tumors 
(Witlox et al., 2007). As expected, the effect was strongly associated to the presence of Rb 
inactivation in the target cells (Witlox et al., 2007).  
 Functional p53 was transduced to osteosarcoma cells using VP22 (a protein of HSV-1 
capable for carrying protein cargo into cells) by Phelan et al. (Phelan et al., 1998). Wild-type p53 
effectively induced apoptosis in p53-negative human osteosarcoma cells. Moreover, in an 
osteosarcoma lung metastasis model, a significant reduction of the tumor nodules was observed 
after aerosol delivery of plasmid DNA encoding p53 (Densmore et al., 2001). The Saos2LM6 
human osteosarcoma cells that were xenografted to establish the lung metastases were derived from 
Saos2, a p53-null cell line. Interestingly, a restoration of the functional p53 has been shown to 
increase the sensitivity of osteosarcoma cells to several chemotherapeutic agents, such as cisplatin, 
adriamycin and doxorubicin (Ganjavi et al., 2005; Song and Boyce, 2001; Tsuchiya et al., 2000a). 
 Although the mutation compensation strategy has shown efficacy both in vitro and in 
vivo, in absence of lateralization or a bystander effect, this approach mandates transduction of every 
tumor cell in order to be curative and with current gene transfer tools this is not achievable. 
Additionally, due to the heterogeneic nature of osteosarcoma the mutation compensation gene 
therapy may be effective only in genetic subpopulations of tumor cells, reducing, but not 
eliminating the entire tumor cell population (Witlox et al., 2007).  
 Suicide gene therapy modalities have been evaluated in preclinical models of 
osteosarcoma, including HSV-TK/ganciclovir, CD/5-FC and CE/CPT-11 (Witlox et al., 2007). The 
HSV-TK/ganciclovir therapy was first studied in osteosarcoma by Charissoux et al. (Charissoux et 
al., 1999). Retrovirus vector coding for HSV-TK was used to sensitize osteosarcoma cell lines to 
GCV. This study reported a strong bystander effect. Furthermore, when ex vivo transduced 
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osteosarcoma cells were implanted into the rat hind limb, GCV treatment was able to reduce tumor 
size and prevent the emergence of lung metastases (Charissoux et al., 1999). 
 Cytosine deaminase/5-fluorocytosine (CD/5-FC) suicide gene therapy is based on 
conversion of the prodrug 5-FC to the cytotoxic drug 5-fluorouracil (5-FU) by CD enzyme. The 
advantage of the CD/5-FC gene therapy is that a bystander effect occurs also without cell-cell 
contacts. Ramnaraine et al. showed that using CD/5-FC approach, that bone sarcomas in 9 out of 10 
mice were eliminated (Ramnaraine et al., 2003).  
 The third enzyme prodrug therapy that has been studied in the context of 
osteosarcoma is carboxylesterase (CE)/CPT-11 therapy. CPT-11, a semi-synthetic water-soluble 
derivative of the topoisomerase I inhibitor, camptothecin, is converted through esterification to its 
much more toxic derivative, SN-38, by the enzyme CE that is present in liver and lung. Although 
SN-38 can be found in the plasma of cancer patients minutes after administration of CPT-11, only 
10 % of CPT-11 is converted into SN-38 (Satoh and Hosokawa, 1998). Adenoviral gene transfer of 
the soluble form of carboxyl esterase (sCE) in combination with CPT-11 significantly delayed the 
growth of osteosarcoma xenograft tumors (Oosterhoff et al., 2003). However, no published data on 
SN-38 as an active agent against osteosarcoma exist so far (Witlox et al., 2007). 
The third main gene therapy strategy evaluated in osteosarcoma models is 
immunopotentiation gene therapy. This includes introduction of genes encoding cytokines or co-
stimulatory molecules in order to enhance the efficacy of immune system (Lafleur et al., 2001; 
Tsuji et al., 2002; Worth et al., 2000). Cytokine IL-12 is an important intermediary of several 
immune functions. Although its anti-tumor activity is incompletely understood, it regulates several 
adhesion molecules, has anti-angiogenic effects and stimulates NK and T cells. Both adenoviral 
(Worth et al., 2000) and PEI (a nonviral DNA carrier) (Jia et al., 2002) mediated IL-12 gene 
transfer via the inhalation route have shown promising efficacy against osteosarcoma pulmonary 
metastases in a nude mouse model. Other cytokines have also been studied in osteosarcoma. When 
compared with IL-12 and IL-18 (i.e. stimulates NK cells along with IL-12), IL-23 was found to be 
less effective.  
B7-1 (CD80) is a well characterized co-stimulatory molecule that promotes T cell 
proliferation and cytokine production. Adenoviral transfer of the rat B7-1 gene induced curative 
immunity against pre-established primary osteosarcoma tumors, systemic immunity against pre-
established lung metastases and activation of CD4+ T cells in regional lymph nodes (Tsuji et al., 
2002). In order to achieve further enhancement of the therapeutic efficiency, a B7-1/Fas chimeric 
gene was constructed. It showed improved efficiency against pulmonary metastases compared to 
B7-1 alone (Tsuji et al., 2003). 
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Virotherapy approach has been studied in osteosarcoma. The emphasis has been on 
conditionally replicating adenovirus vectors (CRAds). The tumor targeted conditional replication 
can be achieved with partial deletions of essential early genes. The CRAd Δ24 harbors deletion of 
the E3 region and a 24 bp deletion in the E1A gene resulting in the loss of the Rb binding capacity 
of the E1A proteins (Fueyo et al., 2000). Since inactivation of the Rb-pathway is frequent in 
osteosarcomas, the Δ24 that selectively replicates in cells that lack functional Rb pathway, has been 
studied in osteosarcoma. However, due to suboptimal expression of CAR in most osteosarcoma 
cells, the Δ24 demonstrated only limited oncolytic activity in human osteosarcoma primary cell 
cultures, cell lines and xenograft tumors at low doses of the virus (Witlox et al., 2004). The 
modification of tropism towards αv integrins by inserting the RGD motif (Arg-Gly-Asp) to the 
capsid (Ad5-Δ24RGD) resulted in an improved oncolytic effect at low MOIs. In addition, Ad5-
Δ24RGD contains the E3 region. The presence of E3 has been found to improve the oncolytic effect 
(Suzuki et al., 2002), since it contains the adenovirus death protein (ADP) encoding gene. ADP 
plays an important role in the adenoviral life cycle, promoting cell lysis and the release of progeny 
viruses (Lichtenstein et al., 2004). Therefore, it is retained and overexpressed in some of the most 
recently designed conditionally replicative adenoviruses (Shashkova et al., 2007). 
Transcriptionally targeted oncolytic adenoviruses have also been developed for 
osteosarcoma. The adenoviral E1A gene is the gate-keeper of the adenovirus replication cascade. 
Two strategies for transcriptional targeting of adenoviral replication to osteosarcoma cells have 
been applied. E1A can be placed under the control of a tissue or tumor specific promoter, e.g. in the 
case of osteosarcoma, the osteocalcin promoter has been utilized (Benjamin et al., 2001; Matsubara 
et al., 2001). In addition, a hTERT promoter targeted CRAd has been constructed (Witlox et al., 
2007). This is a possible candidate against osteosarcoma, as telomerase expression is often found in 
osteosarcoma and is associated with poor prognosis (Bilsland et al., 2007; Ulaner et al., 2003; 
Witlox et al., 2007).   
       
Animal models 
 
Nude mice with human osteosarcoma xenograft tumors have been widely utilized in the preclinical 
evaluation of candidate drugs (Dass et al., 2007; Gorlick et al., 2003). Cultured osteosarcoma cells 
(Dass et al., 2007) or fragments of a tumor resected from a patient (Crnalic et al., 1997) have been 
xenogafted to create animal models.   
For induction of tumors the tumor cells can be implanted to heterotopic location, most 
commonly subcutaneously or intracutaneously, leading to growth of palpable and easily measurable 
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tumor nodules that cause relatively little discomfort to the animals. However, the microenvironment 
of the implanted tumor cells can strongly affect their growth characteristics and metastatic capacity 
(Manzotti et al., 1993). Therefore, orthotopic implantation should be favoured. Orthotopic models 
mimic more closely the clinical characteristics of osteosarcoma, including growth in the bone 
(tumor cells are injected intraosseously, such as proximal tibial bone) and the formation of 
pulmonary metastases (spontaneous metastases from primary bone tumor or after intravenous tumor 
cell injection) (Dass et al., 2007). 
Several human osteosarcoma cell lines, including non-transformed cell lines U2OS 
(Ponten and Saksela, 1967) and Saos-2 (Fogh et al., 1977) can be inoculated into nude mice to 
produce tumors. Later, highly metastatic osteosarcoma models were established by passaging Saos-
2 cells several cycles through lungs of athymic mice (including induction of metastases with 
intravenously injected tumor cells and subsequent isolation of tumor cells from pulmonary nodules 
for the next cycle of intravenous injection). The two resulting derivative cell lines, Saos2LM6 and 
Saos2LM7 dislayed increased metastatic potential in athymic mice (Jia et al., 2003; Jia et al., 1999). 
Furthermore, transformed human osteosarcoma cell lines have been utilized in xenograft models. 
These include KRIB cells (HOS cells transformed with the v-Ki-ras oncogene) (Dass et al., 2007). 
Berlin et al. showed that after intratibial inoculation of as few as 2 × 10
4
 KRIB cells, 100 % of mice 
developed both tibial tumors and spontaneous pulmonary metastases (Berlin et al., 1993). This was 
the first osteosarcoma model giving rise to spontaneous pulmonary metastases. Another 
transformed human osteosarcoma cell line that can be used for orthotopic implantation which 
results in the formation of spontaneous pulmonary metastases is 143B. These are also Ki-ras 
transformed HOS cells (Dass et al., 2007). The advantage of using a stable cell line may be better 
reproducibility compared to tumor fragments obtained from patients. However, experimental 
studies in bladder and pancreatic cancer revealed that after preparation of the cell suspension, the 
cells showed greatly reduced metastatic rates compared to implantation of intact tumor pieces 
(Aznavoorian et al., 1993; Hoffman, 1991). Orthotopic implantation of intact tumor fragments has 
been shown to reproduce the histologic and metastatic characteristics of the original osteosarcoma 
tumor (Crnalic et al., 1997).   
 Nude mice do not have functional T lymphocytes, which makes human tumor 
xenografting possible. However, the immune system may have an integral impact on efficacy or 
safety of a candidate gene drug or a virus vector being tested in an animal model. Therefore, 
syngeneic animal models with a normal immune system have been established. These can be based 
on a cell line isolated from spontaneously occurring osteosarcoma (Khanna et al., 2000; Schmidt et 
al., 1988). A close similarity between the genetic backgrounds of the tumor cells and the recipient 
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animals is mandatory to prevent rejection of the transplanted cells. Thus, only tumor cells of the 
same inbred strain can be utilized.  
 Recently, Walkley et al. described a genetically engineered mouse model of 
osteosarcoma with osteoblast-restricted deletion of p53 and Rb tumor suppressor genes.    
Inactivation of these tumor suppressors is frequently found in sporadic osteosarcoma and analysis 
of hereditary cancer syndromes has emphasized the roles of p53 and Rb in osteosarcoma. In this 
mouse model, the animals developed osteosarcoma tumors after a short latency. The resulting 
tumors possessed several key characteristics of human osteosarcoma, including cytogenetic 
complexity and comparable gene expression signatures, metastatic behaviour and histology 
(Walkley et al., 2008). This animal model revealed the mandatory role of p53 inactivation, which 
was potentiated by inactivation of Rb. Furthermore, osteosarcoma mouse models with clonally 
related variants that differ in their metastatic capacity, such as K7M2/K12 or LM7/LM2 model 
pairs (Khanna et al., 2000; Lisle et al., 2008), have provided valuable insights into the molecular 
pathology of osteosarcoma.       
 Animal models other than rodents have also been used for osteosarcoma studies. A 
valuable large animal model for osteosarcoma is the dog (Mendoza et al., 1998; Withrow, 1998; 
Withrow et al., 1991). Osteosarcoma occurs spontaneously in large breeds, most commonly in 
purebred male dogs (Gorlick et al., 2003). Veterinary patients have been recruited for preclinical 
studies utilizing the canine osteosarcoma model (Khanna et al., 2002; Withrow et al., 1993). A large 
animal model allows more exact estimation of the appropriate doses needed for human patients and 
also enables testing of administration techniques and surgical procedures that cannot be carried out 
in mouse or rat models. 
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3   AIMS OF THE STUDY 
 
The present study was carried out to find novel tools for  therapeutic gene transfer and virotherapy 
of osteosarcoma. The specific aims were defined as follows: 
 
1. To study the utility of adeno- and lentivirus vectors as gene transfer vehicles for HSV-TK/GCV 
suicide gene therapy in human osteosarcoma cell lines (I). 
 
2. To evaluate the efficiency and safety of different helper RNA systems (DH-BB and split helper 
RNAs) for the production of Sindbis virus vectors and to study the capacity of Sindbis vectors to 
transduce osteosarcoma cells (II-III).  
 
3. To investigate the oncolytic Semliki Forest virus vector VA7(74)-EGFP as a novel therapeutic 
agent against osteosarcoma (IV). 
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4   MATERIALS AND METHODS 
Cell lines 
 
Cell lines that were used in this study are presented in Table 9, supplemented with information on  
the tissues and species of origin. DMEM (Dulbecco’s modified Eagle medium) supplemented with 
10 % fetal bovine serum, 2 mM L-glutamine and 50 µg/ml gentamicin was used as growth medium 
for all cell lines. All cells were maintained at + 37 ˚C in the presence of 5 % CO2. 
 
Table 9. Cell lines. 
 
 
Cell line 
 
 
Source 
 
Tissue and species of origin 
 
Reference 
BHK-21  ATCC (CCL-10) Kidney of newborn Syrian golden 
hamster  
II-III 
BT4C a gift from Dr. Rolf 
Bjerkvig (Bergen, Norway) 
 
Glioma of inbred BDIX rat II-III 
K7M3 a gift from Dr. C. Khanna 
(Bethesda, Maryland, U.S.) 
Balb/c mouse osteosarcoma IV 
MG-63 ATCC (CRL-1427) Osteosarcoma of a 14-years old boy I, III-IV 
Saos-2 ATCC (HTB-85) Osteosarcoma of an 11-years old girl I, III-IV 
Saos2LM7 a gift from Dr. E. 
Kleinerman (Houston, 
Texas, U.S.) 
Saos-2 human osteosarcoma cells were 
repeatedly passaged through lungs of 
athymic mice to create Saos2LM7 
with increased capacity to form lung 
metastases 
IV 
SW-1353 ATCC (HTB-94) Chondrosarcoma of a 72-years old 
woman 
I 
TE-671  ATCC (CCL-136) Originally described to represent 
medulloblastoma, later characterized 
as a rhabdomyosarcoma cell line 
III 
U-2-OS ATCC (HTB-96) Osteosarcoma of a 15-years old girl I, III-IV 
293 ATCC (CRL-1573) Human embryonic kidney epithelial 
cells 
I, IV 
293T a gift from Dr. G. Nolan 
(Stanford, California, U.S.) 
Human embryonic kidney epithelial 
cells transformed with SV40 large T 
antigen  
I 
9L ATCC (CRL-2200) Rat gliosarcoma II 
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Vector constructs and oncolytic viruses 
 
 
The vectors and oncolytic viruses used in the present study are summarized in Table 10. Production 
and titration of different vectors has been described in the listed references. Adenoviral, lentiviral 
and alphaviral vector construction has been peviously described (Fueyo et al., 2000; Hakkarainen et 
al., 2006; Loimas et al., 2000; Wahlfors et al., 2000; Vähä-Koskela, 2007). All vectors were 
produced with previously described methods. For details, see references (Hakkarainen et al., 2006; 
Loimas et al., 2000; Määttä et al., 2007 Vähä-Koskela, 2007 #543; Wahlfors et al., 2000). 
Adenovirus vector titration was carried out with standard plaque titration. Titration of lenti- and 
alphaviral vectors expressing fluorescent marker genes was carried out using flow cytometry at the 
4 days (lentivirus vectors), 7 hours (VA7-EGFP) and 6 hours (Sindbis vectors) timepoints after 
transduction. Additionally, plaque titration was used for propagation competent alphavirus vectors 
(see below). 
 
Table 10. Virus vectors. 
 
 
Vector 
 
 
Description 
 
Reference 
HR’TKGFP First generation VSV-G pseudotyped lentivirus 
vector expressing TK-GFP fusion gene under CMV 
promoter 
I 
Ad5-TKGFP First generation, E1/E3 deleted serotype 5 
adenovirus vector expressing TK-GFP fusion gene 
under hEF1α promoter 
I 
∆24 Conditionally replicative E3 deleted serotype 5 
adenovirus with 24 bp deletion in E1A  
IV 
∆24-TKGFP Conditionally replicative E3 deleted serotype 5 
adenovirus with 24 bp deletion in E1A, expresses 
TK-GFP fusion gene under CMV promoter 
IV 
Sindbis-TKGFP DH-BB Replication defective Sindbis virus vector 
expressing TK-GFP under 26S subgenomic 
promoter, DH-BB helper RNA (Bredenbeek et al., 
1993) used for vector packaging 
II-III 
Sindbis-TKGFP split helper Replication defective Sindbis virus vector 
expressing TK-GFP under 26S subgenomic 
promoter, chimeric split helper RNA (Frolov et al., 
1997) used for vector packaging 
II-III 
VA7-EGFP Replication competent oncolytic Semliki Forest 
virus vector, based on attenuated SFVA7(74) 
strain, expressing EGFP under 26S subgenomic 
promoter 
IV 
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The structure of the DH-BB and split helper RNAs used for Sindbis vector production is presented 
in Figure 9. 
 
 
Figure 9. DH-BB and split helper RNAs were constructed from Toto1101 plasmid with 5’ terminus 
of tRNA
Asp
. The DH-BB helper contains the complete structural open reading frame of Sindbis 
virus. In the split helper RNA the structural open reading frame is divided into two parts. 
Additionally, to replace the enhancer element located within the Sindbis capsid gene (not present in 
the Crrv∆3 component of the split helper), partially deleted Ross River virus capsid gene (Crrv∆3) 
was inserted in front of the Sindbis envelope genes. 
 
 
In vitro studies 
 
Determination of transduction efficiency  
 
Cells were split onto 12-well plates 50 000 cells/ well. After o/n incubation, the cells were washed 
with PBS and transduced with adeno- or lentivirus vectors for 1 hour at + 37 °C in 300 µl 
transduction volume, followed by addition of 1.5 ml growth medium. Cells were incubated at  
+ 37 °C until harvested for flow cytometry three (adeno) or four days (lenti) post-transduction. 
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Flow cytometry samples were prepared as described above and the proportion of TKGFP 
expressing viable cells was determined at different timepoints.  
 
Verification of oncolysis 
 
The oncolytic effect of SFVA7(74)-eGFP and Ad5∆24 was studied in five osteosarcoma cell lines 
(U-2-OS, MG-63, Saos-2, Saos2-LM7 and K7M3). Cells were seeded onto 12-well plates, 50 000 
cells/ well and incubated at 37 °C o/n to allow the cells to attach.  
 Transductions with SFVA7(74)-eGFP vector (MOIs 0, 0.2, 2, and 20) were carried 
out in triplicates for each timepoint in 300 µl transduction volume (medium: Optimem 1 with 
Glutamax 1) for one hour and then 1.5 ml growth medium was added to each well. One, two, four 
or eight days after the transductions, the cells were washed with PBS, fixed with 4 % PFA for 20 
min and stained with crystal violet solution (2 g crystal violet in 1000 ml 70 % EtOH) for 15 min. 
Plates were gently rinsed with tap water and allowed to dry.  
 Transductions with Ad5∆24 vector (MOIs 0, 2, 20 and 200) were performed in 
triplicate for each timepoint in 400 µl transduction volume in D4 medium (D4: DMEM with 4 % 
FBS and 50 µg/ml gentamicin) o/n followed by adding of 1.5 ml D4 medium. Fresh D4 medium 
was changed to cells on every other day. Four, eight, twelve or sixteen days after transductions, the 
cells were stained with crystal violet as described above.  
 
Ganciclovir sensitivity 
 
For determination of ganciclovir (GCV) sensitivity, cells (U-2-OS, MG-63, Saos-2 and SW-1353) 
were split to 6-well plates 100 000 or 200 000 cells/ well for lenti- or adenovirus transductions, 
respectively. On the next day, the cells were transduced with Ad-TKGFP serotype 5 adenovirus 
vector or HR’TKGFP first generation lentivirus vector (based on HIV-1). Transductions were 
carried out in 1 ml volume of growth medium (lentivirus transductons in presence of 8 µg/ml 
polybrene) o/n at + 37°C.  After transduction, 2 ml of growth medium was added to cells.  
 Cells were trypsinized three (adenovirus) or four (lentivirus) days after 
transductions. The proportion of transgene positive cells was determined with flow cytometry. 
Transduced and non-transduced cells were mixed to obtain populations with 1 to 20 % of transgene 
positive cells and plated onto 96-well plates, 2500 cells/ well. After five hours of incubation at + 37 
°C, growth medium containing 0, 0.2, 2, 20, 200 or 2000 µg/ml GCV was added to the cells (final 
concentrations in the wells were half of those mentioned above). Ganciclovir treatment was 
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continued for 5 days. Finally, cells were lysed and their viability was analyzed with the MTT assay 
(Cell Proliferation Kit II, Roche) following the manufacturer’s instructions. 
 
Bystander effect 
 
For bystander effect studies, the cells were transduced according to the same protocol as used for 
ganciclovir sensitivity assays. The population with 20 % of transgene expressing cells was obtained 
by mixing the transduced cells with non-transduced cells. Cells were plated at different cell 
densities (500, 1000, 2000, 4000, 8000, 16 000 and 32 000 cells/ well) and incubated o/n followed 
by addition of growth medium without or with GCV (final concentration in wells 5 µg/ml). After 5 
days’ incubation, the cells were analyzed with the MTT assay to determine the cell viability at 
different cell densities.   
 
Verification of vector propagation 
 
Fluorescence microscopy and flow cytometry  
 
For detection of localized propagation of Sindbis-TKGFP split helper vector, MG-63, Saos-2, U-2-
OS, TE-671 and BHK-21 cells were seeded onto 12-well plates, 50 000 cells per well and incubated 
o/n at + 37˚C to allow the cells to attach. Then the cells were transduced with Sindbis-TKGFP split 
helper vector MOI 0.7 (medium: Optimem 1 with Glutamax 1, Invitrogen, U. K.) using a 
transduction volume of  0.3 ml for one hour, followed by addition of 1.5 ml growth medium into 
each well. After incubation for 48 hours at + 37˚C, the cells were fixed with 4 % paraformaldehyde 
and analyzed with fluorescence microscopy. TKGFP expressing cell clusters, the signs of local 
spreading of the vector, were photographed (bright field and fluorescence images).   
To verify the propagation of oncolytic VA7-EGFP and Ad5Δ24-TKGFP vectors, cells 
were seeded onto 12-well plates, 50 000 cells/well. On the next day, transductions were carried out 
using MOIs 0.2, 2 and 20 for VA7-EGFP or MOIs 2, 20 and 200 for Ad5Δ24-TKGFP. VA7-EGFP 
transductions were performed in 300 µl transduction volume of Optimem 1 with Glutamax 1 –
medium for one hour at +37˚C. Then 1.5 ml DMEM with 10 % FBS was added into each well and 
the incubation was continued at + 37˚C. Cells were harvested or fixed with 4 % paraformaldehyde 7 
h, 24 h, 48 h and 72 h after transduction for flow cytometry or fluorescence microscopy. Ad5Δ24-
TKGFP transductions were carried out in DMEM with 2 % FBS using 400 µl transduction volume. 
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Cells were incubated with virus at + 37˚C overnight, followed by addition of 1 ml DMEM with 2 % 
FBS per well. Incubation was continued at + 37˚C and medium was replaced with fresh DMEM 
with 2 % FBS every second day. Flow cytometry and fluorescence microscopy analyses were 
performed 2, 4, 6 and 8 days after transduction. 
 
Serial passaging assay 
 
Testing of Sindbis vector preparations for propagation competent viruses was based on serial 
passaging. A series of dilutions of a vector preparation (in triplicates) was used for transduction of 
logarithmically growing BHK-21 cells (200 000 cells/well in 12-well plates) as described earlier. 
After 48 h incubation at + 37 °C, half of the volume of medium in each well was passaged to fresh 
BHK-21 cells, diluted with an equal volume of growth medium. Vector preparations were passaged 
three or four times to fresh BHK-21 cells. However, three times serial passage was routinely used 
because no additive information was achieved with the fourth passage. The cytopathic effect (CPE) 
was observed with a microscope. After microscopy and passaging of medium to the next plate, cells 
were washed with PBS and fixed with 4 % paraformaldehyde for fluorescence microscopy. The 
frequency of propagation competent viruses in the vector preparations was calculated based on 
vector titer and the last dilution that produced complete CPE in 2/3 of the plates. 
 
Plaque titration for alphaviruses 
 
BHK-21 cells were split on 24-well plates 5 × 10
4
 cells/well. On the next day, the Sindbis or VA7-
EGFP vector preparations  (or serum or homogenized tumors and tissues from VA7-EGFP treated 
animals) were diluted in growth medium and used for transductions that were carried out at + 37˚C 
for two hours. As a quality control of the VA7-EGFP titration, serial dilutions of a previously 
titrated VA7-EGFP preparation were used for the transductions. After incubation, the transduction 
medium was removed and the cells were washed with PBS, followed by overlaying with 0.4 % 
SeaPlaque agarose (BioWhittaker Molecular Applications, USA) in growth medium, 0.5 ml per 
well. Plates were incubated at + 37 ˚C for 48 h. Cells were fixed and stained o/n at + 37 ˚C using a 
solution containing 5 % formalin, 1 % EtOH and crystal violet 2 g/ l in PBS and then agarose was 
removed by inverting and knocking the plates on the desk. Plaques were counted and titers were 
determined based on plaque number and dilution factor.  
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Recombination between replicon and helper RNAs 
 
RNA analysis 
 
Northern blot analysis was used to study the presence of vector and helper RNAs in BHK-21 cell 
cultures infected with Sindbis virus vectors. BHK-21 cells were seeded onto four 10 cm plates 1 × 
10
6
 cells/plate. After six hours of incubation at + 37˚C, the cells were transduced with Sindbis-
TKGFP DH-BB MOI 0.02, Sindbis-TKGFP Split helper MOI 33 or 700 μl Sindbis-TKGFP Split 
helper (CPE +) supernatant acquired from a single well of Sindbis-TKGFP split helper RCV test 
(12-well plate, 2nd passage, where a mild CPE, i.e. about 50 % dead cells, was observed).  
Different MOIs were used for each vector to achieve an optimal yield of viral RNAs for Northern 
blots; high numbers of infected cells without extensive CPE three days after transductions when 
cells were harvested. For a negative control, fresh medium was used. For transductions, 3 ml of 
Optimem 1 with Glutamax 1 medium was used. After one hour of incubation at + 37˚C, 7 ml of 
growth medium was added onto each plate. At the three days time point, the cells were harvested, 
cell pellets were washed with 5 ml PBS and stored at -70˚C. Supernatant from the cells infected 
with the Sindbis-TKGFP Split helper (CPE +) was purified using 0.2 μm cellulose acetate filter and 
stored at -70˚C for titration with flow cytometry and plaque titration assay (described above).  
Plaque titers were also determined from Sindbis-TKGFP DH-BB vector preparation containing 2 × 
10
7
 tu/ ml, based on the flow cytometry titration (see above).                
 For extraction of total cellular RNA, RNeasy Mini kit (Qiagen GmbH, Hilden, 
Germany) or TRIzol reagent (Invitrogen) were used according to the manufacturers’ instructions.  
RNA preparations were stored at -70˚C. Ten μg of total RNA (each sample in duplicates) was 
fractionated with gel electrophoresis and equal loading of each lane was confirmed with ethidium 
bromide staining. For Northern blot, RNA was transferred onto positively charged nylon 
membranes (Roche Diagnostics GmbH, Mannheim, Germany). After UV cross-linking, the 
membranes were prehybridized for two hours with a solution containing 1 mM EDTA, 20 % SDS 
and 0.5 % Blocking reagent (Boehringer) in 0.25 M phosphate buffer (pH 7.2). Hybridization was 
carried out o/n at 68˚C. Double-stranded DNA probes for Sindbis capsid or Sindbis envelope were 
constructed by PCR using 1 U DynaZyme DNA polymerase (Finnzymes), 2.5 μl PCR DIG 
Labeling Mix
PLUS
 (Roche), 20 pmol of Sindbis envelope or Sindbis capsid primers and 200 ng of 
template cDNA. The following PCR conditions were used: 96˚C for 30 s, 60˚C (Sindbis envelope 
probe) or 61˚C (Sindbis capsid probe) for 1 min, and 72˚C for 1 min, for 30 cycles. The primers 
used for generation of the probes were 5'-CCACATGCTATACCCGCGAA-3' (upper) and 5'-
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CGGTGCAACCAGTGATTTCG-3' (lower) for Sindbis envelope probe, and 5'-
AATCCAGCAACTGACCACAG-3' (upper) and 5'-GGTGAATGCCTCACTTCTCA-3' (lower) for 
Sindbis capsid probe. 
 Membranes were washed under high stringency conditions. The Digoxigenin-labeling 
and detection kit (Roche Diagnostics) was used for detection according to the manufacturer's 
instructions with the exception of the doubled blocking time and an additional washing step. The 
membranes were autoradiographed after 15 to 60 min incubation at room temperature.  
 
RT-PCR and sequencing of the recombination sites 
 
A set of different PCR primers complementary to Sindbis virus genome were created to detect and 
characterize potential crosses between the replicon and helper RNAs (Table 11.). Each primer pair, 
with forward and reverse primers located in distinct vector RNAs (replicon and helper RNAs or in 
the two components of the split helper RNA), was designed to amplify a possible recombination 
site.  
 BHK-21 cells were infected with Sindbis-TKGFP DH-BB or split helper vectors or 
Sindbis split helper CPE+ supernatant and overlayed with agarose (see above). Single plaques, 
isolated at 48 h time point, were used to infect BHK-21 cells growing logarithmically on 10 cm 
plates. At the 24 h time point, total cellular RNA was extracted with Trizol and stored at -70°C 
prior to cDNA synthesis. The cDNA synthesis was carried out with 1.5 µg RNA for each reaction 
using random hexamer primers (0.25 µg), 40 U M-MuLV reverse transcriptase (Promega) and 20 U 
RiboLock Ribonuclease inhibitor (Fermentas). RNA was mixed with random hexamer primers in11 
µl volume and incubated at 70°C for 5 minutes, chilled on ice and mixed with the other reagents in 
a total reaction volume of 21 µl. Then, the reactions were incubated at 25°C for 10 minutes, at 37°C 
for 60 minutes and at 70°C for 10 minutes (termination of the reaction).  
The cDNAs were stored at -20°C before use as templates for RT-PCR reactions. RT-
PCR was carried out with 1 U DynaZyme DNA polymerase (Finnzymes), 0.5 µl 10 mM dNTP 
(Finnzymes), 10 pmol of both primers and 2.5 µl template cDNA. PCR conditions were: 96˚C for 
30 s, 60˚C (for all primer pairs) or 63˚C (additional reactions for primer pairs 1 + 7 and 9 + 2) for 1 
min, and 72˚C for 1 min, for 30 cycles. After agarose gel electrophoresis (0.9 % agarose in TAE 
buffer with EtBr), each product was extracted from the gel using the Qiagen Minelute Gel 
extraction kit according to manufacturer’s instructions. The fragments were cloned into pCR-XL-
TOPO plasmid with TOPO
®
 XL PCR Cloning kit (Invitrogen), according to the manufacturer’s 
instructions. The plasmids were transformed into competent DH5α E. coli cells and plated on LB  
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Table 11. PCR primers used in the recombination site analyses 
 
 
Number 
 
 
Orientation 
 
Binding site in Sindbis 
virus genome 
 
 
Sequence 
1 F 7097-7114, nsP4 5’-CGT TAT CGC CAG CAG AGT-3’ 
2 R 9750-9766, E2 5’-ATC ATC GCC ACG GTA GC-3’ 
3 F 11018-11036, E1 5’-GCA GTA TGT ATC CGA CCG C-3’ 
4 R 1167-1188, nsP1 5’-TGT TCC TGT TAG TCC TAC CGT T-3’ 
5 F 684-701, nsP1 5’-CGT AAC ATC GGA CTT TGC-3’ 
6 F 796-818, nsP1 5’-CGA CAC TTT ATC CAG AAC ACA GA-3’ 
7 R 8005-8022, C 5’-TGA CAT CTC CGT CCT CGT-3’ 
8 F 7786-7800, C 5’-CAG CCG TCA GTG CCC-3’ 
9 F 8140-8156, C 5’-AGT TCG CAC AGT TGC CA-3’ 
F = forward, R = reverse 
 
agar plates with kanamycin (50 µg/ml) followed by o/n incubation at +37°C. Single colonies were 
selected for further analysis. Plasmid purification was performed using QiaPrep Spin Miniprep kit 
(Qiagen) according to the manufacturer’s microcentrifuge protocol for plasmid DNA, followed by 
sequencing of the inserts with M13 R and M13 F (-20) primers included in the TOPO
®
 XL PCR 
Cloning kit.  
 
Interferon response 
 
Type I interferon response to transduction 
 
TE-671, BT4C, U-2-OS, MG-63, Saos-2 (III) and Saos2LM7cells (IV) were split onto 6-well 
plates, 150 000 cells per well and incubated at +37˚C o/n. Next day, the cells were transduced with 
Sindbis-TKGFP split helper vector (titer 2.3 × 10
6
 tu/ml) MOI 0.4 (III) or VA7-EGFP vector MOI 
0.01 (IV) in Optimem 1 with Glutamax 1 -medium (or medium only as control) in 1 ml 
transduction volume for four hours (Sindbis) or for one hour (VA7-EGFP) and then 2 ml of growth 
medium was added onto each well. Cells were harvested for flow cytometry and for Western blot 
analysis at 24, 48 and 72 hours timepoints (III-IV). The samples were fixed with 4 % 
paraformaldehyde and the proportion of GFP expressing cells was determined by flow cytometry 
(FACSCalibur, Becton Dickinson) (III).  
 For Western blot analysis, the cells were pelleted and stored at -70˚C until protein 
extraction. For MxA Western blots, 30 μg protein samples were denatured and run on 12.5 % SDS-
PAGE gel using Laemmli buffer system. As a positive control, an equal amount of protein from 
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samples previously verified as MxA positive was loaded into each gel. After transfer of proteins 
onto Invitrolon
TM
 PVDF membranes (45 μm pore size, Invitrogen, Carlsbad, CA, USA), the 
membranes were incubated in the blocking solution overnight at 4˚C. Next day, the membranes 
were first incubated with primary rabbit anti-MxA antibody (30) using 1:2000 dilution for one hour 
at RT, then washed three times, followed by incubation with secondary peroxidase (HRP) 
conjugated donkey anti-rabbit IgG antibody (Amersham Biosciences, Little Chalfont, UK) using 
1:200 000 dilution for one hour at RT. Membranes were washed four times before 
chemiluminescence detection with the ECL
TM
 Plus Western Blotting Detection System (Amersham 
Biosciences, Little Chalfont, UK) according to the manufacturer's instructions. In particular, MxA 
western blotting could not be used for BT4C (rat glioma cells) or BHK-21 (baby hamster kidney 
cells) because of the differences between human, rat and hamster Mx proteins.  
 
Blocking the Sindbis vector spreading with IFN-α 
 
BHK-21 or BT4C cells (50 000 cells/well) were split onto 24-well plates and incubated at + 37˚C 
for four hours (BHK-21) or o/n (BT4C) to allow the cells to attach. Cells were transduced with 
Sindbis-TKGFP Split helper vector MOIs 0, 0.005, 0.05 and 0.5 for BHK-21 or MOIs 0, 0.003, 
0.03 and 0.3 for BT4C in Optimem 1 with Glutamax 1 in 0.3 ml transduction volume for one hour. 
Then 300 μl of growth medium containing IFN-α (IFN-alpha-A/D, human recombinant expressed 
in E. coli, Sigma-Aldrich, Saint Louis, Missouri, USA) was added to yield final concentrations of 
1000, 100, 10, 1 or 0 U/ml IFN-α for BHK-21 cells and 1000, 100 or 0 U/ml IFN-α for BT4C cells. 
After 48 h incubation, the cells were fixed with 4 % paraformaldehyde for fluorescence microscopy 
or harvested for flow cytometry. Subsequently, fluorescence microscopy analysis for detection of 
vector spreading (bright field and fluorescence photographs) and flow cytometry to determine the 
proportion of TKGFP transgene expressing cells were carried out.  
 
In vivo studies 
 
Animal models  
 
Preparation of cells for tumor induction 
 
Saos2LM7 and K7M3 cells were grown in DMEM with 10 % FBS and 50 μg/ml gentamicin on 15 
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cm plates. Cells were harvested with 0.05% trypsin (Invitrogen, U.K.), suspended in growth 
medium, pelleted at 284 g 2 min and washed first with PBS, then with Optimem 1 with Glutamax 1 
-medium. Cells were counted and re-suspended to Optimem 1 with Glutamax 1 medium 1.2 × 10
8
 
cells/ml (K7M3) or 6 × 10
7
 cells/ml (Saos2LM7). The suspensions were kept on ice until injection 
to animals.  
 
Subcutaneous Saos2LM7 human osteosarcoma model 
 
All animal studies were carried out according to national and institutional guidelines. Sixteen five-
week-old HsdCpb:NMRI-Foxn
nu/nu
 nude mice (Harlan, Neatherlands) received  3 × 10
6
 Saos2LM7 
cells in 50 µl volume intracutaneously into both flanks. Tumor size was monitored by measuring 
with a ruler three perpendicular dimensions of each tumor twice a week. Tumor volumes (V) were 
calculated using the equation V = 4/3 × π × A × B × C, where A, B and C represent the semiaxes of 
the tumor (Pasanen et al., 2003). Since the tumorigenicity of the Saos2LM7 cells was below 100 %, 
only the mice that developed bilateral progressively growing tumors were selected for evaluation of 
the virotherapy treatment. When tumors of the selected animals had average volume of about 13 
mm
3 
, the vectors were injected intratumorally using 50 μl Hamilton syringes. Injections were 
repeated after 7 and 14 days. For each injection, 30 μl undiluted virus preparation or 0.9 % NaCl 
(for control group) was used per tumor (1.05 x 10
8
 tu/tumor for VA7-EGFP and 5.52 x 10
8
 
pfu/tumor for Ad5Δ24 treated mice). For tumor cell or virus injections, mice were anesthetized with 
s.c. fentanyl-fluanison-midazolam (FFM) mixture containing 1:1:2 Hypnorm (fentanyl + fluanison, 
Janssen Pharmaceutica, Belgium), Dormicum (5 mg/ml midazolam, Roche) and sterile aqua, 50 
μl/animal. Animals were sacrificed when the average tumor volume in the negative control group 
exceeded 150 mm
3
. The tumors were weighted and fixed in 4 % paraformaldehyde in PBS for 24 h 
for histology. 
 
Orthotopic K7M3 osteosarcoma model 
 
Five-week-old HsdCpb:NMRI-Foxn
nu/nu
 nude mice (Harlan, Netherlands) were anesthetized with 
the FFM mixture as described above for tumor induction. K7M3 cells (1.2 x 10
6
) in 10 µl volume of 
Optimem 1 with Glutamax 1 medium were injected into the proximal left tibia of mice using a 27G 
х ¾" needle (TerumoNeolus) and a stopper that allowed 4 mm penetration depth. The needle was 
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inserted with drill like movements through the cortex of anterior tuberositas tibiae following the 
medial margin of the ligamentum patellae (which could be seen in most mice through the skin) and 
inserted into the diaphysis of the tibia. Ten µl of suspension was injected into bone marrow cavity 
and after ten seconds, the needle was removed. After injection of tumor cells, Temgesic (Reckitt 
Benckiser Healthcare Ltd., U.K.) 0.01 mg/ml, 30 µl/mouse, was injected s.c. for postoperative 
analgesia and to promote rapid recovery from anesthesia. 
 Tumor volume (V) was measured three times per week using a ruler in two 
perpendicular dimensions (a and b) and calculated according to the equation V = 4/3π [1/4(a+b)]2 
(Berlin et al., 1993). When the criteria for sacrificing animal were close to be fulfilled, the 
measurements were carried out daily. Treatment was started when average tumor volume was 13.4 
mm
3
. In the treatment group (n = 8), 30 µl volume of VA7-EGFP vector was injected intratumorally 
with 30G × 1/2'' needle and 1 ml tuberculin syringe. In the control group (n = 8), the animals 
received equal volumes of 0.9 % NaCl. Injections were repeated weekly until the mice were 
sacrificed.    
 The following criteria for sacrificing the animals were used: (i) weight decrease over 
20 % during the experiment, (ii) severe limb swelling (circumference of tumor bearing left hind 
limb more than 1.5 times that of right hindlimb), (iii) tumor volume exceeding 125 mm
3
 or (iv) total 
inability to use tumor bearing limb. These survival endpoints were in line with the national animal 
welfare guidelines. Mice were sacrificed with CO2, followed by sampling of lungs and left tibial 
bones with the tumor mass and surrounding tissues for histology. Lungs and bone containing 
samples were fixed for 24 h with 4 % or for 48 h with 10 % paraformaldehyde in PBS, respectively. 
Brains, part of the tumor and peripheral organs (liver, kidney, heart and spleen) were sampled and 
stored at -70ºC prior to detection of virus. Blood samples were taken from right atrium to BD 
microtainer tubes (Becton Dickinson, USA). Serum was separated from blood samples in a 
centrifuge (10500 g for 3 min) and stored in -70ºC. 
 
Noninvasive in vivo imaging   
 
Magnetic resonance imaging (MRI)  
 
MRI imaging was performed using a 4.7 T magnet (Magnex Scientific Ltd., Abington, UK) 
equipped with a 170 mT/m gradient set interfaced to a Varian 
UNITY
INOVA console (Varian Inc., 
Palo Alto, CA, USA). A half-volume surface coil (High Field Imaging, Minneapolis, MN, USA) 
82 
 
was used as the transmitter and receiver. Mice were anesthesized with halothane (3 % for induction 
and 1-2 % for maintenance in 0.25/0.75 O2/N2). The lower limbs of the mice were fixed in caudally 
extended position for imaging. T2-weighted multislice spin echo images were acquired with the 
following parameters: slice thickness 1 mm, 256 points in free induction decay, 128 phase encoding 
steps in a field of view 2.5 × 2.5 cm
2
, repetition time 2500 ms and echo time 70 ms. 
  
Computed tomography 
  
For computed tomography (CT) imaging of lungs, the mice were anesthetized with isoflurane (4% 
for induction and 1.4 % for maintenance in 0.30/0.70 O2/N2). CT projection images with matrix size 
1120 × 1184 (X-ray tube voltage 60 kV and tube current 425 μA) were acquired using the Flex X-O 
small animal imaging system (Gamma Medica Inc., Northridge, USA). For image reconstruction, 
Exxim reconstruction software (Exxim Computing Corporation, Pleasanton, CA, USA) was used 
with 512 × 512 × 512 final matrix size and pixel resolution 170 μm for all three spatial directions.  
 
Analytical methods  
 
Histology  
 
Bone containing tissue samples were decalcified in a solution consisting of 10 % EDTA and 4 % 
formaldehyde in 0.1 M phosphate buffer for 10 to 12 days. Dehydrated and paraffin embedded 
samples were sectioned into 4 µm sections. After a standard hematoxyline-eosine staining, the 
sampled tissues were analyzed for histology. From the lungs of the K7M3 tumor bearing mice, 
three sections were cut between 240 µm intervals and one of these three sections from each depth 
was stained with HE for detection of micrometastases.  
 Immunostaining was carried out with either rabbit polyclonal anti-SFV antibody 
(1:2500) or rabbit polyclonal anti-Ad2 E1A antibody (1:750, recognizes also Ad5 E1A antigen, 
Santa Cruz Biotechnology Inc., Heidelberg, Germany) coupled with a peroxidase anti-rabbit 
antibody conjugate (Vectastain ABC kit, Vector Laboratories Inc., USA). 
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Detection of neutralizing antibodies  
 
Serum samples of the survival study animals were analyzed to detect neutralizing antibodies. K7M3 
cells were seeded onto 48-well plates, 3 × 10
4
 cells/well, and incubated at + 37˚C overnight to allow 
the cells to attach. VA7-EGFP vector was mixed with different serum dilutions for transductions, 
incubated at + 37˚C for 1 hour and then added onto the cells. The cells were transduced in triplicate 
with MOI 0.1 in the presence of 1:20, 1:100, 1:500 or 1:2500 serum. The transduced cells were 
harvested at 24 h post-transduction and the proportion of EGFP expressing cells was analyzed with 
flow cytometry. Cells transduced with VA7-EGFP virus mixed with rabbit anti-SFV serum were 
used as a positive control. In addition, the following negative controls were analyzed: cells 
transduced with VA7-EGFP virus without serum and with VA7-EGFP mixed with serum from 0.9 
% NaCl treated control animals. 
  
Biodistribution of oncolytic VA7-EGFP vector  
 
Tumor, serum and tissue samples collected from sacrificed animals during the survival study were 
analyzed with a sensitive plaque titration assay for detection of the virus. BHK-21 cells were split 
on 24-well plates 5 × 10
4
 cells/well. On the next day, tumor and tissue samples were homogenized 
and kept on ice until used for the assay. Serum or homogenized tumors and tissues were diluted in 
growth medium and used for transductions carried out at + 37˚C for two hours. As a control, cells 
were transduced with serial dilutions of a previously titrated VA7-EGFP preparation. After 
incubation, the transduction medium was removed and the cells were washed with PBS and 
overlaid with 0.4 % SeaPlaque agarose (BioWhittaker Molecular Applications, USA) in growth 
medium, 0.5 ml per well. After incubation at + 37 ˚C for 48 h, the cells were fixed and stained 
overnight at + 37 ˚C with 5 % formalin, 1 % EtOH and crystal violet (2 g/ l in PBS). Then agarose 
was removed, plaques were counted and the titers were determined based on plaque number and 
dilution factor.  
 
Statistical analyses 
 
Statistical analyses were carried out with GraphPad Prism 3.0 (GraphPad Software Inc., San Diego, 
CA). Tumor volumes and tumor weights were compared using the two-way analysis of variance 
(ANOVA) and one-way ANOVA, respectively, with Bonferroni's multiple comparison test. The 
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survival data was analyzed using the logrank test. P < 0.01 was considered as statistically 
significant.      
 
2   RESULTS AND DISCUSSION 
 
Osteosarcoma and chondrosarcoma as targets for virus vectors and 
HSV-TK/GCV gene therapy (I) 
 
Transduction efficiency 
 
In this study, three osteosarcoma cell lines and one chondrosarcoma cell line were tested as targets 
for an E1/E3 -deleted serotype 5 adenovirus vector and a first generation HIV-1 -based VSV-G 
pseudotyped lentivirus vector, both carrying the TK-GFP suicide-marker fusion gene. All studied 
cell lines were permissive for both vector types (I: Fig. 1). The three osteosarcoma cell lines (U-2-
OS, Saos-2 and MG-63) were excellent or good targets for both vectors. In the U-2-OS cells, MOI 
of 0.1 was sufficient for transduction of above 15 % or above 20 % of cells with adenovirus and 
lentivirus vector, respectively, and MOI 3 yielded almost complete transduction of the cell culture. 
In Saos-2 cells, lentivirus vector MOI 0.3 and adenovirus vector MOI 3 displayed equal 
transduction efficiency of about 40 %. Transduction of more than 80 % of Saos-2 cell culture was 
achieved with lentivirus vector MOI 3 and adenovirus vector MOI 15. Nonetheless, one should be 
cautious when making comparisons between different virus vectors, since the infective titers are not 
absolute values (they depend on the cell line used for titration and the protocol used). For MG-63 
cells, MOI 3 was sufficient for transduction of about 15 to 20 % of cells with lentivirus and 
adenovirus vectors. Lentivirus vector MOI 15 and adenovirus vector MOI 30 achieved transduction 
of more than 60 % of cells. The only studied chondrosarcoma cell line SW1353 was more difficult 
to transduce with either of the vectors than any of the osteosarcoma cell lines. However, due to poor 
availability of commercial chondrosarcoma cell lines, we were unable to analyze whether this was a 
general feature of chondrosarcoma cells or related only to this particular cell line. 
 
Ganciclovir sensitivity 
 
To determine the utility of the HSV-TK/GCV therapy for osteosarcoma and chondrosarcoma cells, 
the cell lines were transduced with adenovirus and lentivirus vectors carrying the TK-GFP fusion 
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gene. Then, cell cultures containing different proportions (0 to 20 %) of transduced cells were 
exposed to different concentrations of GCV (0 to 1000 μg/ml), followed by cell viability analysis. 
Twenty percent of TK-GFP expressing cells in Saos-2 cell culture resulted in destruction of 30 % of 
the cells in presence of 10 μg/ml GCV whereas in U-2-OS and MG-63 cell cultures, the decline in 
viability was 50 % (I: Fig. 2). These results indicate that HSV-TK/GCV therapy can be effectively 
used against human osteosarcoma cells. Human chondrosarcoma cell line SW1353 was found to be 
excellent target for HSV-TK/GCV therapy (I: Fig. 2). SW1353 cells displayed a strong bystander 
effect, 20 % of TK-GFP expressing cells reduced the viability of the cell population by about 90 % 
in presence of 10 μg/ml GCV. Since radical surgery is currently the only effective treatment for 
chondrosarcoma, these results warrant further development of in vitro and in vivo models for 
chondrosarcoma for more extensive evaluation of this novel treatment modality.  
 Some GCV independent toxicity was observed in Saos-2 and MG63 cells in the GCV 
sensitivity assay. Previous studies have revealed adenovirus vector related toxicity in cell culture 
experiments (Loimas et al., 2001). However, we have not detected lentivirus vector mediated 
toxicity before. Thus, according to our previous observations, the TK-GFP transgene can cause 
cytotoxicity  by an unknown mechanism. 
 
Bystander effect 
 
To verify the role of the bystander effect in the therapeutic efficiency of HSV-TK/GCV therapy, we 
utilized an assay introduced by Samejima and Meruelo (Samejima and Meruelo, 1995). that is 
based on increasing number of cell-cell contacts and constant number of TK-GFP positive cells. 
The intensity of the bystander effect correlated with the efficiency of the HSV-TK/GCV therapy in 
human osteosarcoma and chondrosarcoma cell lines. The strongest bystander effect was seen in 
SW1353 cells, which displayed more than 80 % cytotoxicity at 2000 cells/well –density, whereas 
Saos-2 cells showed only 40 % cytotoxicity at the same cell density. These results indicate that the 
bystander effect plays a major role in the therapeutic efficiency of the HSV-TK/GCV treatment. 
The relatively weak bystander effect is also the most likely explanation for the less prominent 
efficiency of HSV-TK/GCV treatment in Saos-2 cells compared to other cell lines studied. In 
particular, it should be noted that Saos-2 is a p53 null cell line. A previous report has indicated that 
p53 mutations can lead to decreased GCV sensitivity and an impaired bystander effect (van Dillen 
et al., 2005).    
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Properties of Sindbis virus vectors produced with a chimeric split 
helper system (II) 
 
Vector production 
 
To compare the efficiency of split helper RNA (Frolov et al., 1997) to DH-BB helper RNA 
(Bredenbeek et al., 1993) in the production of Sindbis virus vectors, the helper constructs were 
electroporated into BHK-21 cells along with SinRep5 replicon carrying the TK-GFP transgene. 
Supernatants were collected after 24 h of incubation. For titration, BHK-21 cells infected with split 
helper or DH-BB vectors were analyzed at 24 h time point with flow cytometry. DH-BB yielded 
high titers of 7 × 10
7
 transducing units (tu)/ml. The titers achieved with the split helper system 
remained lower, 1 × 10
6
 tu/ml.  
 Both vectors were analyzed for the presence of propagation competent viruses or 
virus-like particles (in the referred publication (II) termed as replication comptent virus or RCV) 
with serial passaging. Only the vectors produced with DH-BB helper resulted in an apparent 
cytopathic effect. The frequency of propagation competent virus in vector preparation was 
calculated to be as high as 5 × 10
-2
.  
The transduced cells were also fixed with 4 % PFA for fluorescence microscopy. To 
our surprise, in cell cultures fixed at 24 h after transduction with Sindbis vectors produced with the 
split helper, the initial TK-GFP positive single cells were expanded to clusters that grew larger over 
time. Similar expanding clusters of TK-GFP expressing cells were observed with Sindbis DH-BB 
vectors; this being expected due to the presence of propagation competent viruses (II: Fig. 1). This 
finding was confirmed with flow cytometry: the proportion of the positive cells increased over time. 
With Sindbis split helper vector, the increase was from 1.9 % to 5.5 % during the incubation period 
from 12 to 48 h post-transduction. With Sindbis DH-BB vector, the increase was from 0.9% to 9.2 
%, measured at 12 and 24 h post-transduction, respectively. At the 48 h timepoint, the cell death 
was complete in cultures infected with Sindbis DH-BB vector preparatons, previously shown to 
contain propagation competent viruses with the serial passaging assay (II: Fig. 1). 
 
Role of the split helper components 
 
To investigate the role of the split helper components in vector propagation, the replicon and helper 
RNAs were electroporated in different combinations into BHK-21 cells. The replicon alone or 
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together with the Sindbis capsid encoding part of split helper did not produce infective particles. 
However, when either both components of the split helper RNA or the CrrvΔ3 alone (coding for the 
Sindbis envelope glycoproteins) were used to package the replicon, infective particles emerged. The 
formation of infective vector was more efficient with the complete split helper RNA than with the 
CrrvΔ3 alone (83 % and 20 % of positive cells at 24 h post-transduction, respectively) (II: Fig. 2). 
The properties of vectors packaged with the split helper (CSin + CrrvΔ3) or the 
CrrvΔ3 alone were studied further by monitoring their spreading in BHK-21 cell cultures for four 
days (II: Fig. 3). The vector spreading in the cell culture remained localized at all time points and 
appeared to be restricted to neighbouring cells. Eventually, at the 96 h time point, the vector 
propagation evoked localized cytopathic effects at the center of each propagation focus. The 
cytopathic effect was very mild and delayed compared to that caused by Sindbis DH-BB vector 
preparations (containing propagation competent virus and leading to destruction of the whole cell 
culture). 
The vectors produced with DH-BB or split helper or with CrrvΔ3 component of split 
helper were used to infect BT4C and 9L rat glioma cells (II: Fig. 4). In both cell lines, all vectors 
were able to propagate. The Sindbis DH-BB vectors induced a prominent cytopathic effect in BT4C 
cells. In 9L cells, no cytopathic effect was observed, but the cells were effectively transduced and 
vector propagation lead to clusters of TK-GFP expressing cells. The spreading of vectors produced 
with split helper or CrrvΔ3 was attenuated and the size of the positive cell clusters was smaller in 
BT4C or 9L cells than in BHK-21 cells, suggesting cell type dependent differences in the spreading 
kinetics and toxicity of these vectors.                  
 Alphavirus replicons coding for heterologous viral glycoprotein, such as VSV-G can 
form virus-like particles with lipid bilayer envelopes capable of carrying the replicon RNA to the 
neighbouring cells (Rolls et al., 1994). Therefore, it is possible that the Sindbis envelope 
glycoproteins can package replicon RNA to some extent. However, a more likely explanation is that 
the partially deleted Ross River virus capsid is able to package replicon RNA and support the 
formation of propagation competent particles.  
 Both replicon RNA containing the replicase genes and the helper sequences coding for 
structural proteins are needed for propagation of vector. This can occur if (i) replicon and helper 
RNAs are co-packaged into vector particles, (ii) co-infection with particles containing replicon and 
helper RNAs takes place or (iii) following recombination between the replicon and helper RNAs. 
To clarify the mechanism of vector propagation, the following study was carried out. 
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Wild-type reversion of virus upon Sindbis vector production (III) 
 
Propagation in human osteosarcoma and rhabdomyosarcoma cells 
 
The aim of this study was to examine the mechanisms of Sindbis virus vector transmission observed 
in the previous study (II) and to investigate, whether this local, non-cytopathic spreading could be 
utilized to enhance therapeutic gene transfer - or should it be considered as a safety risk. Since there 
are no previous reports describing the underlying mechanisms of Sindbis-TKGFP DH-BB vector 
propagation and the possibility of propagation competent virus formation due to replicon-helper 
recombination and subsequent wild-type reversion has not been excluded, this vector was also 
analyzed. 
 To test, if Sindbis-TKGFP split helper vectors with a capacity for local non-cytopathic 
spreading could be used for enhanced therapeutic gene transfer into human tumor cells, one 
rhabdomyosarcoma (TE-671) and three osteosarcoma (U-2-OS, Saos-2 and MG-63) cell lines were 
transduced with the vector. When the cells transduced with this vector were examined under the 
fluorescence microscope, TE-671 rhabdomyosarcoma cells showed local spreading of the vector 
indicated by clusters of TKGFP expressing cells. Also in U-2-OS cells, a few transgene expressing 
cell clusters were detected (III: Fig. 4). 
 
Type I IFN response and vector propagation 
 
Alphaviruses are known to efficiently induce interferon response, which is one of the critical 
components of the host antiviral defence and might compromise the virus vector -mediated 
therapeutic gene transfer. Therefore, we analyzed the interferon response from the transduced 
human osteosarcoma and rhabdomyosarcoma cells using the expression of the IFN-inducible 
myxovirus resistance protein A (MxA) as a marker (III: Fig. 5). Only one of the four studied cell 
lines, MG-63, displayed MxA expression as a response to transduction. In these cells, the MxA was 
expressed at very high levels, which is in line with a previous report indicating capacity for robust 
type I IFN production in MG-63 cells (Billiau et al., 1977). The other cell lines analyzed did not 
show any detectable MxA expression. Interestingly, the MG-63 cell line was also the poorest target 
for Sindbis vector mediated gene transfer and no vector spreading could be demonstrated in these 
cells. 
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It has been previously shown that Sindbis virus utilizes a 67 kDa laminin receptor for virus entry 
(Wang et al., 1992). This receptor is frequently overexpressed on malignant cells (Castronovo, 
1993; Martignone et al., 1993; Sobel, 1993). The previously reported tumor selectivity of Sindbis 
virus vectors has been proposed to result from the 67 kDa laminin receptor  
-mediated transduction. However, Unno et al. studied Sindbis AR339 strain as an oncolytic vector 
and found that normal keratinocytes expressing the 67 kDa laminin receptor at high levels were 
resistant to infection. However, the virus effectively destroyed ovarian cancer and cervical cancer 
cells (Unno et al., 2005).  This indicates that other mechanisms of tumor selectivity exist in addition 
to 67 kDa laminin receptor -mediated transduction. Previous studies indicate that defects in the IFN 
pathway are frequently found in cancer cells (Everts and van der Poel, 2005). Our results described 
above suggest that the capacity for localized non-cytopathic propagation and the cellular IFN 
response are related to the ability of the Sindbis-TKGFP split helper vector to elicit efficient gene 
transfer in different cell lines. In order to study if IFN-α could block the vector spreading in cells 
that are known to be good targets for Sindbis virus vector spreading, we transduced BHK-21 and 
BT4C cells with Sindbis-TKGFP split helper vector, followed by addition of growth medium 
containing different concentrations of IFN-α. IFN-α was able to efficiently inhibit vector spreading 
(III: Fig. 6). These results suggest that the ability of Sindbis virus vector for lateral spreading in 
IFN-deficient malignant cells might have played a role in the previously observed tumor targeting 
properties of Sindbis vector after systemic administration into tumor bearing animals (Tseng et al., 
2004).  
 
Replicon-helper recombination 
 
The presence of propagation competent virus capable of evoking cytolytic infection was analyzed 
using serial passage assays and plaque titration. Sindbis-TKGFP DH-BB vector preparations 
frequently contained propagation competent cytolytic viruses, resulting in a complete cytopathic 
effect in serial passaging assays and plaque formation in plaque titration assays. In contrast, with 
the Sindbis-TKGFP split helper preparations, this type of cytolytic propagation was rare. Instead, 
lateral spreading of fluorescent marker gene expression with no signs of any cytopathic effect was 
more frequently detected. In fact, this type of vector propagation mostly appeared to be a self-
limiting process, since fluorescent cell clusters often disappeared upon continued passaging. 
Fluorescent marker -expressing cell clusters without any associated cytopathic effect were not 
detected with Sindbis-TKGFP DH-BB vector in serial passaging assays. However, in the wells 
displaying CPE, a widespread transgene expression was frequently observed. Interestingly, the 
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proportion of transgene expressing wells decreased between the first and third passages. This 
suggests that in context of a propagation competent vector, the presence of transgene was unstable 
and the variants that had expelled the transgene had a selective advantage over the transgene 
containing propagating vectors. These results are in line with a previous study of Weiss et al. They 
reported that the large recombinant genomes that emerged due to crosses between a Sindbis 
replicon and a helper RNA containing the RNA packaging signal, were unstable and evolved 
towards the size of the wild-type Sindbis genome (Weiss and Schlesinger, 1991). The tendency of 
propagation competent Sindbis vectors to expel the transgene could result from the selective 
advantage related to smaller wild-type like genome size, which could facilitate RNA encapsidation. 
Also, faster replication of smaller genomes or possible negative impact of simultaneous transgene 
expression to the viral propagation could facilitate selection of variants with smaller genomes.    
The frequency of cytolytic, propagation competent virus formation in Sindbis-TKGFP 
split helper preparations could not be determined with the serial passage assays due to the rarity of 
the phenomenon. However, supernatant was collected from a single well that did demonstrate an  
attenuated cytopathic effect at the third passage of the assay and used to infect BHK-21 cell 
cultures. RNA was isolated from infected cells and supernatant was collected for further analyses. 
RNA was extracted also from cells infected with Sindbis-TKGFP DHBB and Sindbis-TKGFP split 
helper vectors produced with standard methods, and from non-transduced cells. Two Northern blot 
analyses with probes binding to Sindbis capsid and envelope RNAs confirmed the presence of large 
vector RNAs both in Sindbis-TKGFP DH-BB infected cells and cells infected with the supernatant 
from the CPE displaying well of the Sindbis-TKGFP split helper serial passage assay (III: Fig. 3). 
These large RNA species were close to the size of the wild-type Sindbis virus genomic RNA. As 
expected, the large RNA isolated from Sindbis DH-BB infected cells was recognized by both of the 
probes. However, the large RNA derived from cells infected with the supernatant from serial 
passage assay, was recognized only by the envelope-targeted probe, indicating that CSin-
component of the split helper was not involved. However, a weak band was detected with both 
probes, possibly representing an even larger RNA species, arising from a second recombination 
event involving also CSin RNA. In the Sindbis-TKGFP split helper vector produced with the 
standard method, only the normal size helper RNAs and corresponding subgenomic RNAs were 
found. Non-transduced cells were negative for vector specific RNAs.  
For the first Northern blot analyses, a Sindbis-TKGFP split helper vector produced 
with the standard method (MOI 33) was used to infect the cells. With such a high MOI, the vector 
RNA could function as a defective interfering RNA and thereby suppress the replication of possible 
wild-type -like RNA arising from recombination between the replicon and helper RNAs. Therefore, 
91 
 
we repeated the experiment using MOI 0.02. At this time, we could detect an additional vector-
specific RNA species with the capsid targeted probe. This RNA was larger than CSin RNA and its 
subgenomic RNA, but clearly below the size of the wild-type Sindbis virus genomic RNA and 
smaller than the large RNA species observed in the previous Northern blot analyses. Binding of the 
envelope-specific probe to this large vector RNA could not be detected from samples collected at 
24 h after transduction, indicating that at this time, the CSin, but not the Crrv∆3 component of the 
split helper RNA, was involved in the first recombination event. The idea of the split helper system 
is to divide the helper RNA into two parts to reduce the risk of wild-type virus-like genome 
formation due to recombination between the replicon and helper RNAs. Compared to a single 
helper system (such as DH-BB) that can lead to emergence of wild-type -like genomes upon a 
single recombination event with the replicon, the split helper system requires two independent 
recombination events to combine both parts of the helper to the replicon RNA. These results show 
that both split helper components can be involved in the formation of larger vector RNA species via 
recombination. 
The replicon RNA is the only vector RNA that contains the RNA packaging signal 
needed for efficient encapsidation of viral RNA and recombination between the helper RNA and the 
replicon could lead to efficient packaging of structural protein -encoding sequences. A previous 
study showed that when Sindbis virus replicon is co-transfected with a helper RNA containing the 
packaging signal, these two RNAs can complement each other and give rise to plaques in cultures 
of permissive cells. Furthermore, co-infection with the wild-type Sindbis virus and the virus with 
segmented genome caused suppression of the wild type virus (Geigenmüller-Gnirke et al., 1991). 
Therefore, this type of recombination, even when interrupting the non-structural open reading 
frame, could produce a virus with the capacity for wild-type -like efficient propagation. In that case, 
the recombinant is dependent on the simultaneous transmission of the replicon that contains the nsP 
genes. To verify this supposition, we used RT-PCR with different combinations of primers 
recognizing the replicon and the helper RNAs to yield PCR fragments extending over the 
hypothetical crosses between replicon and helper RNAs or between the two components of the split 
helper RNA (III: Fig. 2). The PCR products were subsequently cloned into plasmids and sequenced 
to identify the recombination sites. The analyses revealed a recombination between the replicon and 
helper RNAs and between the two components of the split helper RNA. These recombinations lead 
to restoration of the wild-type sequence (III: Table 3). However, we also characterized several 
recombinants with disrupted non-structural and structural open reading frames. These recombinants 
carried alternative deletions of nucleotides 7355 to 9626, 7292 to 9735, 830 to 8442, 817 to 9553 
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and 869 to 9567 of the wild-type Sindbis virus genome and it is possible that they play a role as 
defective interfering RNAs.   
 In conclusion, propagation competent virus emerged during Sindbis vector production 
with both DH-BB and split helper RNAs and recombination between the replicon and helper RNAs 
occurs with both helper systems. Additionally, upon vector propagation, the presence of the 
transgene was unstable and during repeated passages, the propagation competent vector often lost 
its ability to express the transgene. Furthermore, a defective IFN response observed in many tumor 
cells may play a role in the tumor targeting capacity of Sindbis virus vector in addition to the 67 
kDa laminin receptor -mediated transduction.  
 
 
Oncolytic Semliki Forest virus vector as a novel candidate against 
unresectable osteosarcoma (IV) 
 
Vector spreading and oncolysis in osteosarcoma cell cultures  
 
The spreading of two oncolytic vectors, a Semliki Forest virus vector VA7-EGFP and a 
conditionally replicating adenovirus vector Ad5∆24-TKGFP was studied in five osteosarcoma cell 
lines (MG-63, U-2-OS, Saos-2, Saos2LM7 and K7M3) (IV: Fig. 1). The cells were transduced with 
the oncolytic vectors and analyzed with flow cytometry or fluorescence microscopy 6, 24, 48 or 72 
hours post transduction (SFV) and 2, 4, 6 or 8 days post transduction (adenovirus). In four out of 
the five studied osteosarcoma cell lines, the proportion of the EGFP marker gene expressing cells 
increased to close to 100 % in 24 hours with MOIs ranging from 0.2 to 20. No substantial decline in 
the proportion of marker gene expressing cells could be detected at the 48 h and 72 h timepoints. 
Fluorescence microscopy verified the oncolytic effects of both viruses and the increase in the 
proportion of fluorescent marker gene expressing cells of all viable cells. Although total number of 
the fluorescent cells decreased due to the viral oncolysis, their proportion remained close to 100 % 
among the few viable cells at later timepoints. VA7-EGFP propagation and efficient oncolysis in U-
2-OS cells is illustrated in Figure 10. Flow cytometry results were consistent to the fluorescence 
microscopy findings. However, one of the human osteosarcoma cell lines, MG-63, seemed to be 
relatively resistant to infection with the oncolytic SFV. In these cells, the vector spreading was 
slower than in the other cell lines studied and the highest observed proportion of transgene 
expressing cells remained around 50 %.  
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Figure 10. VA7-EGFP vector spreading and viral oncolysis in the U-2-OS human osteosarcoma 
cells. 
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With the oncolytic adenovirus vector Ad5∆24-TKGFP that carried the TKGFP suicide-marker 
fusion gene, vector spreading was observed in three out of the five osteosarcoma cell lines studied 
(IV: Fig. 1). However, compared to the rapid spreading of infection observed with SFV, the 
oncolytic adenovirus vector required more time and higher MOIs to spread throughout the cell 
culture. One of the cell lines studied, MG-63, was effectively transduced with high MOIs, but was 
not permissive for efficient replication and transmission of the oncolytic adenovirus vector. Also, 
the K7M3 mouse osteosarcoma cells were highly resistant to transduction with oncolytic 
adenovirus vector as well as to vector replication, as was to be expected, since most rodent cell 
types are considered to be non-permissive for adenovirus replication (Duncan et al., 1978; Ginsberg 
et al., 1991; Thomas et al., 2006).  
 The extent of viral oncolysis and the kinetics of virus propagation were investigated in 
osteosarcoma cell cultures that were infected with VA7-EGFP Semliki Forest virus or Ad5∆24 
adenovirus vectors. The cells were stained with crystal violet at one, two, four and eight days after 
infection with VA7-EGFP or at four, eight, twelve and sixteen days after infection with Ad5∆24 
(IV: Fig. 2). The oncolytic SFV produced extensive cell death in all the cell lines studied. The 
kinetics of vector replication were very rapid, resulting in a powerful oncolytic effect only one day 
after the infection in two out of the five cell lines studied (U-2-OS and Saos-2) and after two days, 
an extensive cell death was observed in all the cell lines. However, in MG-63 cells, a sub-
population of cells resistant to SFV infection emerged. These cells continued dividing in the 
presence of the virus (see the eight days timepoint in IV: Fig. 2). In the other cell lines, the lowest 
MOI 0.2 was enough to induce a complete cell death as rapidly as with the higher amounts of 
viruses.     
 Kinetics of adenovirus infection was much slower compared to that of SFV and larger 
amounts of virus were needed for complete destruction of osteosarcoma cell cultures. In two of the 
four human osteosarcoma cell lines studied (U-2-OS and Saos2-LM7), MOI 2 was sufficient to 
produce a complete oncolysis at day 12 post-infection. In Saos-2 cells, MOI 20 was needed for 
efficient cell destruction at day 16. However, two of the five cell lines studied were highly resistant 
to adenovirus infection, i.e. no oncolytic effect was seen in K7M3 mouse osteosarcoma cells and 
MG-63 human osteosarcoma cells were also found to be highly resistant to adenovirus-mediated 
oncolysis.  
The four human osteosarcoma cell lines used for in vitro evaluation of oncolytic 
adeno- and SFV vectors differed from each other in their genetic profiles. The p16 status is normal 
in Saos-2 cells, but MG-63 and U-2-OS are defective for p16. Furthermore, both MG-63 and U-2-
OS cells display functional Rb, whereas Saos-2 cells are Rb-defective (Hellwinkel et al., 2005). Our 
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results are in line with the statement that replication of the Ad5Δ24 is dependent on a defective 
p16/Rb/E2F pathway (Fueyo et al., 2000): Ad5Δ24 could effectively replicate in both Saos-2 and 
U-2-OS cells as well as in Saos2LM7 cells that presumably are also Rb-defective, like the parental 
cell line Saos-2. It is notable that in MG-63 cells, the replication and oncolysis of the Ad5Δ24 was 
severely restricted despite the defective p16. This is probably related to the low expression of CAR, 
the primary receptor for Ad5 in MG-63 cells (Witlox et al., 2004; Zhang and Bergelson, 2005). It 
has been previously reported that retargeting of Ad5Δ24 towards integrins using an Arg-Gly-Asp 
motif (RGD-4C) significantly enhances the oncolytic effect in MG-63 cells (Witlox et al., 2004). In 
addition, the E3 region was deleted from the Ad5Δ24 used in this study. The E3 region has been 
reported to potentiate the oncolytic effect of conditionally replicating adenoviruses (Suzuki et al., 
2002). The K7M3 mouse osteosarcoma cells were also almost completely resistant to infection with 
Ad5Δ24. Nevertheless, this is not surprising, since most mouse cells are considered to be non-
permissive for adenovirus infection (Duncan et al., 1978; Ginsberg et al., 1991; Thomas et al., 
2006).  
 Oncolytic VA7-EGFP vector was found to effectively replicate and lyse all of the 
studied cell lines. Thus, transduction and replication of this virus was moderately impaired in MG-
63 cells. Furthermore, in this cell line, a subpopulation of resistant cells rapidly emerged in the 
presence of oncolytic SFV. The impairment in the efficiency of SFV mediated transduction and 
oncolysis is likely to be related to the extremely strong type I IFN response and subsequent 
accumulation of MxA observed in these cells following transduction with an alphavirus vector 
(unpublished data, III). The MxA protein itself is known to suppress SFV propagation (Landis et 
al., 1998). 
 
Effects of VA7-EGFP in subcutaneous Saos2LM7 human osteosarcoma tumors 
 
Tumorigenicity of the intracutaneously implanted Saos2LM7 cells was below 100 %. After 
implantation of Saos2LM7 cells, nine of the sixteen mice developed tumors on both flanks and 
were accepted into the study. In the rest of the mice, one (six mice) or both (one mouse) of the 
implanted tumors regressed spontaneously. Mice received intratumoral injections of VA7-EGFP or 
∆24 viruses once a week for three weeks. With both oncolytic viruses, a significant difference in the 
tumor size compared to saline treated controls was observed already 11 days after the onset of the 
treatment (p < 0.001, *** for SFV and p < 0.01, ** for adenovirus) (IV: Fig. 3A).  At the endpoint, 
a statistically significant reduction in tumor volume was achieved (p < 0.001, *** for both viruses) 
(IV: Fig.3A) and in tumor weight (p < 0.001, *** for both viruses) (IV: Fig. 3B). One of the six 
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VA7-EGFP -treated tumors could not be identified at the endpoint – it appeared to have been 
completely cured. The photograph taken at the endpoint clearly highlights the therapeutic effect 
(IV: Fig. 3C).  
 Tumor histology was analyzed from HE stained sections (IV: Fig. 3D). Saline-treated 
control tumors displayed a high mitotic rate in addition of apoptotic cells, indicative of high 
proliferative activity. In the virus treated tumors, reactive fibrosis and calcifications were seen. 
After the VA7-EGFP treatment, only a few tumor cells were found, surrounded by fibrosis. 
Additionally, large areas of cell debris were present as remnants of VA7-EGFP mediated tumor cell 
death.  
 Immunohistochemical stainings verified the presence of oncolytic viruses in the 
tumors (IV: Fig. 3D). In the ∆24-TKGFP treated tumors, large areas of virus positive cells were 
found. In the VA7-EGFP treated tumors, the positively stained cells lined areas of complete cell 
destruction, which were surrounded by fibrosis. The few remanining small clusters of SFV negative 
tumor cells were also surrounded by fibrosis, possibly protecting these cells from SFV infection. 
 VA7-EGFP was demonstrated to be highly efficient against subcutaneous Saos2LM7 
tumors. This may be related to the defective innate immune response of Saos2LM7 cells. After 
VA7-EGFP infection of cultured Saos2LM7 cells, no MxA accumulation could be detected. In the 
cells with an intact innate immune response, MxA expression is induced via type I IFN signaling 
upon alphavirus infection. Furthermore, Saos-2, the parental cell line of Saos2LM7 has been shown 
to express CAR at levels that support efficient infection with ∆24 (Witlox et al., 2004). The in vitro 
experiments showed that, compared to Saos2, Saos2LM7 was at least an equally good target for the 
∆24 mediated oncolysis. CAR has been shown to be expressed in most, but not all osteosarcoma 
tumors (Gu et al., 2004). Therefore, low CAR expression can potentially limit the utility of ∆24 
against osteosarcoma (Witlox et al., 2002). Witlox et al. reported that an oncolytic adenovirus 
targeted towards integrins displayed enhanced efficacy against several osteosarcoma cell lines and 
osteosarcoma primary cell cultures. However, in Saos-2 cells, no further improvement in the 
oncolytic potential was observed with this retargeted virus, compared to ∆24 (Witlox et al., 2004).  
 
VA7-EGFP improves survival in orthotopic K7M3 osteosarcoma model  
 
For further evaluation of VA7-EGFP virotherapy, a survival study was carried out in nude mice 
bearing orthotopically implanted K7M3 tumors in the left proximal tibial bone. The tumorigenicity 
of the K7M3 cells in five-week-old HsdCpb:NMRI-Foxn
nu/nu
 nude mice was 100 %. In 80 % of the 
mice, a palpable tumor nodule was identified by 16 days post-implantation. These mice were 
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accepted for the survival study. In the remaining animals, the tumors were located under the 
muscles of the leg or initially merely growing in the bone marrow cavity, leading to longer latency 
before the appearance of palpable tumor nodus. Additionally, a large proportion of the mice 
developed gross oedema of the tumor-bearing limb. Tissue edema and enlargement of the blood 
vessels were visualized with MRI imaging (IV: Fig 4 A, right). These findings may be explained 
by the previously reported VEGF expression of K7M2 cells, the parental cell line of K7M3. In 
comparison to K7M2, pulmonary metastases (where K7M3 cells were subsequently isolated) 
displayed even stronger angiogenesis (Khanna et al., 2000; Vajanto et al., 2002). In general, MRI 
findings were similar to those encountered in human osteosarcoma (Sundaram et al., 1987). 
Additionally, the utility of CT imaging was studied in the detection of pulmonary metastases. With 
this imaging modality, peripheral pulmonary metastases of at least 1.5 mm in diameter could be 
detected. However, detection of central pulmonary nodules was complicated by vascular structures 
(IV:Fig 4 B).  
 Histopathologic analysis of the tumors revealed a high number of mitoses and 
aggressive invasion to surrounding tissues including bone, bone marrow, cartilage and muscles 
(IV:Fig 4 C). Analysis of the lungs revealed microscopic metastases in several animals. These 
metastases were frequently found in the close vicinity of the blood vessels and sometimes were 
even growing in the vascular lumen. These findings indicate hematogenous spreading of the tumor 
cells into lungs, corresponding to the clinical picture of human osteosarcoma (IV:Fig 4 D). 
 Intratumoral injections of VA7-EGFP or saline (controls) were given once a week 
during the study. Despite the aggressiveness of the K7M3 tumors, the treatment with VA7-EGFP 
significantly improved the survival compared to controls (p = 0.0017) (IV:Fig 5 A). These results 
indicate that VA7-EGFP could be potentially useful for the treatment of osteosarcoma tumors 
arising at unresectable locations or for improving the quality of surgical margins after suboptimal 
tumor resection. Moreover, oncolytic SFV vectors carrying immunomodulatory transgenes for 
augmented anti-tumor immunity would be highly attractive for improved systemic efficacy against 
pulmonary metastases. Therefore, further efforts for optimization of SFV virotherapy against 
osteosarcoma are warranted. 
 In addition, we analyzed the biodistribution of VA7-EGFP vector from samples 
collected at the survival endpoint (IV: Fig 5 D). Almost complete clearance of the virus from 
tumors with residual of 7.6 × 10
3
 pfu/g or less was detected. Three out of eight tumor samples and 
all kidney, liver and serum samples remained negative for the virus. In cardiac muscle and spleen of 
some animals, a low amount of virus was present. However, in five of the eight brain samples, the 
virus was detected, the highest titer being 7.2 × 10
5
 pfu/g. This indicates that the virus could 
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replicate at low levels in the brains of some animals. Nonetheless, none of the mice exhibited any 
neurologic symptoms during the study. The results are in line with a previous report describing a 
persistent, sub-clinical CNS infection by the virus in nude mice. However, immunocompetent mice 
were able to clear the virus from the CNS (Amor et al., 1996). 
 
Potential reasons for treatment failure and strategies to improve the therapeutic effect 
 
Previous studies have identified two mechanisms potentially leading to failure of SFV virotherapy. 
First, a study in a melanoma xenograft model demonstrated that a subpopulation of tumor cells 
resistant for the virus can emerge (Vähä-Koskela et al., 2006). Second, in an orthotopic 
immunocompetent rat glioma model, the IgG antibody response lead to inactivation and clearance 
of the virus (Määttä et al., 2007). In the present study, outgrowth of a resistant subpopulation upon 
viral presence was observed in MG-63 cell cultures (IV:Fig 2). This indicates that the development 
of resistance against the oncolytic SFV may occur also in osteosarcoma cells. 
 Despite the enhanced survival, none of the K7M3 tumors was cured with the SFV 
treatment. Ultimately, all SFV treated animals met the criteria for sacrifice due to disease 
progression. The present study identified the capacity of IgM antibodies to block the SFV infection 
and viral propagation mandatory for the oncolytic effect (IV:Fig 5 B). Immunostaining of 
histologic tumor samples confirmed the clearance of VA7-EGFP from tumors at the survival end 
point (IV:Fig 5 C).  
 These mechanisms of treatment failure are likely to predict potential hurdles to the 
SFV virotherapy in the clinical setting. The rapid onset of the SFV replication and oncolysis leaves 
only a few days time window before the onset of IgM antibody response. During this time frame, 
SFV-mediated oncolysis could be at its most efficient. The emergence and outgrowth of resistant 
tumor cell populations is a common problem in various chemotherapeutic treatments against cancer. 
For this reason, chemotherapeutic agents are commonly used in combinations to reduce the risk that 
a single tumor cell could simultaneously develop resistance against all of the therapeutic agents. 
Therefore, in the future, the efficiency of the SFV virotherapy should be evaluated in combination 
with the chemotherapeutic agents currently used in the clinics to treat osteosarcoma. 
 Although the immune system can prevent efficient propagation of oncolytic SFV and 
inhibit the treatment response, it may also contribute to the therapeutic efficiency in certain 
conditions. In the present study, the therapeutic response achieved with SFV virotherapy was 
superior in the Saos2LM7 model compared to K7M3 model. The osteosarcoma cell lines used to 
generate these models differ from each other in their tumorigenicity, which was lower in Saos2LM7 
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cells (only nine of the sixteen mice developed progressively growing tumors on both flanks) 
compared to K7M3 cells (tumorigenicity was 100 %). Although only the mice with bilateral 
progressively growing tumors were accepted for evaluation of the SFV or Δ24 treatment, it is 
possible that also the selected tumors were more immunogenic compared to the K7M3 tumors. The 
augmentation of pre-existing antitumor immunity by oncolytic SFV is one potential explanation for 
the excellent therapeutic response observed in the Saos2LM7 model. Previous studies have shown 
that due to their high immunogenicity, alphavirus vectors offer a good platform for gene transfer -
based vaccination against infectious diseases. In these applications, the vector itself acts as an 
immunological adjuvant, enhancing the efficiency of immunization. Moreover, interferon has 
demonstrated efficacy against osteosarcoma (Müller et al., 2005) and the ability of SFV infection to 
induce a robust interferon response might play a role in the therapeutic effect of oncolytic SFV.  
Our results suggest that the oncolytic SFV deserves further consideration as a potential vector for 
immunogenetherapy against cancer.    
 
Safety issues   
 
A mouse model is ideal for oncolytic SFV when assessing tumor specificity of the virus replication, 
since SFV is a rodent virus. However, in the case of conditionally replicating adenoviruses, human 
xenograft tumors implanted into mice can be utilized for demonstration of the therapeutic effect, but 
not for studying the tumor specificity of the viral replication, because CRAds are based on human 
adenoviruses and usually do not replicate in rodent cells (Duncan et al., 1978; Ginsberg et al., 1991; 
Thomas et al., 2006). Lack of representative and feasible animal models suitable for evaluation of 
CRAds has lead to development of ex vivo assaying that utilizes tissue culture techniques (Kirby et 
al., 2004). Also, the biosafety of oncolytic adenoviruses has been studied in healthy dogs with a 
canine adenovirus type 2 based CRAd that is transcriptionally targeted to replicate in canine 
osteosarcoma cells. No major signs of virus related toxicity was found in this experimental setting 
(Smith et al., 2006). Furthermore, clinical phase I/II studies with Onyx-015 have confirmed that 
oncolytic adenoviruses can be safely used in humans (Ganly et al., 2000; Lamont et al., 2000; 
Nemunaitis et al., 2000).  
 Although only a few reports connecting wild type SFV infection to clinical human 
disease exist, the fact that the wild type SFV is a neurotropic virus does give rise to questions on the 
safety of oncolytic SFV virotherapy when planning clinical studies. During the survival study, we 
analyzed the biodistribution of the oncolytic VA7-EGFP vector from each animal at the survival 
endpoint. None of the mice developed neurological symptoms during the survival study. Thus, in 
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one of the mice, the vector was found to propagate to some extent in the brain tissue. These results 
obtained in a nude mouse model are consistent with previously published studies (Amor et al., 
1996; Määttä et al., 2007). However, immunocompetent adult mice have been reported to clear the 
virus both from blood and CNS (Amor et al., 1996).  
 The course of SFVA7(74) infection compared to wild type SFV infection is drastically 
different. In contrast to the wild type virus, infection is asymptomatic in immunocompetent adult 
mice and subsequently the virus is cleared by the specific immune responses. In addition, CNS 
infection in the mice with severe combined immunodeficiency (SCID mice) is attenuated into small 
perivascular replication foci, although the number of the replication foci is known to increase over 
time due to continuous viremia and the lack of acquired immune responses (Amor et al., 1996).  
 An important safety aspect in the case of therapeutic viruses is the possibility of wild-
type reversion and transmission to untreated subjects. Genetic instability is a general characteristic 
of RNA viruses (Domingo and Holland, 1997), SFV among the others. However, several attenuated 
replication-competent vaccine strains against clinically important pathogens belonging to RNA 
viruses have been developed. For example, Sabin's oral poliovirus vaccine is used throughout the 
world and is largely responsible for almost complete eradication of polio (Kew et al., 2004). Thus, 
these attenuated polioviruses used for vaccination can effectively spread in human populations in an 
uncontrolled manner and in rare cases undergo mutations leading to restored neurovirulence (Kew 
et al., 2004).  
In contrast to SFV, adenoviruses belong to DNA viruses and are genetically much 
more stable (Heise and Kirn, 2000). However, the possibility of wild-type reversion through 
homologous recombination with an adenovirus vector and the genetic components of adenovirus 
used to immortalize cultured cells, or with a wild type adenovirus circulating in the human 
population has not been thoroughly evaluated so far (Murakami et al., 2002). Therefore, the 
possibility that retargeting modifications or transgenes (for example encoding cytokines) that are 
used to boost the oncolytic effect could enhance the virulence or lead to unexpected clinical 
symptoms in the context of the wild-type adenovirus genome should be recognized when 
constructing improved conditionally replicating adenoviruses. Furthermore, latent adenovirus 
infections are relatively common in human populations (Horvath et al., 1986; Matsuse et al., 1992). 
Since wild-type adenoviruses are capable for transmission via the respiratory route, their 
transmission to other subjects is therefore relatively difficult to control. Notably, no efficient 
antiviral treatment exists for SFV or adenovirus infections. 
 A thorough understanding of the properties of oncolytic viruses, as well as the biology 
of the corresponding wild type viruses is essential for creating safe and effective viral therapeutics. 
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Although much work has been done to achieve these objectives, there are still many unravelled 
mysteries. One of the issues of special interest is the interaction of the immune system with 
therapeutic viruses. The innate and acquired immune responses have a fundamental impact on the 
efficiency of oncolytic virotherapy. Furthermore, the tragic death of an 18-year-old patient due to a 
systemic inflammatory response syndrome following administration of non-replicative adenovirus 
vector (Raper et al., 2003) underlines the importance of studying reactions of the immune system to 
therapeutic viruses. Thus, the immune system is not only a hurdle to overcome for oncolytic 
viruses, but could potentially be utilized for more potent anti-tumor effects (Bennett et al., 2001).  
   
Future prospects 
 
The present study showed efficiency of HSV-TK/GCV suicide gene therapy against human 
osteosarcoma and chondrosarcoma cells in vitro.  Still, due to the lack of commercially available 
chondrosarcoma cell lines, only one chondrosarcoma cell line was examined in the study. In these 
cells, the HSV-TK/GCV approach was highly effective. Taking into account the fact that 
chondrosarcoma tumors frequently arise in the pelvis which often makes definitive surgery highly 
challenging, and that radical surgery is currently the only effective treatment for this tumor type 
(Mitchell et al., 2000; Noel et al., 2003), further studies to confirm the efficiency of HSV-TK/GCV 
treatment against chondrosarcoma are warranted. However, the development of appropriate 
preclinical models for chondrosarcoma remains a challenge for the future. 
 All three studied osteosarcoma cell lines were sensitive to HSV-TK/GCV treatment 
but the extent of the bystander effect was variable. The vast majority of osteosarcoma patients have 
microscopic pulmonary metastases already at the time of diagnosis. Interrestingly, a previous study 
by Charissoux and colleques suggested prevention of pulmonary metastases with HSV-TK/GCV 
treatment in an orthotopic osteosarcoma rat model (Charissoux et al., 1999). Still, systemic efficacy 
against previously established osteosarcoma metastases remains to be shown. Also, HSV-TK/GCV 
therapy should be evaluated in combinations with other therapeutic modalities with systemic 
efficacy. Furthermore, with current gene transfer tools, gene transfer to large primary tumors for 
complete destruction of the tumor mass is complicated due to inadequate gene transfer rates. 
Although HSV-TK/GCV approach is potentiated by the bystander effect, it cannot replace radical 
surgery in the treatment of the primary tumor.   However, HSV-TK/GCV treatment could be useful 
for improving the quality of surgical margins after suboptimal resection and in the treatment of 
tumors that are unresectable due to their anatomic location. Low tissue concentrations of GCV have 
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been proposed to restrict the efficacy of HSV-TK/GCV treatment. In addition to the search for 
novel nucleoside analogs with improved efficacy, such as novel fluorine containing tricyclic ACV 
and GCV analogs (Ostrowski et al., 2005), biodegradable materials releasing GCV locally to the 
target tissue should be evaluated.  Furthermore, some reports indicate the presence of an immune 
mediated distant bystander effect in certain animal models (Barba et al., 1994; Gagandeep et al., 
1996; Kianmanesh et al., 1997). Combining HSV-TK/GCV approach to immunopotentiation gene 
therapy would be of great interest to extend the therapeutic effect to metastatic lesions.  
 Another approach to improve the efficacy of HSV-TK/GCV treatment is to enhance 
the gene transfer rates using improved vectors. Propagation competent vectors or armed oncolytic 
viruses could be useful for augmentation of gene transfer efficiency. The Sindbis virus vectors used 
in this study were previously reported to be propagation incompetent (Frolov et al., 1997; Tseng et 
al., 2004). However, we demonstrated that they were able to propagate in cell cultures, especially in 
cells with a defective IFN response, a common characteristic of malignant cells. We revealed that 
the helper and replicon RNAs used for vector production were able to undergo recombination, 
leading to restoration of full-length Sindbis genome and the formation of propagation competent 
virus. This finding is highly important, since earlier studies have reported promising antitumor 
effects in different animal models after systemic delivery of Sindbis virus vectors, termed as 
propagation incompetent but produced with the same DH-BB helper RNA used in our study (Tseng 
et al., 2004). Our results will strongly affect the interpretation of these previously published results, 
since the wild-type Sindbis virus that emerges during vector production can function as an oncolytic 
virus, explaining the reported systemic efficacy. When planning any clinical trials with these 
vectors, one should consider the safety issues related to use of propagation competent vector or 
oncolytic Sindbis virus. To prevent formation of propagation competent Sindbis virus during vector 
production, a similar approach as used for the construction of the SFV split helper RNA could be 
utilized (Smerdou and Liljeström, 1999). This involves modification of the capsid gene to abolish 
its self-cleaving activity. Thereby, recombination events between the replicon and split helper 
components can not directly lead to wild-type reversion of the virus. However, our observation that 
propagation competent vectors are formed also when only Crrv∆3 RNA but not the CSin 
component of the split helper RNA was used for packaging of the replicon suggest that this 
modification might not totally abolish formation of propagation competent virus-like particles.   
 In this study, the most encouraging results in terms of therapeutic efficiency were 
achieved using an oncolytic Semliki Forest virus vector VA7-EGFP. This replication competent 
alphavirus coding for EGFP marker gene could efficiently destroy human osteosarcoma cells both 
in vitro and when grown as xenograft tumors in nude mice. Compared to a widely studied oncolytic 
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adenovirus Δ24, it showed improved efficiency both in vitro and in vivo.  Moreover, weekly 
intratumoral VA7-EGFP injections improved the survival in a highly aggressive orthotopic K7M3 
osteosarcoma nude mouse model compared to saline treated controls. However, a previous study 
with VA7-EGFP in an immunocompetent rat glioma model failed to demonstrate significant 
differences in survival between treated animals and controls after intravenous administration 
(Määttä et al., 2007).  Nonetheless, VA7-EGFP could serve as a novel tool for treatment of 
osteosarcoma tumors at unresectable locations as well as for improvement of the surgical margins 
after suboptimal resection. Since systemic efficacy against distant metastases would be highly 
desirable in the case of osteosarcoma, VA7-EGFP should be tested in combination with 
immunomodulatory approach. This could be done by replacing the EGFP gene with 
immunomodulatory transgenes augmenting antitumor immunity, such as IL-12, IL-18 or B7-1. 
These genes have been utilized alone or in combinations for potentiation of CTL mediated 
antitumor response either in the context of propagation incompetent SFV vector or oncolytic adeno- 
or herpesviruses (Bortolanza et al., 2009; Ino et al., 2006; Lee et al., 2006; Rodriguez-Madoz et al., 
2005). In this approach, the VA7 vector itself could serve as an immunological adjuvant. 
The orthotopic model established for evaluation of VA7-EGFP virotherapy closely 
mimics several characteristics of clinical osteosarcoma, including hematogenous metastasis to 
lungs, aggressive invasion of the primary tumor to surrounding tissues (bone, bone marrow, 
cartilage and muscles), oedema of the affected limb, hypervascularity and VEGF secretion by tumor 
cells. This animal model could be used in the future for evaluation of several different gene and 
virotherapy strategies, including antiangiogenic gene therapy and other promising oncolytic vectors. 
The main limitations include that it is not suitable for the evaluation of oncolytic adenoviruses, 
since K7M3 is a mouse osteosarcoma cell line and thereby a poor target for adenovirus infection. 
Secondly, immunogenetherapy approaches or the effects of the immune system on the virus vectors 
cannot be thoroughly evaluated using a nude mouse model, since these mice lack T cells.   
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6   SUMMARY AND CONCLUSIONS 
 
 
This work was carried out to study the utility of HSV-TK/GCV suicide gene therapy and oncolytic 
virotherapy against osteosarcoma, a highly aggressive primary bone tumor mainly affecting 
children and young adults.  
 
I HSV-TK/GCV treatment was effective against human osteosarcoma cells. Both 
adenoviral and lentiviral vectors can be used for effective gene transfer to cultured 
osteosarcoma cells. However, the extent of the bystander effect varied between the 
studied cell lines, in two out of the three studied human osteosarcoma cell lines a 
strong bystander effect was observed whereas one cell line displayed a moderate 
bystander effect. 
 
II Sindbis virus vectors have been reported to elicit effective gene transfer to multiple 
cell types. The chimeric split helper RNA has been developed for the production of 
Sindbis virus vectors as a way to reduce the possibility of wild-type reversion via 
recombination of replicon and helper RNAs. To our surprise, Sindbis vector 
preparations produced with split helper RNA contained propagation competent viruses 
or virus-like particles, giving rise to lateral spreading of transgene expression with no 
or minimal cytopathic effect that is normally associated with Sindbis virus 
propagation. 
 
III Sindbis virus vectors produced with the split helper RNA can be used for gene transfer 
to human osteosarcoma cells, however, one of the three studied osteosarcoma cell 
lines was resistant to Sindbis virus vector mediated gene transfer. Nonetheless, 
recombination between the replicon and helper RNAs does occur and recombination 
events can lead to restoration of wild-type Sindbis sequences. Propagation competent 
Sindbis virus vectors may function like oncolytic viruses selectively killing malignant 
cells which have a defective IFN response.  
 
IV Oncolytic Semliki Forest virus vector VA7-EGFP showed promising efficacy against 
osteosarcoma both in in vitro and in vivo against subcutaneous Saos2LM7 human 
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osteosarcoma tumors. In an orthotopic K7M3 mouse osteosarcoma model, weekly 
intratumoral VA7-EGFP injections significantly improved the survival of treated 
animals compared to controls. However, this study demonstrated that osteosarcoma 
cells may develop resistance against VA7-EGFP and serum IgM antibodies can 
neutralize the virus.    
 
As a conclusion, the HSV-TK/GCV suicide gene therapy and oncolytic virotherapy with VA7-
EGFP may represent novel tools for the treatment of unresectable osteosarcoma tumors or 
improving surgical margins after suboptimal resection. In the search for optimal vectors for 
therapeutic gene transfer, both adeno- and lentivirus vectors were shown to elicit efficient gene 
transfer to human osteosarcoma cells. Evaluation of one of the vector candidates, Sindbis virus 
vector, revealed the formation of propagation competent contaminating viruses or virus-like 
particles upon vector production. These had been generated due to recombination between the 
replicon and helper RNAs.  
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